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1. INTRODUCTION 
Eukaryotic organisms have developed elaborate cellular mechanisms to endow themselves 
with differential and cell-type specific expression of genes. Born nearly in 1997, 
Epigenetics, which literally means “upon genetics”, refers to these mechanisms and can be 
defined as changes in state of genes functions and expressions (“on” versus “off”) that are 
mitotically and/or meiotically heritable and do not entail a change in DNA sequence. This 
means that it concerns how eukaryotic DNA, and so chromatin, is distinctively accessed in 
cells during embryonic development and differentiation; and finally how the chromatin 
states are maintained/changed, not only during the normal life of a cell but from a 
generation of cells to an another one in multicellular organisms. The dynamic nature of the 
epigenetic state of cells thus offers a pre-ordered scheme for the development and the 
differentiation of organisms, moreover their changes empower cells of environmental 
plasticity enabling cellular reprogramming and responses to the changing outward 
conditions. Notwithstanding the notable precision of these mechanisms, mistakes may 
occur, and when not appropriately correct, they may lead to aberrant expression and/or 
silencing of critical downstream target genes, with far-reaching implication in the most 
fields of cell biology and human health, including: viral latency, somatic gene therapy, 
cloning and transgenic technologies, metabolic, cardiovascular and neurodegenerative 
diseases and remarkably in cancer. 
For many years oncogenesys has been deemed the outcome of multistep processes 
involving irreversible genetic defects as gene mutations, deletions and chromosomical 
aberrations, leading to loss or gain of function of oncosuppressor genes and oncogenes, 
respectively. However, recent studies have underlined how these processes involved an 
imbalance of normal molecular signalling pathways that regulate the cellular proliferation 
and differentiation and how Epigenetics plays a pivotal role in the activation and/or 
repression of these programs during the normal cell cycle.  
In the late ’70 Lewis and Lewis elegantly showed how critical a fine-tuned epigenetic 
regulation for the functional development of an organism might be. Upon mutations of a 
set of genes on drosophila melanogaster (Polycomb genes), specific body segments of the 
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mutants assume the identity of a completely different, but otherwise normal, body 
segment. This is the case of adult animals having legs in the place of antennas.  
The authors also investigated the biochemical mechanisms underlying the aberrant 
phenotypes and found that Polycomb (PC) mutations caused inappropriate reactivation of 
genes that should have been repressed and are responsible for segment identity. Their 
reactivation leads the body segments to assume new character (the antenna-leg 
transformation). 
The Lewis and Lewis findings opened the way to new and more focused analysis on the 
chromatin on/off state, its modulators (or on/off switchers) and their implication on both 
normal and pathological conditions as neurological diseases, immunological disorders and 
several types of cancer. In particular numerous evidences link deregulated epigenetic 
networks to the loss of function and propagation of cancer cells and more in general to the 
development and also relapse of different tumours.  
Reinstating a correct epigenetic regulation is a current therapeutic goal in cancer, the 
importance of which can be better understood considering the heterogenic and multiple 
nature of tumour cells. Several hypotheses exist accounting for this peculiarity, the most 
important being the cancer stem cell hypothesis and the clonal evolution model. The first 
hypothesis states that only a rare subset of cells (the so called “cancer stem cells” or CSCs) 
is responsible for the maintenance of the neoplasm. The cancer stem cells start the 
propagation and according to the clonal evolution model, lead to different clonal subset in 
which different genetic abnormalities are present. In this way the evolutionary pressure 
allows the sequential selection of the most aggressive subpopulations.  
The propagation and renewal of the cancer stem cells could arise from an inappropriate 
reactivation of some developmental pathways, due to the ability of the tumour-propagating 
cells to hijacked cellular networks that control the normal behaviour of an adult stem cell. 
The reactivation of developmental pathways involves both genetic defects and epigenetic 
alterations, which might be responsible for the evolution of new cancer cell lineages by 
disrupting the expression of oncogenes and oncosuppressor genes that lies at the basis of a 
normal cell development and differentiation. The concrete possibility of completely 
reversing the aberrant epigenetic regulation by tackling down the biochemical mediators of 
chromatin remodelling with small molecules inhibitors has greatly focused the attention on 
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chromatin modifying enzymes as targets and promising clinical trials have boost both the 
academic and private epigenetic research programs. Unfortunately, the suitable set of 
enzymes to inhibit, in order to restore or shut down the expression of target genes, has 
been proved difficult to find. This is mainly due to the inner complexity of the rules 
dictating the chromatin state, where even small modifications of the proteins structure will 
correspond to critical changes on genes expression and functions. Chromatin modifications 
are generally of a covalent type, as acetylation and methylation. Several different families 
of specific enzymes exist, for the vast majority of them, inhibitors have been designed, 
synthesized and tested, some of which have also shown potent and selective activity both 
in vitro and in vivo. Anyway new and more potent compounds are needed to modulate 
different target activities and change specific patterns of covalent modifications to achieve 
the desired therapeutic goal. Several techniques generally adopted in the pharmaceutical 
research and development (R&D) have been applied to this scope. For example high 
throughput screening (HTS) in concert with bioinformatics techniques is responsible for 
early identifying most of the molecules currently tested. Moreover the number of currently 
HTS compatible biological assays is continuously increasing allowing a growing number 
of chemical scaffolds to be tested. Also the number of experimentally solved chromatin 
modifying enzymes crystal structure available in the protein data bank (PDB) is becoming 
bigger and bigger, constituting a valuable tool for computational and medicinal chemists to 
analyse and explore the physicochemical characteristic specific for a particular protein, 
gain insight in the relationship between its structure and function and make a set of rules 
necessary to build inhibitors not just more potent but also with a range of activity covering 
different enzymes at once. All these different approaches gathered together will likely lead 
to better “hits” and will help medicinal chemists in the lead optimization process. 
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2. EPIGENETIC AND CHROMATIN DYNAMICS 
One of the striking aspects that emerges when we consider the inner organization of a 
mammalian cell, is how Nature solved the crucial matter of settling in a 1.7 metres long 
DNA strand into a 5-micrometre nucleus, in a form that not only allows it to be replicated 
through a relatively fast and accurate process, but that permits it to be read and then 
transcribed in a tissue-specific manner too, in a nutshell: chromatin. 
Chromatin is a dynamic macromolecular complex consisting in DNA, histone and non-
histone proteins and represents the form in which DNA is packed within a eukaryotic 
nucleus. It comprises a repetitive sequence of units, the nucleosome, composed of 146 base 
pairs of DNA wrapped, nearly twice, around 4 pairs of highly conserved core proteins, 
called histones: H2A, H2B, H3 and H4. Since a nucleosome based structure compacts 
DNA around seven fold, but eukaryotic cells need, and actually exhibit, an overall 
compaction of several thousand fold, it is glaring that in vivo only a relatively small 
fraction of DNA is under a simple nucleosomal organization, while the most of chromatin 
is further compacted in an highly order architecture
1
. Nucleosomes are still important in 
this higher order folding as they help the arrangement of DNA into the 30-nm fiber by the 
electrostatic neutralization among DNA spacer motifs and the linker histone H1, together 
with RNAs and non-histonic proteins. 
 
Figure 2.1. Chromatin architecture 
Histones, the core components of the nucleosome, are basic proteins, they have a 
comparable overall structure, with a globular hydrophobic internal region, that represents 
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the platform whereby the DNA sequence is rolled up, and a flexible charged amino termini 
protruding out the nucleosome.  
 
 
Figure 2.2. Detailed view of nucleosome structure 
The amino terminal region, so called histone “tail”, consists of ~25-30% of the mass of an 
individual histone and offers an exposed surface for protein-protein interaction. These tails 
are interested by a plenty of covalent reversible Post-Translational Modifications (PTMs), 
which are referred to as epigenetic marks, that can modify the overall structure of the 
nucleosome and eventually regulate the chromatine state acting as a “platform” for the 
recruitment of multi-protein complexes responsible of the transition from an open-access, 
and therefore transcriptionally active folding (euchromatine), to a close conformation or 
transcriptionally silent one (heterochromatine). Histone PTMs can therefore play key roles 
in DNA replication, repair, recombination and notably in genes transcription. Although, 
evaluating the complexity of genes expression as the result of an “on/off” dynamic, could 
appear too much simplistic, it should be considered that nucleosomes are not static entities 
and DNA can transiently unwrap and then rebind the histone template in a finely tuned 
way, depending on the varied epigenetic mark arrays that decorate the histones and also 
the DNA at the promoter and at the enhancer sequences. Genes can thus be accessed by 
transcriptional factors with different rates and strength; thereby, giving a motley 
phenotypic output. 
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After years of intense efforts in unrevealing the epigenetic modification patterns
2
, 
comprehensive literature exhibits an elaborated repertoire of post-translational 
modifications affecting histone tails, among them: lysine acetylation/deacetylation, 
arginine/lysine methylation/demethylation, serine/threonine phosphorylation, 
ubiquitylation, ADP-ribosylation, SUMOylation and citrullination (demethylimination). 
These covalent reversible marks, together with the well-characterized DNA methylation of 
cytosines in the CpG islands, not only crosstalk with each others in a synergistic or 
antagonistic way but are not mutually exclusive, thereby establishing a tangled signalling 
network which can properly address the cell requirements. 
Histone marks patterns effects are determined by proteins or protein complexes which are 
often divided into three functional families. The enzymes that insert histone marks (the 
“writers”) like, for example, the histone acetyltransferases (HATs) and the histone 
methyltransferases (HMTs) add acetyl and methyl groups respectively; the proteins that 
recognize and then decrypt the epigenetic message (the “readers”), which generally 
possess effector domains like plant homeodomain (PHD), bromo, chromo, RING finger 
and tudor domains; finally the enzymes in charge of removing histone marks (the 
“erasers”) as the histone deacetylases (HDACs) and histone demethylases (HDMs). 
The writers/erasers-driven dynamics display different effects on chromatin states, 
depending on the type of modification. Lys acetylation correlates in general with 
transcription  activation, while deacetylation usually leads to gene silencing. Differently, 
arginine/lysine methylation can be associated to transcription activation or repression 
depending on the distinct residue involved, and the type (symmetrical/asymmetrical) or the 
extension of methylation (mono-, di-, or tri-methylation), respectively. Given the wide-
spread implications of chromatine state regulation not only in Epigenetics, but in 
oncology, developmental biology, stem cell fate and regenerative medicines too, the 
“writers”, “readers” and “erasers” are essential targets to further deciphering the histone 
code (epigenome) and its role in human deseases. 
 
 
 
11 
 
3. HISTONE METHYLATION 
Although phosphorylation remains by far the most elucidated PTMs, in recent years 
methyl groups started ascending into prominence as one of the major controlling elements 
in protein function since a remarkable variety of methylation and demethylation reactions 
take place at the side chains of distinct amino acids.  
Methyltransferases are a huge family of proteins, indeed, it has been hypothesized that 
over 1% of mammalian genome encodes for this kind of enzymes
3
, and they catalyze the 
addition of methyl groups to nitrogen, carbon, sulphur, and oxygen atoms of proteins, 
lipids, nucleic acids and small molecules too. These modifications originate a multitude of 
chemical interactions which involve histonic and non histonic proteins thus affecting a 
large number of regulatory pathways ranging from the epigenetic control of gene 
expression and transcription, modulation of the activity effector proteins and of 
transcription factors.
4
 Within histone proteins, arginine and lysine residues are very 
abundant and highly post-translationally modified on their side chains, as they can 
generally undergo acetylation, methylation, ubiquitination, citrullination, SUMOylation 
and ADP-ribosylation reactions. 
As far as methylation is concerned histone methyltrasferases (HMTs) enzymes catalyze 
methylation by removing a methyl group from the donor molecule S-Adenosyl-L-
Methionine or SAM (AdoMet), thus generating a S-Adenosyl-L-Homocysteine or SAH 
(AdoHcy) as product, and transferring this methyl group on the guanidino and ᶓ amino 
groups of arginine (R) and lysine (K) residues, respectively (Figure 3.1). Thus, HMTs are 
divided in two groups: the Histone Lysine Methyltransferases (HKMTs or KMTs) and the 
Protein Arginine Methyltransferases (PRMTs). As reported in a broad number of in vitro 
and cell based studies, both HKMTs and PRMTs are able to methylate only specific 
residues on their substrates, thus being capable of a substrate selectivity, but additionally 
they methylate this residues only to a distinct methylation state, which is referred to as 
product specificity. Indeed, PRMTs can mono- and then di-methylate arginines side chain 
in a symmetric or asymmetric fashion, while KMTs can mono-, di- and trimethylate the ᶓ 
amino group of lysines.  
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Figure 3.1. Proposed mechanism for lysine methylation by SAM 
 
3.1 Protein Arginine Methyltransferases (PRMTs) 
Arginine is a positively charged amino acid which is deemed unique as its guanidino group 
mediates for amino-aromatic interactions and can generate up to five potential hydrogen 
bonds with the counterpart acceptors in biological systems
5
. Consequently the addition of a 
methyl group not only prevents the formation of a potential hydrogen bond but imparts 
also bulkiness to arginine, influencing the protein-protein interactions both positively and 
negatively. Importantly, methylation does not neutralize the cationic charge of an arginine 
residue
6
. As a proof of concept for the far reaching implications of arginine methylation 
effects, it should be accounted for that arginine residues participate in a multitude of 
protein-protein interactions especially in protein-DNA complexes, where they are the main 
responsible of hydrogen bonding to the backbone phosphate groups and to thymine, 
adenine and guanine bases
7
; they can interact with flanking phosphate groups in specific 
RNA loops
8
 and, moreover, owing to two H-bond interactions, arginine-aspartate dimers, 
are known to be especially stable in proteins
9
.  
In mammal cells, nine protein arginine methyltransferases (PRMTs), divided into three 
different classes, have been identified so far
10
. Type I (PRMT1, PRMT2, PRMT3, 
PRMT4/CARM1, PRMT6 and PRMT8) and Type II (PRMT5 and PRMT7) enzymes both 
catalyze the formation of monomethylarginine (MMA) as an intermediate, but while Type 
I enzymes facilitate the formation of ω-NG,NG-asymmetric dimethylarginine (ADMA), 
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Type II members lead to the formation ω-NG,NG-symmetric dimethylarginine (SDMA) 
(Figure 3.2). 
 
Figure 3.2. Types of methylation on arginine residues. 
(Image courtesy of Yang Y. et al Nature review/Cancer 2013) 
Upon certain substrates PRMT7 seems to generate only ω-NG-monomethylation (MMA) 
arginines thus being classified as a Type III enzyme too; while PRMT9 activity has not 
been well characterized yet. To date, no enzymes forming both asymmetric and symmetric 
dimethylarginines have been identified
11
.  
PRMTs are ubiquitously expressed in most human cell types and tissues, even though they 
can also endow themselves with tissue specificity by alternative splicing
12
, and with the 
unique exception of PRMT8, which is thought to be selectively expressed in brain 
neurons
13
 and has the characteristic to be incorporated into plasma membrane via N-
terminal myristoylation
14.. They are constitutively active and essential for existence since 
they take part at the early development of embryos, as ablation experiments of PRMT1 on 
dyes and PRMT4/CARM1 on mice have attested
15,16
.  
As far as the substrate recognition is concerned PRMTs generally methylate in 
correspondence of glycine- and arginine rich motifs
8,17
 (GAR), and this is particular true 
for PRMT1, PRMT3 and PRMT6, but there are exceptions to this general rule. PRMT4 or 
CARM1 (Co-activator Associated Arginine Methyltransferase 1) exhibits an higher degree 
of specificity since it recognizes arginines flanking proline-, glycine- and methionine-rich 
(PGM)  motifs-containing substrates
18
 and does not interact with GAR motifs
19
. Instead, 
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PRMT5 simmetrically methylates arginines either within GAR and PGM motifs
20
. Once 
considered mostly active on RNA-binding proteins (RPBs), nowadays PRMTs are widely 
recognised as histone marks writers too, since they methylate arginine residues on H3 and 
H4. More recently proteins, like p53, P300/CBP, ERα, pRb, TAF10 and HIV tat have also 
shown to be PRMTs targets
21,22,23
. 
The different PRMT subfamilies are characterized by common structural features. Each of 
them harbours motifs of seven-β-strand, typical of methyltransferase family24, as well as 
an additional “double E” and “THW” sequence motifs, which characterizes the specific 
subfamily
25
. 
Among PRMTs, only four crystal structures are currently available (rat PRMT1, rat 
PRMT3, yeast RMT1/hmt1 and CARM1/PRMT4), their core structures are proven similar 
and provide some insights into the mechanism of methylation process and substrate 
recognition. Structural evidences show that PRMTs are ring-like dimer, and their 
methyltransferase activity is strictly dependent from the dimerization
26,27,28,29
. Moreover, 
PRMTs (but also KMTs) have two binding regions: the substrate binding pocket and the 
cofactor binding site
30
.  
Once activated, these enzymes endow themselves with an ordered sequential bi-bi kinetic 
mechanism, in which SAM binds prior to the substrate
31
. The substrate binding pocket and 
the cofactor binding site, almost flanking each other, are joined by a narrow hydrophobic 
channel, large enough to allow the terminal amino group of the substrate to come within 
bonding distance of the cofactor (Figure 3.3). Two conserved residues (Glu-100 and Arg-
54 in PRMT1) interact with the two ribose hydroxyls and carboxylate from SAM, 
respectively, placing the methylsulfonium  group of the cofactor at the base of the channel 
where arginine side chain of the substrate raises. In the same manner two hydrogen bonds 
by other invariant glutamate residues (Glu-144 and Glu-153 of PRMT1) are established 
with the guanidinium side chain of the arginine substrate. These two H-bonds are critical 
interactions as they are supposed to concentrate the delocalized positive charge onto an 
only one nitrogen of the guanidinium group, leaving the lone pair of the other one 
available for the nucleofilic substitution (SN2 mechanism) to the methylsulfonium group. 
After the methyl transfer, the proton elimination step is supposed to be by a His-Asp 
proton relay mechanism
25
.  
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Figure 3.3. GLP-H3 co-crystal structure (PDB: 2RFI, H3K9me2 shown in green) with SAH (cyan) 
depicting the hydrofobic channel joining the substrate binding pocket and the cofactor binding site  
As proof of concept for the importance of these two glutamate residues, in vitro data have 
shown that mutations of either, even to the closely related glutamine or aspartate, reduce 
the methyltransferase activity by >3000-fold and >10-fold, respectively
26
. Once 
methylation transfer has occurred, S-Adenosyl-Homocystein (SAH) is released, but mono-
methylated arginine may still undergo to a second methylation, depending on the specific 
case, before leaving the substrate binding pocket
32,33
. 
PRMTs can methylate and modulate a large fraction of the proteome and their substrates 
take part into different cellular activities, among them: gene expression and transcription, 
mRNA splicing, nuclear/cytoplasmic shuttling, DNA repair and signal transduction. 
As far as is known, tudor domain-containing proteins (TDRDs) are the unique PRMTs 
cellular effectors, since they are the only “readers” to recognise methylarginine motifs, not 
only on histones but on other proteins too
34
. Tudor domains may be subdivided into 
methylarginine- and methyl-lysine-binding groups and their selective recognition is 
essentially based on the different width of the aromatic cage, which harbours the 
aminoacidic residues: methylated arginines are narrower than lysine ones by virtue of the 
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planarity of the methylguanidinium group
35
. Being able to methylate arginines on histone 
tails (most frequent sites of histone arginine methylation are H3R2, H3R8, H3R17, H3R26 
and H4R3), as well as on transcriptional factors and RNA polimerase, PRMTs directly 
play a notable role (as writers) in the epigenetic regulation of gene expression
11
; on the 
other hand as they methylate co-activators (e.g. p300, CBP and SRC3) they indirectly 
affect the epigenetic marks patterns by regulating the competences of these 
acetyltransferases. Owing to this “cloud” of methylation11, TDRDs localize themselves on 
Transcriptional Start-Sites (TSSs) where they exert their control on genes transcription. 
The remarkable role of PRMTs not only in the epigenetic control of genes expression and 
transcription, but in different cellular pathways may be well exemplified by the activity of 
the best characterized PRMTs: PRMT1, PRMT4/CARM1 and PRMT5 (Figure 3.4).  
 
Figure 3.4. Cellular signalling processes in which arginine methylation has integral roles. 
(Image courtesy of Yang Y. et al Nature review/Cancer 2013) 
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PRMT1 is the founding member of the arginine methyltransferase family and its activity 
accounts for more than 85% of the methylarginines among mammalians
36
. It selectively 
dimethylates arginine 3 on histone H4 in an asymmetrical manner (H4R3me2a), which is 
an epigenetic mark usually correlated with transcriptional activation
37,38
 and that has been 
found associated with increasing prostate cancer grade and with the risk of the tumour 
recurrence
39
. H4R3me2a mark is recognised by TDRD3 (the former member of the tudor 
domain-containing proteins) which is probably the ultimate effector for the transcription 
activation, however the complete molecular pathways that lie behind this effect has not 
been elucidated yet
40
. The first evidence that PRMT1 plays a role in oncogenesis arose in 
studies demonstrating that mouse primary hematopoietic cells that are transduced with the 
MLL-EEN gene fusion product displayed enhanced self-renewal abilities and can form 
compact CFU-GEMM-like colonies in vitro
41
. Another study shed light on to the fact that 
PRMT1 mRNA levels have been reported to be higher in a panel of breast cancer cell lines 
than in normal controls.
42
 A plenty of non histonic substrates of PRMT1 have been found 
so far, linking its aberrant activity to possible roles in cancer onset and progression. 
PRMT1 can methylated proteins involved in DNA repair pathway such as MRE11 (also 
known as MRE11A) and p53 binding protein 1 (53BP1) within their GAR motif and thus 
regulates its exonuclease activity on double-stranded DNA. Cells containing 
hypomethylated MRE11 displayed intra-S phase DNA damage checkpoint defects; 
likewise cells with hypomethylated 53BP1, which is involved in the early steps of 
detection and repair of damaged DNA, show alteration in the 53BP1 localization to 
damaged DNA and forms fewer γH2AX foci43. Another study has indicated that PRMT1 is 
associated with human telomerase, and in particular that telomeric repeat-binding factor 2 
(TERF2) a component of the sheltering proteins which protects the telomeres, is a 
substrate of PRMT1
44
.  
Oestrogen receptor (ER) pathway is also a target of PRMT1, indeed it has been found that 
PRMT1 methylates ERα in the DNA-binding domain (R260), both in vitro and in cells, 
and oestrogen treatment of MCF7 cells rapidly increases this methylation. ERα 
methylation seems to influence the downstream activation of ERα effectors as it has been 
shown that the R260 methylation is required for the assembly of ERα with SRC and focal 
adhesion kinase (FAK), as proof of the concept the mutation of ERα-R260 to alanine or 
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results in the inability of oestrogen to activate AKT
45
. Hence PRMT1-mediated ERα 
methylation is a triggering process for the activation of the SRC–PI3K–FAK cascade and 
AKT, moreover hypermethylation of ERα in breast cancer might cause hyperactivation of 
this signalling pathway, thus affording survival advantage to tumour cells, even in the 
presence of anti-oestrogen drugs
46
. 
PRMT Deregulation in cancers 
PRMT1 
Overexpressed and/or aberrantly spliced in 
breast, prostate, lung, colon and bladder cancer 
and leukemia 
PRMT2 
Overexpressed in breast cancer and correlated 
with ERα-positive status 
PRMT3 
Breast tumors may display higher levels of 
PRMT3 activity owing to DAL1 loss 
CARM1 
Overexpressed in breast, prostate and colorectal 
cancers 
PRMT5 
Overexpression or increase enzymatic activity 
observed in gastric, colorectal and lung cancer, 
and lymphoma and leukemia  
PRMT6 Overexpressed in lung and bladder cancers 
PRMT7 
Gene expression meta-analysis identified PRMT7 
as a candidate gene involved in breast cancer 
metastasis 
PRMT8 
Somatic mutations were found in ovarian, skin 
and large intestine cancers 
Table 3.1. Aberration of PRMTs and cancer. 
PRMT4/CARM1 (Co-activator-Associated-Arginine-Methyltransferase 1) was the first 
PRMT to be associated to the regulation of genes expression, its ability to methylate 
histonic arginines (H3R17me2a and H3R26me2a), which is correlated with transcriptional 
activation
5
, provides a direct mean to insert into the epigenetic marks network. Moreover, 
being able to methylate the histone acetyltransferases (HATs) CREB-binding protein (CBP 
or CREBB) and p300, it indirectly controls their epigenetic output
47,48
. In general CARM1 
mediated methylation of CBP leads to an increase of its activity. On the contrary the 
methylation of p300-R2142, in its C-terminal domain, inhibits the interaction with the 
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Glucocorticoid Receptor-Interacting Protein 1 (GRIP1), which is necessary for the cell 
cycle arrest in response to DNA damage, whereas the methylation of R754 in the KIX 
domain, lead to the induction of the cell cycle regulator p21
49
. It’s nowadays well accepted 
that CARM1 levels are elevated in castration-resistant prostate cancer
50,51
 and in 
aggressive breast tumours
52
. The aggressive breast tumours that overexpress CARM1 
exhibits high levels of the oncogenic co-activator AIB1, which is a well established marker 
for breast cancer and associated with poor prognosis
53
. There is a functional synergism 
between CARM1 and AIB1 in breast cancer, indeed CARM1 methylates AIB1 and 
regulates its activity and stability, while CARM1 recruitment to ERα-regulated promoters 
relies on the presence of AIB1
54
. CARM1 also play important role in colon rectal cancer, 
through its positive modulation of WNT–β-catenin-driven transcription. Depletion of 
CARM1 expression in colorectal cancer cells suppresses clonal survival and anchorage-
independent growth, supporting the clinical evidences showing that 75% of colorectal 
cancers have CARM1 overexpression
55
. 
PRMT5 is the major type II arginine methyltransferase, it was upfront recognised as a 
transcriptional repressor and it is in this framework that it has an oncogenic potential, 
owing to its capacity to induce tumour suppressor genes silencing
56
. Once recruited to the 
promoter it symmetrically dimethylates H3R8 (H3R8me2s) and H4R3 (H4R3me2s) which 
are two key repressive epigenetic marks
57,58
. Since, as previously mentioned, H4R3 is also 
the epigenetic site of action of PRMT1, which inserting a symmetrical dimethyl group 
induces a transcriptional activation; hence PRMT1 and PRMT5 exert a counteracting 
activity on gene expression just dimethylating H4R3 side chain with a different symmetry. 
PRMT5 cooperates and has been found in complex with different transcriptional factors 
such as BRG1 and hBRM
59
, Blimp1
60
, SNAIL
61
 and E2F1
62
 and seems to play a central 
role into the epithelial-mesenchymal transition (EMT) process. This process allows cancer 
cells to migrate and invade tissues much more efficiently, thus PRMT5 can be correlated 
with metastasis and therefore with tumour progression An characteristic feature of EMT is 
the loss of E-cadherin expression, which is repressed by the transcription factor SNAIL, 
which form a macromolecular complex with PRMT5 and AJUBA
63
. 
Programmed cell death protein 4 (PDCD4) is another substrate of PRMT5, it has been 
correlated with a positive outcome in different cancer types, even if there are exception to 
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this general evidence depicting PDCD4 as an oncogenic protein. In this concern PRMT5 
seems to play a pivotal role into this switch of function, as it is able to methylate PDCD4 
in its GAR motif at N terminus
64
. Moreover, PRMT5 has a regulatory role at two different 
nodes of the epidermal growth factor receptor (EGFR)–RAS–ERK signalling pathway. 
PRMT5 destabilizes CRAF (also known as RAF1) by methylation moreover EGFR is 
arginine methylated by PRMT5 at R1175, this aminoacidic modification doesn’t seem to 
affect the ligand binding to EGFR, instead it enhances subsequent phosphorylation of 
Y1173 which in turn acts as a docking site for the SH2 domain of the phosphatase SHP1, 
thus dampening EGFR signalling
65
. 
Despite the fact that most of PRMTs are constitutively active proteins, suggesting that 
these enzymes have a basal activity that does not need any PTMs or modulation, 
mechanisms for fine-tuning their activity exist and can be ascribed into: PTMs, association 
with regulatory proteins, subcellular compartimentalization, factors that influence 
enzyme–substrate interactions and microRNAs interference (miRNAs). Below, only the 
most remarkable ones will be reported. 
Post Translational Modifications (PTMs): albeit a few evidences currently report that 
PRMTs are influenced by PTMs, some studies addressing the crosstalk between 
phosphorylation and arginine methylation are arising
66,67
. For example, CARM1 (Co-
activator Associated Arginine Methyltransferase 1) is prevented from binding the S-
adenosyl-1-methionine cofactor (SAM) after being phosphorylated on S217 by a not yet 
identified kinase, thus blocking its methyltransferase activity
68,69
. Similarly, PRMT5 has 
been shown to be phosphorylated by a Janus Kinase 2 (JAK2) mutated form, (V617F), 
which is found constitutively active in most of patients with myeloproliferative 
neoplasms
70
. The phosphorylation affects the interaction with methylosome protein 50 
(MEP50) and inhibits PRMT5 methyltransferase activity
71
. However PTMs not only can 
modulate methyltransferases activity directly, but can affect the sites of methylation and 
also the methylation itself by exerting an effect on PRMTs substrates, and thus creating a 
crosstalk between arginine methylation and the other epigenetic marks: histone H3 lysine 
18 acetylation (H3K18ac) trigger the asymmetric dimethylation on H3R17me2 by 
CARM1
72,73
. Interestingly, histone 4 lysine 5 acetylation (H4K5ac) induces a shift from an 
asymmetrical to a symmetrical methylation of H4R3, by PRMT1 to PRMT5, respectively; 
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hence influencing the balance from an activating ADMA mark to a repressive SDMA 
mark at the H4R3 site
74
.  
Regulation proteins: binding of proteins with regulating factors is a very common tool 
used by cells to modulate their activity; in this concern PRMTs are not an exception. 
PRMT5 activity is strictly dependent by MEP50 interaction
75
, as previously mentioned the 
tyrosine phosphorylation of PRMT5 by a mutant form of JAK2, deeply affects its 
interaction with MEP50 and therefore its activity. Another phosphorylation of MEP50 by 
the cyclin D1-cyclin-dependent kinase 4 (CDK4) complex further stimulates PRMT5 
methyltransferase activity, prompting neoplastic growth in vitro
76
. Some binding factors 
can modulate the activity of the PRMT5-MEP50 complex itself, among them the 
SWI/SNF chromatin remodelling complex, which focuses the methyltransferase activity 
towards histonic substrates
77
, or the histone-binding protein cooperator of PRMT5 
(COPR5) which lead the MEP50-PRMT5 complex to methylate H4R3 rather H3R8
78
.  
As for PRMT1 activity, it is down-regulated by the orphan nuclear receptor TR3
79
 and its 
activity is “switched off” by the BTG1-binding chromatin assembly factor 1 (CAF1) 
complex
80
. Interestingly, PRMT1 activity has been proposed to be enhanced by the 
heterodimerization with PRMT2
81
. 
miRNA regulation: this type of regulation has been found particularly relevant for PRMT5 
mRNA levels since their 3’-untranslated regions have been supposed to be annealed by 
more than 50 miRNAs. Moreover, miRNAs like: miR-19a, miR-25, miR-32, miR-92, 
miR-92b and miR-96, are found downregulated in several lymphoid cancer cell lines
82
. 
PRMTs can also regulate the expression of miRNAs by themselves, regarding to this it has 
been proposed that PRMT1 and CARM1 could upregulate miRNAs levels in order to 
lower PRMT5 expression
83
. 
 
 
3.2 Histone Lysine Methyltransferases (HKMTs) 
As previously mentioned protein methylation may occur also on lysines and specifically 
on the ᶓ amino groups of their side chains. This covalent reversible modification is inserted 
by a distinct family of methyltransferases, called Protein Lysine Methyl Transferases 
(PKMTs). This enzymes are capable of a substrate selectivity being able to modify only 
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distinguishing lysinic residues of their substrates, and moreover of a product specificity 
being endowed to methylate these residues only to a characteristic state as mono- (me1), 
di- (me2) and trimethylated (me3). 
As well as protein arginine methyltransferases, the PKMTs catalyze the methylation 
transfer using SAM or S-Adenosyl-L-Methionine (AdoMet) as cofactor and affording SAH 
or S-Adenosyl-L-Homocysteine (AdoHcy) and the methylated substrate as products. 
More than 50 human lysine methyltransferases have been identified and characterized so 
far. According to structural and sequence criteria of their catalytic domain, these can be 
classified into two families: the DOT1-like (DOT1L) and the SET-domain-containing 
methyltransferases. To date only the DOT1L enzyme belongs to the former family, which 
is distinguished by the presence of seven-stranded β-sheet motif, which also structurally 
characterizes the PRMTs family
84
. Another aspect that makes DOT1L unique is the fact 
that it is the only methyltransferase catalyzing the methylation reaction of Lysine 79 on 
histone H3 (H3K79), which differs from the other lysines as it is located in the inner part 
of the nucleosomes. H3K79 methylation is a transcriptional activating histone mark 
playing pivotal roles in early embryonic development, and DOT1L has been found 
involved in MLL translocation effects in mixed lineage leukemia
85
.  
Most of the PKMTs belong to the SET-domain-containing protein subset which is in turn 
organized into five subfamilies according to their founding member: RIZ, SET1, SET2, 
SMYD3 and SUV39
86
 (Figure 3.5). 
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Figure 3.5. Phylogenetic tree of Protein Methyl Transferases (PMTs). 
(Image courtesy of Arrowsmith C.H. et al Nature review/Drug discovery 2012) 
 
The SET domain is a sequence of 130 amino-acids and it takes its name from the 
Drosophila genes Su(var)3-9, E(z) (Enhancer of zeste) and Tritorax where it was initially 
identified
87
. Structurally it’s organised in a “thread-the-needle” folding, called pseudo-
knot, characterized by the juxtaposition of two conserved peptides, in which one of the 
motif inserts into the loop created by the other one
88
. As for the PRMTs, within the SET 
domain the substrate and the cofactor bind in different sites, flanking each other, and meet 
at the core of the domain through a narrow hydrophobic channel, where the methyltransfer 
takes place. Albeit SET domain is the responsible for the methyltrasferase activity, the 
catalysis also relies on the simultaneous presence of other domains that act as “framework” 
for the recruitment of the substrate or other partners within large multiunit complexes or 
modulate the catalytic step, like for example in the Polycomb Repressive Complex 2 
(PRC2), where the catalytic subunit EZH2 displays a methyltransferase activity only in 
complex with the non-catalytic partners EED and SUZ12. All these surrounding domains 
act like a bark around the SET sequence and can be divided into two subsets: the I-SET 
and post-SET motifs (respectively inserted within and C-terminal shifted respect to the 
SET domain) that participate to the substrate recognition and in a lesser extent to the 
cofactor binding; and the Pre-SET (cysteine-rich also referred to as a CXC domain), 
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MYND (between I-SET and SET) and CTD (C-terminal to Post-SET) domains, which are 
thought to be interfaces for the interaction with other proteins and DNA. The pre-SET 
motif, with its triangular Zn3Cys9 zinc cluster seems to play an important role also in the 
catalytic event
89
. According to this, distinct domains with different sequence and structure 
may decorate the SET fold in assorted combinations to obtain selective recruitment of 
interaction partners and therefore specific functions. Being involved in the substrate 
recognition, the I-SET and post-SET domain are always found in the SET 
methyltransferases. Even if the amino acidic sequence can change, the I-SET sequence has 
a overall conserved structural organization, while the Post-SET domain is more dynamic 
and can adopt different conformations.  
As far as the substrate recognition is concerned, different mechanistic analysis has 
displayed that the Lys- and Arg-rich electropositive histone tails and the overall 
electronegative substrate-binding groove, spatially defined by pre-formed I-SET and the 
open folded Post-SET, initially interplay through a long range electrostatic interactions. 
Once this loose complex has been formed, SAM binding induces a partially folded Post-
SET conformation which keeps close the PKMT and the substrate, allowing the sequence 
specific recognition to start. In this proposed model, the PKMT slides along the substrate 
peptide, with I-SET domain acting as a reading template. Once specific interactions have 
been established, the lysine substrate looses a proton to the solvent and fits into the 
hydrofobic channel. The loose complex thus turns into a catalytically competent 
conformation and the substrate peptide is further fasten by the Post-SET domain, which 
closes on it and shields the active site from the surrounding solvent. Owing to a tyrosine 
residue, the deprotonated ε-amino group of lysine substrate aligns its lone pair with the 
assailable methyl-sulfur bond, raising from the bottom of the channel, and methyltransfer 
takes place
90
.  
In all the available co-crystal structures with substrate peptides, an arginine side-chain, 
positioned one to four residues upstream or downstream in respect to the substrate lysine, 
makes wide-ranging interactions with a specific cleft of the I-SET domain. Both the shape 
and the position (relative to the substrate lysine) of this cleft and the structure of the active 
site are peculiar of each PKMTs and suggest that is theoretically possible to develop 
selective PKMTs inhibitors. 
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As previously stated SET-domain containing methyltransferases not only exhibit a 
substrate selectivity but also a product specificity. EZH2 has the greatest catalytic activity 
in mono-methylating the H3K27 but can achieve all three methylated states of this lysine, 
SET7/9 affords only monomethylated H3K4 (H3K4me1) after one round of catalysis, 
while G9a and GLP are either mono- and dimethyltransferases for H3K9 
(H3K9me1/me2)
91
. This product specificity can be realized on the basis of structural and 
sequence explanations: the ability to mono-, di- and trimethylate lysine substrates seems to 
be correlated to a “tyrosine-phenylalanine switch” and in general to the steric crowding of 
the hydrophobic channel, since some PKMTs (Dim5, G9a) change their specificity 
following point mutations from tyrosine to phenylalanine, and vice versa, nearby the active 
site
92
.  
The protein lysine methyl transferases exert their activity mainly on histones even if other 
proteins have been identified as PKMTs substrates
93,94,95
. A extensive example may be 
represented by the tumour suppressor protein p53, also known as the “genome guardian”, 
which can be targeted by different PKMTs with opposing cellular outcomes depending on 
the site of lysinic methylation: p53-responsive genes may be transcriptionally repressed 
after methylation at K370 by SMYD2
96
 or on K382 by SETD8
97
, while methylation of 
K372 by SET7/9 result in transcriptional activation
98
; p53 may be also inactivated because 
of the methylation on K373 by G9a and GLP
99
. 
Histones represent the main site of action of lysine methyltransferases which are therefore 
referred to as Histones Lysine Methyl-Transferases (HKMTs). As epigenetic “writers” 
they are correlated with both transcriptional activation and silencing, depending on the 
specific residue involved and on the extent of methylation, since lysine may be methylated 
up to three times. Nonetheless, generally methylation on H3K4, H3K36 and H3K79 is 
associated with activation of transcription whereas methylation at H3K9, H3K27 and 
H4K20 is correlated with transcriptional silencing
100
. Differently from the lysinic 
acetylation, whose transcription-activating mechanism is essentially based on the 
neutralization of the positive charge of the lysine side chains (which in turn interrupts the 
electrostatic interaction with phosphate groups of DNA backbone); lysine methylation 
doesn’t affect the overall charge of the residues. Methyl groups rather seem acting as 
“hubs” for the recruitment of highly evolved methyl-lysine-binding proteins able to 
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distinguish distinct level of methylation and the surrounding amino acid sequence, 
especially along histone tails. The most remarkable biological consequences of the 
enhanced specificity of HKMTs in respect to HDACs is that each component of the former 
family of enzymes controls genes expression in a narrower group of cell types, being them 
normal or cancerous, thus proving to be more promising targets for drug development. In 
this concern a multitude of evidences draw attention to the wide spreading involvement of 
HKMTs in the human diseases related biochemical pathways including oncogenic 
transformation, inflammation, metabolic and neuropsychiatric disorders, finally in the 
handling of stem cells as tools for regenerative medicine
101
.  
HKMTs may contribute to the diseases development or maintenance by gaining aberrant 
activity due to mutations, altered expression or translocations that directly affect cellular 
genes expression, or being involved in altered upstream cellular signals.  
In cancer, MLL1 (mixed –lineage leukemia 1) methyltransferase is subject of more than 50 
chromosomal translocations, especially in human lymphoid and myeloid leukemias, where 
these are associated with very poor prognosis
102
. Despite the translocations are responsible 
for the loss of the carboxy-terminal SET domain, the N-terminal fusion proteins upregulate 
expression of several target genes including HoxA7, HoxA9 and the Hox factor MEIS1 
that are important for proliferation and final differentiation of hematopoietic cells
103
. 
During normal hematopoiesis, expression of HoxA7, HoxA9 and HoxA10 promote stem 
cell self-renewal, and the downregulation of these genes correlates with terminal 
differentiation
104
. The inappropriate transcriptional activation seems to arise from the 
interplay with transcriptional elongation partners like AFF4, AFF1, AF9, and ENL, and 
with other epigenetic factors such as the methyltransferase DOT1-like protein (DOT1L). 
MLL-DOT1L and MLL-AF10 fusion proteins lead to the abnormal expression of 
leukemia-relevant genes, like Hox9A, and the transcriptional “prime” due by H3K79 
instead of H3K4 methylation, respectively own of DOT1L and MLL1 methyltransferases, 
could be the prompting signal for oncogenic transformation in hematopoietic cells
105
. 
Other MLL fusion proteins can interact with factors that promote malignancy: MLL-AF9 
fusion protein holds AF9 (also know MLLT3) capacity to recruit YEATs domain-
containing 4 (YEATS4), which is upregulated in neuroblastoma and is required for the 
aberrant inactivation of p53
106
. 
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Being composed of multipotent precursor cells interested by cellular differentiation and 
clonal expansion following a triggering stimulus (antigens), which then turn into 
specialized lymphocytes, the adaptive immune system shows all the hallmarks of a cellular 
process that can be regulated by epigenetic pathways. Though acetylation is the most 
firmly recognised histone modification playing important role in these mechanisms, the 
immune system regulation represents a new field of application of histone lysine 
methylation; in particular, G9A has been found to silence specific genes in the endotoxin 
shock through its H3K9 dimethylation
107
.   
SET-domain-containing protein 7 (SETD7) and Suppressor of Variegation 3-9 homolog 1 
(SUV39H1), two other lysine methyltransferases, contribute to hyperglycaemic memory. 
Together with LSD1, they maintain the glucose response-related upregulation of p65 gene 
(a subunit of NF-kB), which is associated with diabetic vascular injury
108
. 
Modulation of epigenetic proteins find application also in the newest regenerative 
medicine, as they can direct the differentiation of embryonic stem cells and induce a 
pluripotent stem cellular state starting from somatic cells
109
. Small modulators of 
epigenetic proteins, including HDACs, PKMTs and Histone Lysine Demethylases 
(HDMs), when associated with biological techniques like transduction with transcription 
factors (OCT3, SOX2, MYC and KLF4), give the same cellular output, improve the 
reprogramming efficacy and avoid the risk of carcinogenesis. For example the G9A 
inhibitor BIX-01294 improves the stem cell reprogramming process in neural progenitors 
when in association with only OCT3 and KLF4
110
. 
 
 
3.2.1 Enhancer of Zeste Homologue 2 (EZH2) 
Enhancer of Zeste Homologue 2 (EZH2 or KMT6A) is a SET-domain-dependent lysine 
methyltransferase whose main currently recognized activity is the sequential methylation 
(mono-, di- and trimethylation) of lysine 27 on histone 3 (H3K27). Some studies have 
displayed that EZH2 can insert also the H3K9me3 repressive mark but this point is still 
controversial
111
. Albeit all the different methylated state of H3K27 can exist at the same 
moment in a cell, the tri-methylated form is presently viewed as the predominant type that 
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mediate the biological function in vivo. Demethylated form of H3K27 is then regenerated 
by the subfamily of UTX and JMJD3 histone demethylases
112
. 
Mostly recognized as a repressive transcriptional histone mark, the methylation of H3K27 
is an epigenetic mechanism for silencing genes normally involved in cellular development 
and differentiation and in the early steps of X-chromosome inactivation
113
. According to 
this, up-regulated function of EZH2 can result in the wrong inactivation of tumor 
suppressor genes, which at the end leads to cancer
114
. Different studies have recently 
displayed that EZH2 is overexpressed and related to aggressiveness, metastasis and poor 
prognosis of a variety of solid tumors (table 3.2) including prostate
115,116
, breast
117,118
, 
bladder
119
, colon
120
 and skin
121
 cancers, glioblastoma multiform (GBM) as well as blood 
malignancies like lymphoma
122
; consequently it has stood out as an attractive anti-cancer 
drug target. 
Type of cancer Functions 
Prostate cancer 
Cellular transformation 
Proliferation 
Invasion and metastasis 
Breast carcinoma 
Cellular transformation 
Proliferation 
Invasion and metastasis 
Lymphomas Proliferation 
Myeloma 
Proliferation 
Anti-differentiation 
Bladder carcinoma 
Cellular transformation 
Proliferation 
Colon cancer Proliferation 
Cutaneous melanoma Proliferation 
Hepatocellular carcinoma 
Proliferation 
Invasion and metastasis 
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Endometrial cancer Proliferation 
Lung cancer 
Proliferation 
Anti-differentiation 
Pancreatic cancer 
Proliferation 
Anti-apoptosis 
Gastric cancer 
Proliferation 
Invasion and metastasis 
Ewing’s sarcoma 
Proliferation 
Invasion and metastasis 
Table 3.2. EZH2 aberrations and cancer. 
EZH2 mainly exerts its activity as the catalytic subunit of the Polycomb Repressive 
Complex 2 (PRC2), which is a multi-protein cluster, essentially active as chromatin 
modifier, that is highly conserved across the organisms from plants to flies and humans
123
.  
Polycomb Group (PcG) proteins include two members: the polycomb repressive complex 
1 (PRC1) and 2 (PRC2)
124
, whose transcriptional repressive outcome is counteracted by 
the activity of another big family of chromatin regulating proteins: the Trithorax Group 
(TrxG) proteins.  
PcG and TrxG proteins control the expression of genes involved in cellular early embryo 
development and differentiation (e.g. Hox transcription factors), through two opposing 
histone marks: the transcriptional repressive EZH2-dependent methylation of H3K27 and 
the activating MLL (Mixed –Lineage Leukemia)-dependent methylation of H3K4, 
respectively
114
. Thus, PcG and TrxG proteins act together to regulate chromatin dynamics 
and to maintain differential gene expression patterns (cellular memory) throughout the life 
of a multicellular organism (Tritorax group proteins are not subject of this thesis, for more 
informations see ref. 114).  
PRC2 complex includes five highly cooperative subunits: EZH2, EED (Ectoderm 
Embryonic Development), SUZ12 (Suppressor of Zeste 12), RbAp48/46 (also called 
Retino Blastoma Binding Protein 4 or RBBP4 and RBBP7, respectively) and AEBP2 
(Figure 3.6), and it silences genes primary involved in stem cell differentiation and embryo 
development. The exposed surface of the PRC2 complex offers interfaces for the 
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recruitment of other protein factors that can modulate directly or indirectly the 
methyltransferase activity or strengthen the epigenetic H3K27me3-related biological 
effect, even though they are not core components. In the former case human EZH2 can 
also associate with PHF1 (Plant Homeodomain Finger protein 1) which enhances its 
trimethyltransferase activity instead of the dimethyltransferase one
125
. 
 
Figure 3.6. Architecture of mammalian PRC2 complex and domain organization of each subunit. Domain 
“1”, binding region for PHF1 in human cells; domain “2”, binding region for SUZ12; CXC, cysteine-rich 
domain; SANT, domain that allows chromatin remodeling protein to interact with histones; SET, catalytic 
domain of EZH2; VEFS, VRN2-EMF2-FIS2-SUZ12 domain; WD, WD-40 domain; WDB, WD-40 binding 
domain; Zn, Zn-finger region. 
(Image courtesy of Tan, J. et al. Acta Pharmacologica Sinica 2014) 
EZH2 lacks a methyltransferase activity on its own but displays a robust turnover when in 
complex with two non-catalytic subunits of PRC2: namely the WD40-repeat protein EED 
and the zinc-finger protein SUZ12
126
. Among the PRC2 non-catalytic subunits, EED is the 
most characterized one since its crystal structure has been determined: it consists of a 
sequence of WD (Trp-Asp) domains that fold into a seven bladed β-propeller127. Three 
modules have been defined up to now, among them the surface on the bottom of the β-
propeller (residues 39-68) is responsible for the interaction with an N-terminal fragment of 
EZH2, while a pocket on the top of it binds H3K27me3 or other histone marks and 
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mediates the allosteric activation of EZH2
128. Concerning SUZ12 it’s still unclear how it 
cooperates to the overall activity of PRC2. However SUZ12 has a highly conserved 
domain on its C-terminus, namely VRN2-EMF2-FIS2-SUZ12 (VEFS) and it’s deletion 
prevents the SUZ12-EZH2 interplay
129
. Moreover it has been reported that the presence of 
chromatin activation marks such as H3K4me3, H3K36me2, and H3K36me3 can inhibit 
PRC2 activity if they are located in cis on the same histone peptide which is next to be 
methylated on the target lysine H3K27, and SU(Z)12 is responsible for mediating this 
inhibition in conjunction with the E(Z) SET domain
130
. About the two remaining PRC2 
components: AEBP2 is a zinc finger protein and is endowed of interfaces to bind all the 
other PRC2 subunits so it acts as a stabilizing co-factor, while the exact role of RbAp48 
hasn’t been fully unraveled yet. 
Concerning the cellular localization EZH2 is usually found into the nucleus fractions, most 
probably owing to the fact that it has nuclear localization signals (NLS), however recent 
studies have shown that in ex vivo isolated thymocytes EZH2 fractions are present also in 
cytoplasm
131
. Next generation sequence analysis have deeply assisted the discovery of 
mutations of KMTs in cancer and even if in rare cases EZH2 heterozygous mutations have 
been found in blood malignancies. Initially considered as a disactivating switch, the point 
mutation of tyrosine 641 (Y641) is presently recognized to result in a gain of function and 
it has been found in 7% of follicular lymphomas and 22% of germinal center B-cell and 
diffuse B-cell lymphomas (DLBCLs)
132
. Y641 mutants (Y641F, Y641N, Y641S, Y641H 
and Y641C) show an increased affinity for the di-methylated form of H3K27, thus 
increasing the levels of H3K27me3, while they lose affinity for the unmethylated and 
mono-methylated H3K27, characteristic of the wild type EZH2
133
. Therefore co-
expression of heterozygous Y641 mutants with wild-type EZH2 increase the overall levels 
of H3K27me3 and may functionally correspond to overexpression of EZH2. The same 
functional outcome has been observed consequently to another point mutation (A677G) in 
a very small  fraction of lymphoma cell lines (2-3%). As for the mutation of Y641, the 
replacement of alanine with glycine results in an increased affinity for H3K27me2, but 
differently the wild type-like activity on unmethylated and monomethylated substrates is 
still present
134
, so the A677G replacement leads to a mutant efficiently active on all the 
three form of H3K27. 
32 
 
One of the astonishing feature of the EZH2 (and of course of PRC2) function and activity 
as “writer” of the histone code is the strong cooperation with the other epigenetic, 
generally silencing, enzymes. Comprehensive studies have indeed shown that there are 
physical and functional links between EZH2, the polycomb repressive complex 1 (PRC1), 
the DNA Methyltransferases (DNMTs) and the Histone Deacetylases (HDACs), 
strengthening the hypothesis of the existence of a wide-spreading crosstalk between 
different epigenetic factors.  
PRC1 complex is a multi-protein cluster composed of different homolog of chromo-
domain-containing proteins (CBX2, CBX4, CBX8), polyhomeotic proteins (PHC1, PHC2, 
PHC3), BMI1 and RING-finger proteins (RING1, RNF2)
135
. According to the currently 
proposed model transcription factors and their associated molecular machinery point out 
the loci to be silenced and recruit in situ the PRC2 complex to tag these promoters by 
methylating H3K27. This mark is then recognized and finally bound by the 
chromodomain-containing proteins (CBXs) within the PRC1 complex, which in turn is 
responsible of the ubiquitynation of the lysine 119 on histone H2A, strengthening the 
incipient silencing mark
136
. In addition, evidences arising from in vitro assays suggest that 
PRC1 can cooperate with PRC2-mediated transcription silencing also by blocking the 
anchoring of transcriptional activating factors
137
, and therefore the RNA Polymerase II 
(RNA Pol II) and then preventing its elongation
138
. However, the details of the molecular 
partnership between PRC2 and PRC1 are not fully unravel yet, not all the PRC2 genes are 
then bound by PRC1, and in some cases PRC1 and PRC2 have been found simultaneously 
bound to DNA, thus the sequential mechanism in which PRC2 tags loci that afterwards 
will undergo ubiquitination on H2AK119 has to be still elucidated
139
. 
The close interplay between PRC2 and PRC1 is even more evident if we consider that 
EZH2 represses the transcription of several microRNAs (miRNAs), including miR181a, 
miR181b, miR200b, miR200C and miR293, generally involved in the regulation of PRC1 
components. Repressing the transcription of this microRNAs, EZH2 in turn induces the 
de-repression or the upregulation of PRC1 proteins, therefore playing a positive 
feedback
140
. 
Concerning the functional synergism between EZH2-mediated lysine methylation and 
lysine deacetylation, HDAC1 and HDAC2 have been purified in human PRC2 
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complexes
141
, moreover PRC2-mediated transcriptional silencing is blocked by HDAC 
inhibitor TSA
142
. Taken together these biochemical data suggest that HDACs are not core 
subunit of PRC2, but can transiently associate to it and have a positive influence on 
histone lysine methylation. In this view, since a lysine can’t be methylated as far as it’s 
acetylated on its side chain, HDACs could directly deacetylate H3K27 to make the ε 
amino group available for methylation by PRC2 or alternatively HDACs could modify the 
surrounding histone marks (on H3K9, H3K14, H4K8 for example) to allow the following 
H3K27 methylation
143
 (Figure 3.7).  
Although DNA methylation has been thought for a long as an independent genes silencing 
mechanism, a pioneering study
144
 showed that PRC2 subunits (EZH2 and EED) co-
immuneprecipitated with human DNMTs (DNMT1, DNMT3A, DNMT3B)
145
. Following 
studies on stem cells displayed that genes undergoing H3K27 methylation by EZH2 were 
predisposed to DNA hypermethylation on their CpG islands, as result of triggering inputs 
during the normal development, arising the hypothesis that EZH2 could prompt some 
distinct genes for the subsequent long-term transcriptional inactivation by GpC 
hypermethylation
146
. Further RNAi knockdown analysis in osteosarcoma cells exhibited 
that EZH2 presence is mandatory for DNMTs binding and the following CpG methylation 
but that, on the contrary, DNMTs are not necessary for the EZH2 recruitment, proving the 
idea that this synergism could be exploited also in cancer cells for silencing tumor 
suppressor genes. However it hasn’t been elucidated yet if the DNMTs are recruited 
directly by EZH2 through a mutual protein-protein interaction or by the methyl H3K27 
histone mark. As a whole, all these studies depict a scenario in which EZH2 tags certain 
genes for later undergoing to CpG hypermethylation, and therefore long-term silencing 
during the normal cellular development and differentiation, but this cooperation has been 
found also in cancer cells
147
 (Figure 3.7). 
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Figure 3.7. A proposed model for the synergism among epigenetic silencing enzymes, including the core 
subunits of PRC2 complex: SUZ12, EZH2, EED; histone deacetylase (HDAC) and DNA methyltransferase 
(DNMT). The hypothesis considers that if K27 is acetylated, HDAC may deacetylate it at first, then 
allowing the target genes to be then silenced through K27 methylation by PRC2 complex. DNMTs can also 
be recruited after pre-tag by EZH2-mediated methylation, and mediate long-term silencing by 
hypermethylation of CpG islands. Ac: acetylation; Me: methylation.  
(Image courtesy of Tan, J. et al. Acta Pharmacologica Sinica 2014) 
Although EZH2, by virtue of the tri-methylation of H3K27, is widely considered a 
transcriptional repressive histone methyltransferase, recent evidences have raised a new 
and functionally opposite activity of EZH2. Xu et al
148
 reported that the oncogenic 
function of EZH2 in castration-resistant prostate cancer relies on a transcriptional 
activation rather than on silencing of its target genes and moreover this activation is PRC2 
independent. As proof of concept, they showed that in hormone-refractory prostate cancer 
cells a subset of EZH2-responsive genes didn’t bind SUZ12 subunit neither exhibited 
H3K27me3 histone mark, moreover some of these genes were transcriptionally silenced 
after EZH2 knockdown and EZH2 methyltransferase activity was determinant for 
androgen-independent growth. 
In the effort to explain this unexpected result Xu et al hypothesized that EZH2 may shift 
it’s activity, from a polycomb repressive to a transcriptionally activating outcome, after the 
PI3K-Akt phosphorylation on its Ser21. The phosphorylated EZH2 then could methylated 
the Androgen Receptor (AR) or other associated proteins, enabling the activation of its 
target genes. This finding reveals a new role of EZH2 in the methylation of non-histone 
proteins and prompts the possible development of inhibitors that selectively target the 
activating function of EZH2 in hormone refractory prostate cancer cells (Figure 3.8).  
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Figure 3.8. A proposed model of the functional switch from a 35olycomb repressor to a transcriptional 
activator in castration-resistant prostate cancer. 
(Image courtesy of Tan, J. Et al. Acta Pharmacologica Sinica 2014) 
EZH2 establishes thick interplays not only with other epigenetic effectors as previously 
mentioned, like PRC1, HDACs and DNMTs, but also with different transcriptional factors, 
enzymatic modulators and signaling effectors. In this view, one clear example is 
represented by the interrelation between EZH2 and p53. This well established tumor 
suppressor has been found in correspondence of the EZH2 promoter, where it represses its 
expression maintaining the genetic stability. One of the implications of this evidence could 
be that cancer progression associated with loss of p53 can be partially attributable to the 
increased activity of histone methylation as a consequence of EZH2 de-repression
149
. 
Furthermore, Myc transcription factor has been proved to influence EZH2 cellular levels 
by two different mechanisms. It directly binds to the EZH2 promoter, thus increasing the 
mRNA amount of EZH2, whereas it is simultaneously capable to repress transcription of 
the host gene encoding miR-26a and miR-26b, which exert a negative control on the EZH2 
mRNA. Both these mechanisms have been found to contribute to prostate cell 
transformation and carcinogenesis
150,151
. 
E2F, a target of the reti-noblastoma protein (pRB), plays a critical role in regulating cell 
cycle progression through activating genes that control entry into the S phase and genes 
associated with DNA replication, in this concern, after phosphorylation of pRB, E2F turns 
activated and binds to the promoter of EZH2 and EED, positively modulating their 
expression.
152
. 
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EZH2 expression is also controlled by hypoxia through HIF response elements (HRE) in 
the EZH2 gene promoter In hypoxic microenvironment, EZH2 expression is increased and 
thereby promotes proliferation of breast tumor initiating cells
153
. 
 
3.2.2 EZH2 aberrations and cancer 
Soon after the discovery of EZH2 and its characterization as an histone modifying enzyme, 
many reports appeared displaying it as deeply involved in cancer cells transformation and 
maintenance. Generally EZH2 is not expressed in adult tissues, but its aberrations, coming 
from mutations, overexpression, hyperactivation are correlated with aggressiveness, 
metastasis, and poor prognosis in most of the above mentioned cancers, among these, 
altered EZH2 activity has been most completely described in prostate and breast cancer. 
Apart from some exceptions, as the recently reported co-activator function in castration-
resistant prostate cancers, EZH2 oncogenic properties in cancer tissues rely on the 
silencing of genes that promote differentiation, restrain proliferation and arrest cell cycle 
progression.  
Gene profiling studies ranked EZH2 as the most significant gene up-regulated in 
metastatic prostate cancer compared to clinically localized prostate cancer
154
. Loss of 
EZH2 gene inhibits growth of prostate cancer cells while its over-expression led to 
silencing of a set of more 100 target genes, whose expression is dependent on a fully active 
SET domain. All these findings suggest that EZH2 methyltransferase activity is essential 
for its oncogenic function in prostate cancer cells and seems to be related to its lysine 
chromatin hypermethylation. EZH2 levels could provide a valuable prognostic indicator of 
patient outcome too and subsequent studies have described the prognostic value of 
combined sets of prostate markers that include EZH2 overabundance. Another report 
focused on the interplay between EZH2 and androgen signaling cascade, showed that 
EZH2 expression is repressed by androgens and this repression requires a functional 
androgen receptor (AR). Thus a controversial hypothesis on EZH2 involvement in 
castration-resistant prostate cancer could be that its oncogenic role may implicate the 
activation of AR-repressed genes as EZH2 is frequently overexpressed in hormone-
refractory prostate cancers.  
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EZH2 expression has been shown to be negatively modulated at the post-transcriptional 
level by miRNAs. This represent another proof of involvement of EZH2 in prostate cancer 
since over the years miR-101, miR-26a, and miR-26b have been found significantly 
decreased in prostate cancer through miRNA profiling studies
155,156,157
.  
One of the characteristic genetic signature in prostate cancers is the fusion between the 
androgen-responsive TMPRESS2 promoter and the ERG coding sequence, this fusion 
gene is able to substantially upregulate ERG expression, which at the end run to cell 
proliferation and invasion
158
. In this concern, a milestone in supporting EZH2 involvement 
in prostate cancer is that ERG can directly activate EZH2, which synergistically result in 
cancer progression through a process of de-differentiation associated with histone 
methylation
159
. Among the multitude of silenced genes it was demonstrated that EZH2 can 
activate Ras and NF-κB pathway by epigenetically repressing the expression of homolog-
2-interacting protein (DAB2IP), which is a negative modulator of the aforementioned 
signaling pathways
160
, thus turning at the end to promotion of initiation and metastasis of 
prostatic tumors. Moreover, EZH2 can trigger cancer cell invasiveness and progression to 
advanced tumor stage by silencing CDH1 gene, which encodes for the epithelial marker E-
cadherin, whose loss often prompts epithelial-mesenchymal transition
161
. Likewise, 
another mechanism by means of EZH2 can stimulate progression in prostate cancer is the 
downregulation (by trimethylation of H3K27) of MSMB gene, which encodes for PSP94 
that is known to promote prostatic tumor cell apoptosis, to inhibit secretion of matrix 
metalloproteinases (MMPs) and decrease VEGF-mediated angiogenesis
162
. 
A direct link between EZH2 and the MMPs TIMP2 and TIMP3, which are tissue inhibitors 
of metalloproteinases has been recently uncovered. This further evidence strengthens the 
idea that EZH2 can lead to degradation of extracellular matrix (ECM) and subsequently 
cell invasion in prostate cancer
163
. 
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Figure 3.9. EZH2 regulation and function in prostate cancer. 
(Image courtesy of Yang, Y.A. et al. Protein Cell 2013) 
 Aberrantly elevated EZH2 levels have been described to be deeply linked with 
invasiveness and increased cellular proliferation in breast carcinomas too. Likewise for 
prostate cancer, it has been proposed that EZH2 could be a promising biomarker for 
aggressive breast cancers with a poor prognosis and that it can be an independent indicator 
of clinical outcome.  
One of the most common molecular aberration in breast cancer is the mutation of BRCA1, 
which is responsible for the onset of basal like breast carcinomas that are ER, PR and 
Her2-neu negative and which intriguingly are characterized also by increased levels of 
EZH2
164
. Germline Brca1 mutations are also reliable prognostic markers for breast cancer 
in women, and this is partly due to the BRCA1’s role in DNA repair and genomic stability 
as well as in estrogen receptor modulation
165
. EZH2 overexpression inhibits BRCA1 
phosphorylation at Ser1423 thus promoting an increase of Cdc25C, an essential player for 
G2/M checkpoint control, which leads to the end to cell progression into cell cycle. This 
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evidences support the hypothesis that elevated EZH2 concentrations in ER-negative breast 
cancer cell lines confer increased cell proliferation partly through the inhibition of BRCA1 
phosphorylation
166
. A member of runt-related (RUNX) family of transcriptional factors: 
RUNX3 has been found functionally correlated with EZH2. Inactivation of RUNX3 
expression through DNA hyper-methylation has been reported in various cancers, 
including those of prostate, lung and pancreas, but intriguingly upon EZH2 levels 
reduction in MCF-7 breast cancer cell line, RUNX3 expression was recovered. RUNX3 
expression also increased upon treatment with the deacetylase inhibitor TSA, therefore it 
has been suggested that RUNX3 downregulation may be controlled by H3K27me3 through 
EZH2 and HDAC1
167
. RUNX3 reduction leads to the decrease of the cyclin-dependent 
kinase inhibitor p21WAF/Cip1 expression, which finally results in the induction of cell 
proliferation in breast cancer
168
. 
The Wnt signalling pathway, which regulates the ability of the β-catenin protein to prompt 
the activation of specific target genes, is nowadays gaining momentum as an important 
cause of the development of different human cancers
169
. DACT3, a Wnt antagonist 
interacting with Dishevelled, has been found transcriptionally repressed in colorectal 
cancer
170
, upon H3K27me3 chromatin modification, this lead to the activation of Wnt/ β-
catenin signalling, allowing cancer cells to escape from apoptosis
171
.  
 
 
3.3 Targeting Histone Arginine and Lysine Methyltransferases 
Over the past decade, knowledge of the proteins involved in the post-translational 
modification of histones has grown tremendously, and this is due not only to the intense 
efforts made by cell biologist in unrevealing the tangled epigenetic pathways but also to 
the development of small molecules able to modulate this molecular targets. These 
proteins includes several families of related enzymes and chromatin-interacting proteins, 
and are a rich source of potential therapeutic targets. Despite that, only four drugs have 
been developed up to now, including DNMT inhibitors 5-azacytidine (Vidaza
R
) and 
decitabine
172
 (20-deoxy-5-azacytidine, Dacogen
R
) and the histone deacetylase (HDAC) 
inhibitors suberoylanilide hydroxamic acid
173
 (SAHA, Zolinza
R
) and the natural product 
romidepsin
174
 (Istodax
R
) (Figure 3.10). 5-azacytidine and decitabine were approved by the 
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FDA for treatment of haematological malignancies like acute myeloid leukemia and 
myelodysplastic syndrome, while SAHA and romidepsin are currently second line 
therapeutic options for the treatment of cutaneous T cell lymphoma (CTCL). 
 
Figure 3.10. Structures of approved drugs addressing epigenetic targets 
These DNMT inhibitors are nucleoside structures and are characterized by a low 
specificity to DNMTs and tumor cells too, on the other hand histone deacetylases have 
broad substrate specificity, being involved in the modification of different proteins, 
including many non-histone proteins that are not involved in epigenetic regulation
175,176
. 
Consequently, the “proof of concept” supporting the theory of epigenetic therapies using 
DNMT and HDAC inhibitors for specific cancer treatment, is still far away from being 
accomplished. In contrast to HDACs and DNMTs that generally control gene expression 
on different cell types, recent evidences pointed out that histone arginine/lysine 
methyltransferases (PRMTs and HKMTs) and histone lysine demethylases (KDMs) may 
affect gene expression in specific way non only in normal cells, but in cancerous cells 
too
177
. 
Moreover, HMTs and KDMs are frequently affected by genetic alterations in cancer cells 
including chromosomal translocations, gene mutations and fusion proteins, which recently 
have been linked to oncogenic transformation by loss of tumor suppressing functions, as 
well as linked to the developmental plasticity of cancer cells. Taken together, these 
observations strengthen the hypothesis that targeting aberrant HMTs and KDMs in cancer 
may achieve a higher degree of specificity in epigenetic therapy and prevention by 
blocking tumor specific epigenetic alterations or mutations. 
The first non-nucleoside specific inhibitors of PRMTs were discovered in 2004 by Bedford 
and co-workers
178
, through a random screening approach of 9000 compounds from 
ChemBridge, using RNA binding protein, Npl3p, as substrate of the yeast Hmt1p arginine 
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methyltransferase (Figure 3.11). The hits found were named Arginine Methyltransferase 
Inhibitors (AMIs) and were able to inhibit  the human PRMT1 with potency ranging from 
0.19 to 16 µM. Further studies were carried out to determine specificity among the nine 
active compounds, thus AMIs were tested on a set of PRMTs. In this concern AMI-1 arose 
as a selective type II PRMT5, but afterwards it showed, even if in less extent, activity over 
some lysine methyltransferases like Suv39H1, Suv39H2, SET7/9 and DOT1L and some 
Sirtuins (class III histone deacetylase)
179
. 
 
Figure 3.11. Structures of Arginine Methyltransferases Inhibitors (AMIs) 
Several groups have used AMIs as leads for PRMTs drug discovery programs and in 
particular their bromo- and dibromo phenolic moiety have been object of structural 
simplification approaches which at the end led to the synthesis of a number of analogs 
exhibiting selectivity for PRMT4 over PRMT1 and SET7/9 at a concentration of 100 
µM
180,181
 (1, Figure 3.12). 
Following attempts by Bonham and co-workers to develop a less polar analog of AMI-1 
prompt them to synthesize a scaffold bearing structural elements from AMI-1, like 
aminonaphtol sulfonate, decorated with elements from AMI-6 and AMI-9
182
. The most 
potent compound obtained was compound 2 (Figure 3.12). 
 
Figure 3.12. Structures of analogues obtained by AMI-5 
Further hit discovery programs also made use of target based virtual screening study for 
PRMTs Spannhoff and co-workers
183,184
, in 2007, virtually screened hPRMT1 and fungal 
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RmtA, a PRMT1 homologue, against the NCI diversity subset (1990 compounds). 
Compounds that were successfully docked, were then tested in vitro against RmtA and 
recombinant hPRMT1. In this study, seven of the 36 virtual hits were able to inhibit RmtA 
and hPRMT1 with micromolar potency (IC50 hPRMT1 = 2–90 μM). Two of the hits, 
allantodapsone and stilbamidine (Figure 3.13), exhibited inhibition of methylation at the 
PRMT1 target H4R3 in a dose-dependent manner with only a marginal effect on 
methylation levels of PKMT target H3K4. In addition, kinetic assays showed 
allantodapsone and stilbamidine did not inhibit RmtA in a SAM-competitive manner but 
were rather competitive with regard to the histone substrate. On the follow up of this 
approach, ChemBridge compound collection, containing 328.000 compounds, was used in 
another virtual screening study and a after a first filter using a pharmacophore search, nine 
inhibitors of PRMT1 were found (with an IC50 rangin from 13 to 37 μM). The three most 
potent compounds are depicted as follows, together with the Allantodapsone and 
Stilbamidine. 
 
Figure 3.13. Arginine methyltransferase inhibitors obtained by virtual screening approach. 
Chaetocin, a fungal mycotoxin (Figure 3.14), was the first small-molecule inhibitor of 
recombinant Drosophila Su(var)3-9 (IC50 = 0.6 µM) to be identified in 2005, after a 
screening of a library of ca. 3,000 compounds using a standard radioactive filter-binding 
assay.
185
 Chaetocin was also found to inhibit H3K9 PKMT SUV39H1 (IC50 = 0.8 µM), the 
human orthologue of Su(var)3-9. Subsequently mechanistic studies unravelled chaetocin 
mechanism as a SAM-competitive inhibitor, which remained active even after the 
reduction of disulfide bonds. 
43 
 
The first selective small-molecule inhibitor of G9a and GLP: BIX01294 (Figure 3.14), was 
identified by a high throughput screening of ca. 125,000 compounds from the Boehringer 
Ingelheim  compounds collection. It showed also weaker potency in vitro assay (not below 
45 μM ) over other H3K9 PKMTs including SUV39H1 and SETDB1, H3K4 PKMT like 
SET7/9, and arginine methyltransferase PRMT1
186
. In vitro experiments attested that 
BIX01294 inhibited G9a and GLP with IC50 values of 1.9 μM and 0.7 μM, respectively 
whereas in cellular assays BIX01294 exhibited toxicity at a concentrations of more than 
4.1 μM. 
As a proof of concept for BIX01294 selectivity, when cells were treated at an inhibitor 
concentration of 4.1 μM, it reduced H3K9me2 levels of bulk histones, while methylation  
levels of other lysine residues, including H3K27, H3K36, and H4K20, remained 
unaffected. Subsequent X-ray crystal structure studies of GLP in complex with BIX01294  
(PDB: 3FPD) have revealed that differently from chaetocin, it didn’t act as a SAM-
competitive inhibitors but rather interact with the histone peptide binding pocket. The 
same X-ray structure revealed that while BIX01294 did not bind in the SAM-binding site, 
it also did not fits into the lysine binding channel
187
. Through the same aforementioned 
approach were also discovered non-selective Lys and Arg methyltransferase inhibitors like 
BIX01338 (Figure 3.14). 
 
Figure 3.14. Structure of Chaetocin and of first inhibitors developed by Boehringer Ingelheim 
Starting from crystal structure of GLP in complex with BIX01294, structure activity 
relationships studies were carried out, and in this concern the 7-methoxy moiety of the 
quinazoline scaffold was investigated with the aim to design analogs that would interact 
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with the lysine channel. Using the G9a ThioGlo assay, these efforts led to the 
identification of  UNC0224 (Figure 3.15), which is a seven times more potent G9a 
inhibitor (IC50=15 nM) in comparison with BIX01294 (IC50=106 nM), this result was also 
confirmed by isothermal titration calorimetry too
188
. UNC0224 proved to be 1000 fold 
selective over other PKMTs, such as SET7/9 and SETD8 and over a broad panel of G-
protein coupled receptors, ion channels and transporters, however it exhibited a G9a-like 
potency against GLP (IC50=20 nM). Nonetheless UNC0224 represents the first small 
molecule inhibitor with a high resolution (1.7 Å) X-ray co-crystal structure (PDB: 3K5K) 
in complex with G9a and showing the 7-dimethylamino propoxy side chain occupying the 
lysine binding channel of G9a. 
UNC0321 (Figure 3.15), the most potent G9a inhibitor to date (IC50=6 nM with 
AlphaScreen; 9 nM, in ThioGlo assay) was developed starting from the evidences that 7-
alkoxy side chain did not completely occupy the lysine binding channel. Further SAR 
studies of the 7-alkoxy side chain of UNC0224 were made to explore the space left in the 
channel and led to the synthesis of analogs bearing a longer side chain
189
. 
Differently from UNC0224, UNC0321 showed some selectivity for G9a (IC50=6 nM, with 
AlphaScreen) over GLP (IC50=23 nM) and exhibited specificity over other PKMTs, like 
SET7/9 and SETD8, as well as PRMT3 (IC50> 40µM in ThioGlo assay). 
To overcome UNC0321 poor cellular activity and improve membrane permeability new 
series of analog compounds were designed and synthesized. Among them UNC0638  had 
excellent in vitro potency (Morrison Ki G9a = 3.7 nM; Ki = 3.0 nM) and was more then 
100-fold selective over different epigenetic and non epigenetic targets
190
. As well as its 
precursors, like UNC0224, the newly synthesized UNC0638 (Figure 3.15) occupied the 
substrate  binding groove and lysine binding channel and  not the SAM binding pocket, as 
the X-ray crystal structure of the G9a-UNC0638-SAH complex (2.56 Å resolution, PDB: 
3RJW) confirmed. UNC0638 excellent biochemical properties corresponded to good 
cellular activity too. Treatment of a variety of cell lines with UNC0638 led to the reduction 
of global H3K9me2 levels but more importantly it reduced the H3K9me2 mark at the 
promoter of known G9a-regulated endogenous genes and did not reduce the H3K9me2 
mark at the promoter of a non-G9a-regulated gene, proving its selectivity in cellular assays 
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too and making UNC0368 a valuable tool for further investigating the biological function 
of G9a its role in health and disease. 
Another potent G9a inhibitor, discovered by Chang and co-workers on the follow up of the 
previous quinazoline scaffolds was E72 (Figure 3.15). It exhibited high activity on G9a 
and GLP (IC50 GLP=100 nM) with binding affinities determined by ITC (Kd GLP=136 
nM; Kd G9a=164 nM) and it was also crystallized in GLP in presence of SAH (resolution 
2.19 Å, PDB: 3MO5). Resolution of co-crystal structure showed that E72 occupied both 
the surface of the peptide binding cleft and the lysine binding channel similar to UNC0224 
with G9a
191
. 
 
Figure 3.15. Structures of G9a and GLP inhibitors 
Even more efforts have been done to target selectively DOT1L methyltransferase and 
different inhibitors have been found, all of them competing with the enzyme SAM cofactor 
and sharing a common adenosine scaffold. Different research groups attempted to 
developed selective and potent inhibitors of DOT1L
 
(for more details see Ref. 71) but 
currently only one molecule is in phase I clinical trial for patients with MLL-rearranged 
leukemia: EPZ5676 (actually it’s the only HMT inhibitor to be evaluated in a clinic). 
Modification of the urea-containing inhibitor EPZ004777 (Ki=0.3 nM, Figure 3.16) led to 
the identification of EPZ5676 possessing an increased potency (Ki=0.08 nM) and 
selectivity, over a panel of eight HMTs (only weakly active against PRMT5). The -
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CH2CH2CH2- linker and the 4-tert-butylphenyl substituted urea moiety of EPZ4777 were 
replaced with a  cis-ethylcyclobutane linker and a 5-tert-butylbenzimidazole ring in order 
to reduce conformational flexibility and hydrogen bond donors
192
. 
 
Figure 3.16.  Structures of selective DOT1L inhibitors developed by Epizyme. 
As far as the EZH2 inhibitors are concerned, till 2012 only a few inhibitors were known 
but these exhibited low potency and poor selectivity. Among them 3-deazaneplanocin A 
(DZNep, Figure 3.17), a S-adenosylhomocysteine hydrolase inhibitor, stunts EZH2 activity 
and induces the decrease of H3K27me3 levels. DZNep interferes with S-
adenosylmethionine and SAH metabolism being an inhibitor of S-adenosylhomocysteine 
(SAH) hydrolase and its mechanism is believed to be related to the increased cellular SAH 
concentration, an inhibitory byproduct of cellular methyltransferase reactions, which at the 
end leads to the degradation of the PRC2 complex
193
. DZNep treatment can induce 
apoptosis in breast and colon cancer cells
194
, however the interpretation of induced cellular 
phenotypes is complicated as DZNep reduces methylation at multiple histone residues 
targeted by different protein methyltransferases, in addition to EZH2. As a proof of the 
close epigenetic interaction between EZH2 methyltransferase activity and other histone 
marks like the aforementioned acetylation and DNA methylation, it has been reported that 
DZNep is synergistic with histone deacetylase inhibitors and DNA methyltransferase 
inhibitors in the activation of silenced genes
195
. 
SAH, the universal product of SAM hydrolysis, can also be used as EZH2 inhibitor (Ki 
=75μM, IC50=0.1–20μM) but because of its own nature it suffers of poor selectivity 
against the other methyltransferases. As well DZNep, the natural product sinefungin 
(Figure 3.17) is another nonspecific SAM analog that has similar potency (IC50=0.1–
20μM)196.  
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Figure 3.17. First generation of EZH2 inhibitors addressing the SAM binding pocket 
Soon after an high-throughput screening program in 2012, different SAM-competitive 
potent inhibitors, with Ki value in the low nanomolar range, were identified, all of them 
bearing a 4,6-dialkyl-pyrid-2-one scaffold.  
EPZ005687 (Figure 3.18) was the first highly selective SAM-competitive EZH2 inhibitor 
to be announced. It has a Ki value of 24 nM and is over 500-fold more selective for EZH2 
versus 15 other PMTs (Protein Methyltransferases) and 50-fold more selective for EZH2 
versus the closely related enzyme EZH1. Treatment of lymphoma cells bearing an EZH2 
Tyr641 or Ala677 mutation with EPZ005687 leads to concentration-dependent cell killing, 
whereas this shows minimal effects on the proliferation of lymphoma cell lines containing 
wild-type EZH2
197
. 
EI1, another highly potent inhibitor of EZH2 developed by Novartis (Figure 3.18), shows 
comparable  selectivity with a low Ki value (approximately 13 nmol/L, IC50=15nM ). EI1 
exhibited equal activity against both wild type and the Y641 mutant form of EZH2, and 
the inhibition of the EZH2 Y641 mutant in B-cell lymphomas leads to decreased 
proliferation, cell cycle arrest, and apoptosis
198
. 
Further improvements into the SAR studies led to the most potent inhibitor of EZH2 as yet 
identified. GSK126 (Ki= 0.5–3nM, Figure 3.18) has a selectivity more of 1000-fold higher 
over 20 human methyltransferases containing SET or non-SET domains, and it is over 
150-fold more selective for EZH2 than for EZH1. GSK126 efficacy has been evaluated on 
EZH2 mutants in DLBCL cells and more importantly in studies on animals, where it 
inhibits the growth of EZH2-mutant DLBCL xenografts in mice
199
. 
UNC1999 (Figure 3.18), an analogue of GSK126, represents the first orally bioavailable 
inhibitor that has high in vitro potency against wild type and mutant EZH2 over a broad 
range of epigenetic and non-epigenetic targets. UNC1999 potently reduced H3K27me3 
levels in cells (IC50<50nM) and selectively killed DLBCL cell lines harboring the Y641N 
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mutation
200
. Since no crystal structure of EZH2 is available at the moment, it is still not 
clear how structural changes contribute to the high selectivity of GSK126 (over 150-fold) 
versus UNC1999 (approximately 10-fold) for EZH2/EZH1. 
In 2013, Epizyme announced the development of a new compound: EPZ6438 (Figure 
3.18), with a superior potency and pharmacokinetic properties relative to their previously 
described tool compound EPZ005687. EPZ6438 inhibits the activity of human wild-type 
EZH2 with an inhibition constant (Ki) value of 2.5±0.5 nM, and in a similar extent, all its 
mutant forms. It exhibits excellent selectivity (more than 4500-fold) over a panel of 14 
HMTs and of 35-fold over EZH1. It displayed apoptotic effects and induced differentiation 
on SMARCB1-deficient rabdoid tumor cells, leading to dose-dependent decreasing of 
trimethylation levels of lysine 27 on histone H3 and prevention of tumor regrowth after 
dosing cessation
201
. 
Although EZH2 inhibitors are not currently approved for treatment of human diseases, on 
February 2014 successful pre-clinical trial outcome of candidate EPZ6438 on genetically 
defined Non-Hodgkin lymphoma has been made available, strengthening the assessment of 
EZH2 as an attractive anti-tumor target. 
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Figure 3.18. Structures of second generation of selective EZH2 inhibitors addressing the SAM binding 
pocket. 
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4. DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF 
NOVEL EZH2 HISTONE METHYLTRANSFERASE INHIBITORS 
As previously stated in 2004 Cheng and co-workers first reported some dye-like small 
molecules as inhibitors of PRMTs and HKMTs
202
. In particular they described AMI-1 (see 
above in the arginine and lysine methyltransferase inhibitors paragraph) as the first 
specific PRMT inhibitor and AMI-5 also known as Eosin (Figure 4.1) as a potent but not 
selective inhibitor of different epigenetic enzymes. As part of previous medicinal 
chemistry projects, AMI-5 structure was selected as template to design and to develop 
series of simplified analogues, postulating the presence of two dibromo-hydroxy-phenyl 
moieties as crucial for PRMT and/or HKMT inhibitory activity
203,204
. In this concern, a 
large series of compounds bearing bis(monobromo- or bis(dibromohydroxy-phenyl 
portions separated by variously substituted spacers were synthesized (Figure 4.1) and then 
tested against two PRMTs (PRMT1 and CARM1, also known as PRMT4) and against 
SET7 as representative of HKMTs family. Since the structure of the designed compounds 
reminded of chemical features typical of HAT and SIRT modulators
205,206
 such as 
curcumin and resveratrol (Figure 4.1), some of them were tested against p300 HAT and 
SIRT1/2 enzymes. From these assays, it resulted that compounds carrying two 3,5-
dibromo-4-hydroxyphenyl moieties linked through a penta-1,4-dien-3-one, 2,6-
dimethylene(hetero)cycloalkanone, 1,1-(1,3-phenylene)diprop-2-en-1-one, or hepta-1,6-
diene-3,5- dione spacer behaved as epigenetic multiple ligands (epi-MLs), inhibiting at the 
same time all the tested PRMT, HAT, and SIRT enzymes, as well as SET7
205
. Among the 
1,4-diphenylpenta-1,4-dien-3-one derivatives, those showing either a 3-bromo-4-
hydroxy/3,5-dibromo-4-hydroxy or a bis(3,5-dibromo-4-hydroxy) substitution at the 
phenyl rings (compounds 1 and 2) were epi-MLs, while the bis(3-bromo- 4-hydroxy) 
analog (3) showed PRMT1, CARM1, and SET7 inhibition, but was totally inactive against 
HATs and SIRTs.  
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Figure 4.1. AMI-5, curcumin, resveratrol and some simplified AMI-5 analogues. 
To further investigate the effect of such compounds against HKMTs, we tested compound 
1-3 against PR-SET7, G9a, and SET7/9, three HKMTs different from SET7. In particular, 
PR-SET7 is a H4K20 lysine methyltransferase highly involved in cell cycle regulation and 
progression
207
, G9a
208
 acts on H3K9 and has been found expressed in aggressive lung 
cancer cells, with its elevated expression related to poor prognosis
209
, and SET7/9 (with its 
epigenetic mark H3K4me1) has been associated to inflammatory diseases and diabetes
210
. 
As expected, 1-3 confirmed their wide inhibitory spectrum against epigenetic targets, and 
the results are reported in the following table. 
compd 
EC50, µM 
PR-SET7 G9a SET7/9 
1 17.4 44.6 31.9 
2 23.8 62.5 55.9 
3 4.3 11.0 9.6 
Table 4.1. Enzymatic activity of compound 1-3 on PR-SET7, G9a and SET7/9. 
Then, with the aim to identify selective HKMT inhibitors among this library of 
compounds, we noticed that analogs of derivatives 1-3, bearing methoxy instead of 
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hydroxyl group on the two phenyl wings of the penta-1,4-dien-3-one scaffold (4 and 5, 
Figure 4.2) as well as simplified products such as the bis(3,5-dibromo-4-
hydroxyphenyl)methanone 6 and the 4-(3- bromo- and 3,5-dibromo-4-hydroxyphenyl)but-
3-en-2-ones 7 and 8 (Figure 4.2), led to compounds inactive against PRMT1, CARM1 and 
SET7, or endowed with slight CARM1 inhibiting activity (compound 5)
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. Thus, we 
prepared the 2,6-bis(3-bromo- and 3,5-dibromo-4-methoxybenzylidene)cyclohexanones 9 
and 10 (Figure 4.2) as constrained analogs of 4 and 5, and we tested the derivatives 4-10 
against PR-SET7, G9a, and SET7/9. In addition, selected bis(bromo or dibromo-
methoxyphenyl) compounds 4, 5, 9, and 10 were tested against Enhancer of Zeste 
Homolog 2 (EZH2), to assess their capability to inhibit its enzymatic activity. Moreover, 
compounds 4, 5, 9, and 10 were tested in human leukemia U937 cells to determine their 
effects on some methylation marks, H4K20me1, H3K9me2, H3K4me1, and H3K27me3, 
related to PR-SET7, G9a, SET7/9, and EZH2 activity, respectively. Such compounds have 
been tested in the same cellular model to study their outcome on cell cycle, cell death 
induction and granulocytic differentiation.  
 
Figure 4.2. Structure of compound 4-10.  
The 2,6-bis(3-bromo- and 3,5-dibromo-4-methoxybenzylidene) cyclohexanones 9 and 10 
were prepared by condensation of cyclohexanone with 2 equivalents of the properly 
substituted benzaldehyde in presence of barium hydroxide in methanol at room 
temperature (Scheme 4.1). 
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Scheme 4.1. Synthesis of compounds 9 and 10; reagents and conditions: Ba(OH)2, CH3OH, room tempera-
ture, 2 h, 78-82%. 
Compounds 4-10 (Figure 4.2) were tested against PR-SET7 using nucleosome as a 
substrate, and against G9a and SET7/9 using in both cases the histone octamer as a 
substrate. The resulting EC50 (effective compound concentration able to inhibit 50% of the 
enzyme activity) values are reported in Table 4.2. The bis(bromo- and dibromo-
methoxyphenyl) derivatives 4, 5, 9, and 10 as well as the bis(3,5-dibromo-4-
hydroxyphenyl)methanone 6 were able to selectively inhibit PR-SET7, whereas the 4-
phenylbut-3-en-2-ones 7 and 8 were totally ineffective. Against PR-SET7, the bis(3,5-
dibromo-4-methoxyphenyl) analogs 5 and 10 displayed the highest potency, while the 
benzophenone 6 was the less potent. Selected compounds 4, 5, 9, and 10 were then tested 
against EZH2 (Table 4.2). In this assay, the human 5-component PRC2 (containing EZH2, 
EED, SUZ12, RBAP48, and AEBP2) was used as the enzyme source, and histone H3 was 
used as a substrate. Against EZH2, the bis(3-bromo-4- methoxyphenyl) derivatives 4 and, 
to a lesser extent, 9 were the most effective inhibitors, suggesting that in this case the 
bis(3,5- dibromo) substitution, respect to the bis(monobromo) substitution, is detrimental 
for the inhibiting activity. 
Compound 
IC50, (µM) 
PR-SET7 G9a SET7/9 EZH2 (IC50 or % inhibition)  
4 9.0 >250 >250 74.9 
5 3.3 >250 >250 8.7% @ 75 µM  
6 38.8 >250 >250 - 
7 >250 >250 >250 - 
8 >250 >250 >250 - 
9 10.2 >250 >250 313.8  
10 2.6 >250 164.4 6.2% @ 75 µM  
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Table 4.2. Inhibitory activity of compounds 4-10 on PR-SET7, G9a, SET7/9 and EZH2. Activity on EZH2 
was determined only for the most interesting compounds. Values are means ± SD determined from at least 
three experiments. 
Western blot analyses were performed with 4, 5, 9, and 10 at 50 M in human leukemia 
U937 cells treated for 24 h (Figure 4.3). H3 methylation marks, H3K4me1 H3K9me2 and 
H3K27me3, and H4K20me1 have been evaluated using specific antibodies. Concerning 
H4K20me1 compound 5 and, to a lesser extent, 9 and 10 displayed a signal reduction, in 
agreement with the PR-SET7 inhibitory data. Differently, H3K9me2 and H3K4me1 
expression levels appear unmodified after treatment with 4, 5, 9, and 10, according to their 
lack of G9a and SET7/9 inhibitory activity. On the other hand, H3K27me3 strongly 
decreased after treatment with 4 and 9, and was less evident with 5 and 10, in accordance 
with their different degree of EZH2 inhibition.  
 
Figure 4.3. Western blot analyses for compounds 4, 5, 9, and 10 in U937 cells: levels of H3K4me1, 
H3K9me2, H4K20me1, and H3K27me3 methylation. Ponceau Red (PR) staining of histones or total 
histone H4 were used for equal loading. 
Compounds 4, 5, 9, and 10 were tested at 25 and 50 M in human leukemia U937 cells for 
30 h, to determine their effect on cell cycle, cell death (pre-G1 peak), and granulocytic 
differentiation (Figure 4.4). In the tested conditions, only derivatives 4 (at 25 M) and 5 
(at 25 and 50 M) affected cell cycle, inducing a slight increase of the cells at the G1 
phase. At 50 mM it was not possible to analyze the cell cycle effect of 4 due to the 
extensive cell death caused. As regards cell death induction (pre-G1 peak), at 50 M 
compound 4 displayed a massive effect (near 100%, we considered a cut-off of 90%), and 
5 induced 41% of cell death. Granulocytic differentiation was evaluated by determining 
the number of CD11c positive cells with subtraction of the propidium iodide (PI) positive 
cells (% CD11c+/PI- cells). In such assay, compounds 4 and 10 at 50 M showed high 
differentiation effects, with 28 and 20% of CD11c positive cells. 
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Figure 4.4. Effects of treatment of U937 cells with 4, 5, 9, and 10 for 30 h at the indicated concentrations: 
A) Cell cycle effect; B) Cell death induction (pre-G1 peak); C) Granulocytic differentiation (CD11c 
method). 
After these preliminary studies and with aim to shed light on to the effect of the solely 
bromine atom, we prepared other derivatives, removing the 4-methoxy substitution and 
progressively introducing a bromine substitution in ortho, meta and para of the two phenyl 
rings, separated by a penta-1,4-dien-3-one as spacer. We also explored the effect given by 
the central linker, maintaining the 3 bromo substitution as fixed and inserting different 
etero-aliphatic cyclic spacers. The above mentioned compounds were prepared by 
condensating etero-aliphatic ketones with 2 equivalents of the properly substituted 
benzaldehyde in presence of barium hydroxide in methanol at room temperature, and for 
the piperid-4-onic compounds, by performing the alkylation reaction with benzyl cloride in 
presence of K2CO3 in acetonitrile at room temperature or 60 °C (Scheme 4.2).  
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 Scheme 4.2. Synthesis of bis-monobromine compounds; reagents and conditions: a) Ba(OH)2, CH3OH, 
R.T.; b) benzyl chloride, K2CO3, acetonitrile, R.T. or 60 °C 
EZH2 assays were carried out using histone H3 as substrate and afforded results showing 
this general trend for the phenyl substitution position: ortho>meta>para (Table 4.3). 
Among the tested cyclic linkers, the N-benzyl moiety afforded the best enzymatic activity 
(MC2884: IC50 = 46.4 µM) and was selected to confirm bromine substitution trend. Again, 
the bis-orthobromine analogue (MC2908) arose as the most effective derivative (IC50 = 
30.6 µM), even compared to the bis(3,5-dibromo) compound (MC2910) (Table 4.3). 
Structure 
 
Compound X/Br position IC50, (µM) or % 
inhibition 
 
MC2911 CH
2 
 16% (75 µM) 
MC2912  O  36% (75 µM)  
MC2913  S  13% (75 µM) 
MC2914  N-CH
3 
 62.6  
 
MC2887  2  7.94  
MC1945  3  14.2  
MC2886  4  44.8  
MC3084  3,5  28% (75 µM) 
 
MC2908 2  30.6  
MC2884  3  46.4  
MC2909  4  66.9  
MC2910  3,5  11% (75 µM) 
Table 4.3. Inhibitory activity on EZH2 of bis-monobromo series compounds. Values are means ± SD 
determined from at least three experiments. 
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To evaluate the activity in vivo, and specifically the effect on cell cycle and cell death (pre-
G1 peak) cellular assays on U937 cells (human leukemia) were carried out at 25 µM for an 
incubation time of 30 h, using SAHA a well known HDAC inhibitor as positive reference 
(Figure 4.5). 
In the tested conditions, N-benzyl derivatives exhibited effects on cell cycle distribution, in 
particular compound MC2908, namely the bis-orthobromine N-benzyl piperidone 
analogue, induced a strong arrest in all the cell cycle stages. Within the same series also 
the bis-meta (MC2884) and bis-para (MC2910) substituted derivative showed cell cycle 
activity, being able to lead to G1/S and G2 arrest, respectively. Among the other 
analogues, compound MC2914 elicited an arrest in G1 and G2, with no cell detected in 
phase S. Likewise, N-benzyl piperidone compounds proved to exert pro-apoptotic effects, 
with particular regard to MC2908, which exhibited an extremely robust pre-G1 
accumulation (more than 90% of the cells) in respect to the positive reference SAHA 
(Figure 4.5); this effect was so intense to require in the future a new measurement but at a 
lower concentration. 
 
Figure 4.5. Celle cycle effect and pro-apoptotic induction in U937 leukemia cells. 
To further investigate the potential of our bis-monobromo derivatives in vivo, we selected 
most active compounds: MC2887, MC1945 and MC2908, to be tested on two different 
cell lines of colon cancer stem cells (colon CSC CRO and 1.1) and glioblastoma cancer 
stem cells (GBM CSC 30P and 30PT). These two cell lines strongly resemble the 
phenotype of cancer cells responsible for the recurrence of cancer in patients, and are 
useful models to predict the activity on highly undifferentiated cancer cells that are 
characteristic of the most advanced stages in tumors. Compounds MC2887 and MC2908 
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showed comparable CC50 activity in the single digit or submicromolar range in each cell 
line of cancer stem cells and similarly to the in vitro and in vivo assay results showed 
above, they exhibited higher activity in respect to the bis-metabromine derivative 
MC1945, further confirming our initial phenyl rings substitution trend. Cellular activities 
were measured in triplicate and are reported as CC50 in Table 4.4 and 4.5. 
compd 
colon CSC CRO colon CSC 1.1 
CC50, µM slope CC50, µM slope 
MC2887 0.37 1.7 0.98 2 
MC1945 5.25 2 11.4 3.9 
MC2908 0.80 4.6 1.0 3.8 
Table 4.4. Cellular activity of compounds MC2887, MC1945 and MC2908 on colon cancer stem cells. 
compd 
GBM CSC 30P GBM CSC 30PT 
CC50, µM slope CC50, µM slope 
MC2887 1.8 3.25 1.2 3 
MC1945 27 5.4 26 2.5 
MC2908 0.9 3 2.5 1.6 
Table 4.5. Cellular activity of compounds MC2887, MC1945 and MC2908 on glioblastoma cancer stem 
cells. 
After subsequent studies on 3,5-bis(3-bromine-4-hydroxybenzylidene)piperid-4-one 
analogues, originally developed as CARM1 and PRMT5 selective inhibitors, another 
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compound (MC2298), bearing a N-(2-oxo-phenylethyl) substitution, ascended into 
prominence as EZH2 inhibiting hit compound (Figure 4.6).  
According to our previous results and knowledge on phenyl “wings” substitutions patterns, 
and in the perspective of increasing enzymatic activity on EZH2, we decided to remove the 
4-hydroxy substituent and to shift the bromine atom in ortho and meta of the phenyl rings. 
Furthermore, since we hypothesized that the enhance in activity could be due by the 
insertion of the benzoyl carbonyl group we planned to explore this effect by increasing in 
turn its distance from the phenyl substituent and the nitrogen of the piperidonic scaffold. 
Moreover we also designed some derivatives lacking the carbonyl group, thus bearing only 
a ω-phenyl aliphatic chain moiety (Figure 4.6). 
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Figure 4.6. Structure of MC2298 and MC2298-like derivatives. 
Likewise to the previously described compounds, the central nucleus was prepared by 
condensing the piperid-4-one with 2 equivalents of the properly substituted benzaldehyde 
in presence of barium hydroxide and methanol. Subsequent N-alkylation with 
corresponding chloride was performed with K2CO3 in acetonitrile at room temperature or 
heating to 60°C, whereas the N-acyl series was obtained by treating the common 
intermediate with respective acylclorides in presence of triethylamine and DCM at 0°C. 
Finally the 4-phenyl-butan-4-one derivative was achieved by reductive amination of the 
common piperidone with the proper aldehyde (Scheme 4.3). 
61 
 
 
Scheme 4.3. Synthesis of MC2298-like compounds; reagents and conditions: a) Ba(OH)2, CH3OH, R.T.; b) 
PhCO(CH2)nCl/Ph(CH2)nCl, K2CO3, CH3CN, R.T. or 60°C; c) Et3N, RCOCl, DCM, 0°C; d) (AcO)3BHNa, 
DCM, R.T. 
Compound Structure M.P. (°C) 
Solvent of 
crystallization 
Yield 
(%) 
MC3127 
 
124-126 Cyclohexane/Benzene 76 
MC3146 
 
135-137 Cyclohexane/Benzene 78 
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Compound Structure M.P. (°C) 
Solvent of 
crystallization 
Yield 
(%) 
MC3128 
 
126-128 Cyclohexane/Benzene 67 
MC3183 
 
139-141 Cyclohexane/Benzene 70 
MC3141 
 
95-97 Cyclohexane 69 
MC3187 
 
113-115 Cyclohexane 67 
MC3182 
 
98-100 Cyclohexane 60 
MC3206 
 
106-108 Cyclohexane 63 
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Compound Structure M.P. (°C) 
Solvent of 
crystallization 
Yield 
(%) 
MC3201 
 
109-111 Cyclohexane 78 
MC3207 
 
121-123 Cyclohexane/Benzene 75 
MC3208 
 
95-97 Cyclohexane 69 
MC3199 
 
100-102 Cyclohexane 71 
MC3243 
 
84-86 Cyclohexane 74 
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Compound Structure M.P. (°C) 
Solvent of 
crystallization 
Yield 
(%) 
MC3240 
 
93-95 Cyclohexane 70 
MC3268 
 
105-107 Cyclohexane 65 
MC3269 
 
120-123 Cyclohexane/Benzene 63 
MC3271 
 
93-95 Cyclohexane 67 
MC3272 
 
121-123 Cyclohexane/Benzene 75 
Table 4.6. Physico-chemical data of MC2298-like compounds. 
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Compounds were initially tested in vitro on EZH2 in single dose duplicate mode at a 
concentration of 100 µM to preliminary evaluate their activity. Assay reactions were 
carried out at 1 µM of SAM and results, expressed as percentage of inhibition, are reported 
in table 4.7. 
Compound EZH2 % inhibition 
MC3127 28.69 
MC3146 2.15 
MC3128 34.90 
MC3183 38.63 
MC3141 15.79 
MC3187 28.02 
MC3182 N.I. 
MC3206 32.62 
MC3201 28.15 
MC3207 23.31 
MC3208 37.61 
MC3199 N.I. 
MC3243 17.99 
MC3240 36.81 
MC3268 22.37 
MC3269 20.30 
MC3271 15.15 
MC3272 22.14 
Table 4.7. Enzymatic activity expressed as percentage of inhibition on EZH2. N.I: No Inhibition 
In vivo activity for described compounds was assessed on U937 cells. Evaluation on cell 
cycle, pro-apoptotic effect (pre-G1 arrest) and cytodifferetiating effect were obtained by 
treating leukemia cells for 30 hours at a dose of 25 µM of our compounds and using 
SAHA and MS-275 (also known as SNDX-275), two well known HDACs inhibitors, as 
positive references (25 µM). Cellular assessment results are displayed only for compounds 
showing most interesting compounds (Figure 4.7). As shown, compounds MC3127, 
MC3128, MC3141 and MC3187 and MC3206, namely compounds in which the 
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piperidone scaffold and phenyl ring are connected by an N-acyl bond, exhibited a strong 
G1 arrest comparable with MS275 reference, with no cell detected in S phase, except for 
the analogue MC3127 which however showed a reduced number of cells in this phase in 
comparison with the control. Likewise, these compounds also induced a robust 
accumulation in the G2 phase (around 40%), again MC3127 was the less effective in this 
sense. Compounds MC3199, MC3201, MC3207 and MC3240, derivatives obtained by N-
alkylation of piperidone and showing the carbonyl group flanking the phenyl ring, led to 
cell cycle alterations, decreasing the number of cell in G1 phase and inducing a remarkable 
arrest in G2 phase (around 40%)(Figure 4.7, A).  
Accordingly with our previously and aforementioned results, bis-orthobromine substitution 
of phenyl rings afforded higher activity in respect to corresponding bis-metasubstituted 
compounds, as can be readily appreciated comparing the cell cycle profile of MC3128 and 
MC3127 with MC3146 and MC3183, respectively bis-ortho and bis-meta derivatives of 
N-benzoyl and N-phenylacetyl analogues. Instead, out of line with the general trend bis-
ortho N-cinnamoyl analogue MC3183 showed less cellular activity in respect to the 
corresponding bis-meta compound MC3206 (Figure 4.7 A). 
Concerning the pro-apoptotic induction, all the MC2298-like compounds displayed higher 
activity in comparison to the control. Moreover compounds MC3199, MC3201, MC3207 
and MC3240, the same inducing cell cycle alteration in G1 and G2 phase, exhibited an 
outstanding pro-apoptotic activity (around 30-40%), which is comparable with the FDA 
approved drug SAHA (Figure 4.7, B). 
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Figure 4.7. MC2298-like compounds cellular assay results. A) Cell cycle effects on U937 leukemia cells. 
B) Pro-apoptotic induction on U937 cells. 
To confirm the activity of our compounds western blot analyses were performed on U937 
leukemia cells (Figure 4.8) using histone H4 and Ponceau Red as reference and SAHA and 
MS275 as negative control. Compounds were tested at 10 µM and after an exposure time 
of 15 minutes. For experimental procedure regarding the assay and the histone extraction 
see the experimental part section.  
 
Figure 4.8. Western blot analysis results. 
Experimental section 
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Chemistry. Melting points were determined on a Buchi 530 melting point apparatus. 
1
H-
NMR and 
13
C-NMR spectra were recorded at 400 MHz using a Bruker AC 400 
spectrometer; chemical shifts are reported in δ (ppm) units relative to the internal reference 
tetramethylsilane (Me4Si). Mass spectra were recorded on a API-TOF Mariner by 
Perspective Biosystem (Stratford, Texas, USA), samples were injected by an Harvard 
pump using a flow rate of 5−10 μL/min, infused in the Electrospray system. All 
compounds were routinely checked by TLC and 1H NMR. TLC was performed on 
aluminum-backed silica gel plates (Merck DC, Alufolien Kieselgel 60 F254) with spots 
visualized by UV light or using a KMnO4 alkaline solution. All solvents were reagent 
grade and, when necessary, were purified and dried by standard methods. Concentration of 
solutions after reactions and extractions involved the use of a rotary evaporator operating 
at reduced pressure of ~ 20 Torr. Organic solutions were dried over anhydrous sodium 
sulfate. Elemental analysis has been used to determine purity of the described compounds, 
that is >95%. Analytical results are within 0.40% of the theoretical values. All chemicals 
were purchased from Sigma Aldrich s.r.l., Milan (Italy) or from TCI Europe N.V., 
Zwijndrecht (Belgium), and were of the highest purity. As a rule, samples prepared for 
physical and biological studies were dried in high vacuum over P2O5 for 20h at 
temperatures ranging from 25 to 40 °C, depending on the sample melting point. 
Syntheses of compounds 4-8 was carried out as reported in literature and their chemical 
and physical data can be found at Ref. 211. 
 
General Procedure for the synthesis of the 2,6-bis(3-bromo and 3,5-dibromo-4-
methoxybenzylidene)cyclohexanones (9-10). 
Example: synthesis of 2,6-bis(3-bromo-4-methoxybenzylidene) cyclohexanone (9). 
Cyclohexanone (1.15 mmol, 0.12 mL) was added to a suspension of barium hydroxide 
octahydrate (4.6 mmol, 1.45 g) in methanol (20 mL), and the mixture was stirred for 5 
min. Then a solution of 3- bromo-4-methoxybenzaldehyde (2.3 mmol, 0.5 g) in methanol 
(10 mL) was added, and the resultant mixture was stirred for 2 h at room temperature. The 
precipitate was filtered, washed with water, dried and recrystallized by acetonitrile to 
afford the pure product. Melting point: 170-172 °C; yield: 82%; 
1
H-NMR (DMSO-d6) 
δH/ppm: 1.72-1.75 (m, 2H, cyclohexanone protons), 2.86-2.89 (m, 4H, cyclohexanone 
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protons), 3.90 (s, 6H, OCH3), 7.19-7.21(d, 2H, benzene protons), 7.55-7.59 (m, 4H, 
benzene protons and PhCH=CCO), 7.78 (s, 2H, benzene protons); 
13
C-NMR (DMSO-d6) 
δC/ppm 25.1, 26.1 (2C), 55.1 (2C), 112.1 (2C), 112.2 (2C), 128.4 (2C), 129.2 (2C), 130.9 
(2C), 132.2 (2C), 137.1 (2C), 156.2 (2C), 190.4; MS (EI): m/z [M+H]
+
: 491.98. 
2,6-bis(3,5-dibromo-4-methoxybenzylidene)cyclohexanone (10). 
1
H-NMR (DMSO-d6) 
δH/ppm: 1.73-1.76 (m, 2H, cyclohexanone protons), 2.84-2.87 (m, 4H, cyclohexanone 
protons), 3.84 (s, 6H, OCH3), 7.51 (s, 2H, PhCH=CCO), 7.83 (s, 4H, benzene protons); 
13
C-NMR (DMSO-d6) δC/ppm: 25.1, 26.1 (2C), 60.8 (2C), 118.3 (4C), 129.9 (4C), 131.9 
(2C), 132.2 (2C), 137.1 (2C), 154.2 (2C), 190.4; Recrystallized by: acetonitrile; melting 
point: 204-206 °C; yield: 78%; MS (EI): m/z [M+H]
+
: 649.80. 
General Procedure for the synthesis of 1,5-bis(2/3-bromobenzylidene)penta-1,4-dien-
3-ones, 2,6- bis(2/3-bromobenzylidene)-cyclohexanones, 3,5 bis(2/3-
bromobenzylidene)-pyranones, -thiopyranones, N-methyl and N-benzylpiperidones. 
Example: synthesis of (3E,5E)-1-benzyl-3,5-bis(3-bromobenzylidene)piperidin-4-one 
(MC 2884). 1-benzylpiperidin-4-one (1.06 mmol, 0.2 mL) was added to a suspension of 
barium hydroxide octahydrate (4.24 mmol, 1.34 g) in methanol (10 mL), and the mixture 
was stirred for 5 min. Then a solution of 3- bromo-benzaldehyde (2.12 mmol, 0.39 g) in 
methanol (10 mL) was added, and the resultant mixture was stirred at room temperature. 
After 2 hours water was added and the resulting suspension was filtered, the precipitate 
was washed with water (3 x 10 mL), dried and recrystallized by acetonitrile to afford the 
pure product. m.p.: 238-240 °C; yield: 78%; 
1
H-NMR (DMSO-d6) δH/ppm: 3.71 (s, 2H, 
PhCH2), 3.81 (s, 4H, N(CH2)2, 7.19 (s, 5H, benzene protons), 7.37-7.45 (m, 4H, benzene 
protons), 7.60-7.65 (m, 6H, benzene protons and PhCH=CCO); 
13
C-NMR (DMSO-d6) 
δC/ppm: 53.4 (2C), 64.4, 123.0 (2C), 127.2, 127.5 (2C), 128.4 (2C), 128.8 (2C), 129.6 
(2C), 130.8 (2C), 132.6, 132.7 (2C), 136.1 (2C), 140.6 (2C), 145.9 (2C), 186.0; MS (EI): 
m/z [M+H]
+
: 523.46. 
 
(3E,5E)-2,6-bis(3-bromobenzylidene)cyclohexan-4-one (MC 2911). 
1
H-NMR (DMSO-
d6) δH/ppm: 1,73 (m, 2H, cyclohexanone ring), 2.88 (m, 4H, cyclohexanone ring), 7.41-
7.44 (m, 2H, PhCH=CCO), 7.54-7.61 (m, 6H, benzene protons), 7.73 (s, 2H, benzene 
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protons); 
13
C-NMR (DMSO-d6) δC/ppm: 22.7, 25.3 (2C), 115.1 (2C), 126.9 (2C), 128.0 
(2C), 130.8 (2C), 131.5 (2C), 135.2 (2C), 138.8 (2C), 185.4; recrystallized by 
benzene/acetonitrile; for m.p. see literature
212
; yield 69%; MS (EI): m/z [M+H]
+
: 429.87. 
 
(3E,5E)-3,5-bis(3-bromobenzylidene)dihydro-2H-pyran-4(3H)-one (MC 2912). 
1
H-
NMR (DMSO-d6) δH/ppm: 4.91 (s, 4H, O(CH2)2, 7.43-7.45 (m, 4H, benzene protons), 
7.65-7.69 (m, 6H, benzene protons and PhCH=CCO); 
13
C-NMR (DMSO-d6) δC/ppm: 67.3 
(2C), 123.0 (2C), 127.5 (2C), 129.6 (2C), 130.8 (2C), 132.7 (2C), 136.1 (2C), 143.8 (2C), 
146.1 (2C), 186.0; recrystallized by benzene/acetonitrile; m.p. 170-172 °C: yield: 83%; 
MS (EI): m/z [M+H]
+
: 433.93. 
 
(3E,5E)-3,5-bis(3-bromobenzylidene)dihydro-2H-thiopyran-4(3H)-one (MC 2913). 
1
H-NMR (DMSO-d6) δH/ppm: 3.97 (s, 4H, O(CH2)2, 7.41-7.45 (t, 2H, benzene protons), 
7.53-7.57 (m, 4H, benzene protons), 7.61-7.63 (d, 2H, benzene protons), 7.73 (s, 2H, 
PhCH=CCO); 
13
C-NMR (DMSO-d6) δC/ppm: 30.2 (2C), 123.0 (2C), 127.5 (2C), 129.6 
(2C), 130.8 (2C), 132.7 (2C), 136.1 (2C), 139.0 (2C), 146.9 (2C), 186.0; recrystallized by 
benzene, m.p.; 148-150 °C; yield: 80%; MS (EI): m/z [M+H]
+
: 449.91. 
 
(3E,5E)-3,5-bis(3-bromobenzylidene)-1-methylpiperidin-4-one (MC 2914). 
1
H-NMR 
(DMSO-d6) δH/ppm: 2.39 (s, 3H, CH3), 3.73 (s, 4H, N(CH2)2, 7.42-7.46 (t, 2H, benzene 
protons), 7.50-7.52 (d, 2H, benzene protons),7.57 (s, 2H, benzene protons),7.62-7.64 (d, 
2H, benzene protons), 7.71 (s, 2H, PhCH=CCO); 
13
C-NMR (DMSO-d6) δC/ppm: 45.0, 
56.0 (2C), 123.0 (2C), 127.5 (2C), 129.6 (2C), 130.8 (2C), 132.7 (2C), 136.1 (2C), 140.6 
(2C), 145.9 (2C), 186.0; recrystallized by cyclohexane/benzene; m.p.: 130-132 °C; yield: 
74%; MS (EI): m/z [M+H]
+
: 446.97. 
 
(1E,4E)-1,5-bis(2-bromophenyl)penta-1,4-dien-3-one (MC 2887). 
1
H-NMR (DMSO-d6) 
δH/ppm: 7.34-7.42 (4H, m, benzene protons and PhCH=CHCO), 7.49-7.52 (t, 2H, benzene 
protons), 7.75-7.77 (d, 2H, benzene protons), 7.95-8.00 (m, 4H, benzene protons and 
PhCH=CHCO); 
13
C-NMR (DMSO-d6) δC/ppm: 120.3 (2C), 122.9 (2C), 125.1 (2C), 127.9 
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(2C), 128.7 (2C), 133.0 (2C), 138.1 (2C), 147.1 (2C), 183.3; for m.p. see literature
213
, 
yield: 71%; MS (EI): m/z [M+H]
+
: 389.56. 
 
(1E,4E)-1,5-bis(3-bromophenyl)penta-1,4-dien-3-one (MC 1945). 
1
H-NMR (DMSO-d6) 
δH/ppm: 7.38-7.44 (m, 4H, benzene protons and PhCH=CHCO), 7.63-7.65 (d, 2H, benzene 
protons), 7.75-7.79 (m, 4H, benzene protons and PhCH=CHCO), 8.04 (s, 2H, benzene 
protons); 
13
C-NMR (DMSO-d6) δC/ppm:123.0 (2C), 123.3 (2C), 127.5 (2C), 129.6 (2C), 
130.8 (2C), 133.1 (2C), 137.4 (2C), 142.2 (2C), 188.6; recrystallized by methanol; m.p.: 
118-120 °C; yield: 97%; MS (EI): m/z [M+H]
+
: 391.91. 
 
(1E,4E)-1,5-bis(4-bromophenyl)penta-1,4-dien-3-one (MC 2886). 
1
H-NMR (DMSO-d6) 
δH/ppm: 7.36-7.40 (d, 2H, PhCH=CHCO), 7.69-7.98 (m, 10H, benzene protons and 
PhCH=CHCO); 
13
C-NMR (DMSO-d6) δC/ppm: 119.8 (2C), 123.1 (2C), 125.8 (4C), 133.7 
(4C), 135.0 (2C), 140.3 (2C), 183.6; for m.p. see literature
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; yield: 81%; MS (EI): m/z 
[M+H]
+
: 389.43. 
 
(1E,4E)-1,5-bis(3,5-dibromophenyl)penta-1,4-dien-3-one (MC 3084). 
1
H-NMR 
(DMSO-d6) δH/ppm: 7.43-7.47 (d, 2H, PhCH=CHCO), 7.72-7.76 (d, 2H, PhCH=CHCO), 
7.92 (s, 2H, benzene protons), 8.06 (s, 4H, benzene protons); 
13
C-NMR (DMSO-d6) 
δC/ppm: 123.3 (6C), 128.9 (4C), 133.9 (2C), 142.2 (2C), 144.1 (2C), 188.6; recrystallized 
by acetonitrile; m.p.: 230-232 °C; yield: 70%;  m/z [M+H]
+
: 549.74 
 
(3E,5E)-1-benzyl-3,5-bis(2-bromobenzylidene)piperidin-4-one (MC 2908). 
1
H-NMR 
(DMSO-d6) δH/ppm: 3.60 (s, 2H, PhCH2), 3.71 (s, 4H, N(CH2)2, 7.16 (s, 5H, benzene 
protons), 7.30-7.42 (m, 7H, benzene protons), 7.73-7.75 (m, 4H, benzene protons and 
PhCH=CCO); 
13
C-NMR (DMSO-d6) δC/ppm: 53.4 (2C), 64.4, 125.2 (2C), 127.0 (2C), 
127.2, 127.5 (2C), 127.6 (2C), 128.4 (2C), 128.8 (2C), 132.6 (3C), 134.3 (2C), 140.6 (2C), 
145.9 (2C), 186.0; recrystallized by benzene; m.p.: 144-146 °C; yield: 82%; MS (EI): m/z 
[M+H]
+
: 522.70. 
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(3E,5E)-1-benzyl-3,5-bis(4-bromobenzylidene)piperidin-4-one (MC 2909). 
1
H-NMR 
(DMSO-d6) δH/ppm: 3.71 (s, 2H, PhCH2), 3.80 (s, 4H, N(CH2)2, 7.20-7.25 (m, 5H, 
benzene protons), 7.39 (m, 4H, benzene protons), 7.58-7.64 (m, 6H, benzene protons and 
PhCH=CCO); 
13
C-NMR (DMSO-d6) δC/ppm: 53.0 (2C), 57.8, 124.0 (2C), 125.3, 126.8 
(2C), 128.3 (2C), 130.7 (4C), 133.0 (4C), 134.9, 136.3 (2C), 138.9 (2C), 141.7 (2C), 
187.4; m.p.: 178-180 °C; yield: 73%; MS (EI): m/z [M+H]
+
: 523.78. 
 
(3E,5E)-1-benzyl-3,5-bis(3,5-dibromobenzylidene)piperidin-4-one (MC 2910). 
1
H-
NMR (DMSO-d6) δH/ppm: 3.71 (s, 2H, PhCH2), 3.79 (s, 4H, N(CH2)2, 7.22 (s, 4H, 
benzene protons), 7.56 (s, 2H, benzene protons), 7.87 (s, 2H, PhCH=CCO); 
13
C-NMR 
(DMSO-d6) δC/ppm: 53.4 (2C), 64.4, 123.3 (4C), 127.2, 128.4 (2C), 128.8 (2C), 128.9 
(4C), 132.6, 133.9 (2C), 139.6 (2C), 140.6 (2C), 145.9 (2C), 186.0; recrystallized by 
benzene/acetonitrile; m.p.: 178-180 °C; yield: 73%; MS (EI): m/z [M+H]
+
: 680.82. 
 
General procedure for the synthesis of N-acyl 3,5-bis(2/3-
bromobenzylidene)piperidin-4-onic compounds. Example: synthesis of (3E,5E)-3,5-
bis(3-bromobenzylidene)-1-(3-phenylpropanoyl) piperidin-4-one (MC3187). 
To a stirring solution of (3E,5E)-3,5-bis(3-bromobenzylidene)piperidin-4-one (0.45 mmol, 
195 mg) and Et3N (0.76 mmol, 0.11 mL) in dry dichloromethane (5 mL), 
hydrocynnamicacyl chloride (0.67 mmol, 0.1 mL) was slowly added at 0 °C. The resulting 
mixture is then allowed to stir at room temperature. After 1 hour the reaction was 
quenched with water (50 mL) and extracted with dichloromethane (3 x 30 mL). The 
collected organic layers were washed with HCl 2N (3 x 30 mL) and then with a saturated 
solution of NaCl (30 mL). The organic phase was dried with anhydrous Na2SO4, filtered 
and evaporated under vacuum to afford a crude that was then purified on silica gel 
(AcOEt/n-hexane 1:3) to afford the desired product (170 mg, 67%). 
1
H-NMR (DMSO-d6) 
δH/ppm: 2.45-2.49 (t, 2H, -COCH2), 2.83-2.87 (t, 2H, PhCH2), 4.57 (s, 2H, -NCH2), 4.90 
(s, 2H, -NCH2), 6.98-7.00 (d, 2H, benzene protons), 7.18-7.63 (m, 9H, benzene protons), 
7.77 (s, 2H, benzene protons); 
13
C-NMR (DMSO-d6) δC/ppm: 31.4, 33.6, 47.4 (2C), 123.0 
(2C), 125.9, 127.5 (2C), 127.7 (2C), 128.6 (2C), 129.6 (2C), 130.8 (2C), 132.7 (2C), 136.1 
(2C), 140.6 (2C), 141.3, 145.9 (2C), 172.3, 186.0; MS (EI): m/z [M+H]
+
: 565.24. 
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General procedure for the synthesis of N-alkyl 3,5-bis(2/3-
bromobenzylidene)piperidin-4-onic compounds. Example: synthesis of (3E,5E)-3,5-
bis(3-bromobenzylidene)-1-(4-oxo-4-phenylbutyl)piperidin-4-one (MC 3243). To a 
stirring solution of (3E,5E)-3,5-bis(3-bromobenzyliden)piperidin-4-one (0.46 mmol, 0.2 g) 
and 4-oxo-4-phenylbutanal (0.46 mmol, 0.075 g) in dry dichlorometane (10 mL), sodium 
triacetoxy borohydride (0.55 mmol, 0.117 g) was added portionwise and the resulting 
suspension is stirred at room temperature. After two hours the reaction was quenched with 
H2O (30 mL) and extracted with dichloromethane (4 x 20 mL). The collected organic 
phases were then washed with a saturated solution of NaCl (30 mL) and then dried with 
anhydrous Na2SO4, filtered and evaporated under vacuum to afford a crude that was 
purified on silica gel (AcOEt/n-hexane 1:3) to obtain the desired compound (197 mg, 
74%). 
1
H-NMR (DMSO-d6) δH/ppm: 1.90-1.94 (m, 2H, -NCH2CH2CH2CO-), 2.65-2.68 (t, 
2H, -NCH2CH2CH2CO-), 2.97-3.01 (t, 2H, -NCH2CH2CH2CO-), 3.80 (s, 4H, piperidonic 
protons), 7.32-7.33 (m, 4H, benzene protons), 7.40-7.44 (t, 2H, benzene protons), 7.52-
7.54 (m, 5H, benzene protons), 7.72 (s, 2H, PhCH=CCO), 7.89-7.91 (d, 2H, benzene 
protons); 
13
C-NMR (DMSO-d6) δC/ppm: 22.2, 36.4, 53.8 (2C), 56.9, 123.0 (2C), 127.5 
(2C), 128.6 (2C), 128.8 (2C), 129.6 (2C), 130.8 (2C), 132.7 (2C), 133.1, 136.1 (2C), 
136.7, 140.6 (2C), 145.9 (2C), 186.0, 200.1; MS (EI): m/z [M+H]
+
: 578.87. 
 
General procedure for the synthesis of N-alkylphenyl piperidonic compounds. 
Example: synthesis of (3E,5E)-3,5-bis(2-bromobenzyliden)-1-(3-phenylpropyl) 
piperidin-4-one (MC 3271). To a suspension of anhydrous K2CO3 (0.69 mmol, 0.954 g) 
in acetonitrile (10 mL), the (3E,5E)-3,5-bis(2-bromobenzyliden)piperidin-4-one (0.46 
mmol, 0.2 g) and the 3-bromo-1-phenylpropane (1.38 mmol, 0.21 mL) were added and the 
resulting suspension was stirred at 60 °C. After 2 hours the solvent was evaporated, water 
(50 mL) was added and the aqueous solution was extracted with dichloromethane (3 x30 
mL). The collected organic phases were washed with a saturated solution of NaCl (30 mL) 
and then dried with anhydrous Na2SO4, filtered and evaporated under vacuum to afford a 
crude that was purified on silica gel (AcOEt/n-hexane 1:3) to obtain the desired compound 
(170 mg, 67%). 
1
H-NMR (DMSO-d6) δH/ppm: 1.65-1.71 (m, 2H, -NCH2CH2CH2Ph), 2.47-
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2.51 (t, 2H, -NCH2CH2CH2Ph), 2.54-2.58 (t, 2H, -NCH2CH2CH2Ph), 3.68 (s, 4H, piperidonic 
protons), 7.05-7.38 (m, 11H, benzene protons), 7.67-7.69 (d, 2H, benzene protons), 7.96 (s, 2H, 
PhCH=CCO); 
13
C-NMR (DMSO-d6) δC/ppm:27.5, 31.0, 53.8 (2C), 57.0, 125.2 (2C), 126.0, 
127.0 (2C), 127.5 (2C), 127.6 (2C), 128.1 (2C), 128.8 (2C), 132.6 (2C), 134.3 (2C), 140.6 (2C), 
142.0, 145.9 (2C), 186.0; MS (EI): m/z [M+H]
+
: 551.41. 
 
Biochemical assay procedures for compound 1-10 
2.2.1. PR-SET7, G9a, and SET7/9 inhibitory assays Assays were performed essentially as 
described previously for PR-SET7
215
, G9a
208
, and SET7/9
216
. Briefly, the samples were 
incubated at 30 °C for 10-60 min in a reaction buffer containing 50 mM TriseHCl (pH 
8.5), 5 mM MgCl2, 4 mM DTT, and 1 mM Sadenosyl- L-[methyl-3H]methionine 
(Amersham Pharmacia Biotech). Two micrograms of octamer, oligonucleosomes, or 
mononucleosome were used as substrates. The total volume of the reaction mixture was 
adjusted to 25 mL. The reaction was stopped by addition of SDS sample buffer and then 
fractionated on 15% SDSPAGE. Separated histones were then transferred onto an 
Immobilon-P membrane (Millipore) and visualized by CBB staining. The membrane was 
sprayed with EN3HANCE (NEN), and exposed to Kodak XAR film overnight. 
 
EZH2 inhibitory assay 
Reagent. Reaction buffer; 50 mM TriseHCl (pH 8.0), 50 mM NaCl, 1 mM EDTA, 1 mM 
DTT, 1 mM PMSF, 1% DMSO.  
Reaction conditions. EZH2: Complex of human EZH2 (Gen- Q1 Bank Accession No. 
NM_004456), (amino acids 2-end) with N-terminal His tag, MW = 86 kDa, human EED 
(NM_003797) (a-a 2-end) with N-terminal Flag tag, MW = 51 kDa, human SUZ12 
(NM_015355) (a-a 2-end) with N-terminal His tag, MW = 87 kDa, Human AEBP2 
(NM_153207) (a-a 2-end) with N-terminal His tag, MW = 53 kDa, and human RbAp48 
(NM_005610) (a-a 2-end) with N-terminal His tag, MW = 48 kDa, co-expressed in 
baculovirus expression system. Substrate: 5 mM Histone H3. Methyl donor: 1 mM S-
adenosyl-L-[methyl-3H]methionine. Enzyme: 100 nM EZH2 complex. Reaction 
Procedure: prepare indicated substrate in freshly prepared reaction buffer; deliver EZH2 
into the substrate solution and mix gently; deliver compounds in DMSO into the EZH2 
reaction mixture by using Acoustic Technology (Echo 550, LabCyte Inc. Sunnyvale, CA) 
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in nanoliter range, incubate for 15 min; deliver 3H-SAM into the reaction mixture to 
initiate the reaction; incubate for 1 h at 30 °C; deliver reaction mixture to filter-paper for 
detection.  
Cellular assays 
Compounds. All compounds were dissolved in DMSO (Sigma-Aldrich) and used at 25 
mM or 50 mM. 
Cell lines. U937 (human leukemic monocyte lymphoma cell line-ATCC) were grown in 
RPMI 1640 medium (Euroclone) supplemented with 10% heat-inactivated FBS 
(Euroclone), 1% glutamin (Lonza), 1% penicillin/streptomycin (Euroclone) and 0.1% 
gentamycin (Lonza), at 37 °C in air and 5% CO2. 
Cell cycle analysis. 2.5 x 10
5
 U937 cells were collected by centrifugation after 30 h 
stimulation with compounds at 25 M and 50 M. The cells were resuspended in 500 L 
of hypotonic buffer (0.1% NP-40, 0.1% sodium citrate, 50 g/mL PI, RNAse A) and 
incubated in the dark for 30 min. The analysis was performed by FACS-Calibur (Becton 
Dickinson) using the Cell Quest Pro software (Becton Dickinson) and ModFit LT version 
3 software (Verity). The experiment was performed in triplicate. 
Granulocytic differentiation analysis. 2.5 x 10
5
 U937 cells were collected by 
centrifugation after 30 h stimulation with compounds at 25 M and 50 M. The cells were 
washed with PBS and incubated in the dark at 4 °C for 30 min with 10 L of PE-
conjugated anti-CD11c surface antigen antibody or with 10 L of PE-conjugated IgG, in 
order to define the background signal. At the end of the incubation the samples were 
washed again and resuspended in 500 L of PBS containing 0.25 g/mL PI. The analysis 
was performed by FACS-Calibur (Becton Dickinson) using the Cell Quest Pro software 
(Becton Dickinson). The experiment was performed in triplicate and PI positive cells were 
excluded from the analysis. 
Histone extraction. After stimulation with compounds, the cells were collected by 
centrifugation and washed two times with PBS. Then the samples were resuspended in 
Triton extraction buffer (PBS containing 0.5% Triton X 100 (v/v), 2mMPMSF, 0.02% 
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(w/v) NaN3), and the lysis was performed for 10 min at 4 °C. Next, the samples were 
centrifugated at 2000 rpm for 10 min at 4 °C, and the pellets were washed in TEB (half the 
volume). After a new centrifugation under the same conditions, the samples were 
resuspended in 0.2 N HCl and the acid histone extraction was carried out overnight at 4 
°C. The supernatant was recovered by centrifugation and the protein content was ensured 
by BCA
TM
 Protein Assay (Pierce). 
Western blot. 5 mg of histonic extracts were loaded on 15% polyacrylamide gel. The 
histone H3 methylation was assessed with anti-dimethyl-K9-histone H3 antibody 
(Abcam), with anti-monomethyl K20 histone H4 (Diagenode), with anti-monomethyl K4 
histone H3 (Diagenode), and with anti-trimethyl-K27-histone H3 antibody (Diagenode). 
To check for equal loading, Ponceau Red (Sigma) staining and the anti-histone H4 
antibody (Abcam) were used.  
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5. HISTONE LYSINE DEMETHYLASES 
Differently from other histone post-translational modifications, like acetylation and 
phosphorylation whose epigenetic “writers” and “erasers” were almost simultaneously 
identified, till 2003 a plenty of histone lysine methyltransferases were known, but no 
histone lysine demethylases weren’t identified yet. Therefore histone lysine dimethylation 
was strongly believed irreversible, also because of the high thermodynamic stability of the 
C-N bond. Regeneration of un-methylated proteins seemed to be possible only after a 
complete cellular protein new synthesis.  
This wide-spread idea completely changed in 2004 soon after the discovery of the first 
histone lysine demethylases, namely the Lysine Specific Demethylase 1 or LSD1. 
Afterwards, other histone lysine demethylases (HKDMs or KDMs) had been identified and 
classified into two classes based on a enzymatic mechanistic criteria. The former includes 
the lysine-specific demethylase 1 (LSD1,  also known as KDM1A) and LSD2 (also known 
as KDM1B), which are flavin-dependent amine oxidase domain-containing enzymes, 
whereas the latter comprises the recently discovered Jumonji domain-containing protein 
(JMJD) histone demethylases, which are Fe(II) and α-ketoglutarate-dependent enzymes. 
Hence, lysine-specific demethylases (KDMs) work in coordination with histone lysine 
methyltransferases to maintain global histone methylation patterns. 
 
 
Figure 5.1. Phylogenetic tree of histone Lysine Demethylases (KDMs). 
(Image courtesy of Arrowsmith C.H. et al. Nature review/Drug discovery 2012) 
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As various evidences underlined HKDMs have been found correlated with different 
disease states and are thus emerging as attractive targets for new drugs development. 
Name    
(alternative name) 
Substrate 
Effect on 
transcription 
Disease 
KDM1A (LSD1) 
H3K4me1/2; 
H3K9me1/2 
Repression      
Activation 
Overexpressed in 
neuroblastoma, 
retinoblastoma, 
prostate, breast, lung, 
pancreatic and bladder 
cancers; regulates 
transcription in herpes 
simplex and varicella 
zoster viruses 
KDM1B (LSD2) H3K4me1/2 Activation/not clear Not Known 
KDM2A (FBXL11) H3K36me1/2 Repression Non known 
KDM2B (FBXL10) 
H3K4me3; 
H3K36me1/2 
Repression 
Required for initiation 
and maintenance of 
acute myeloid 
leukemia 
KDM3A (JMJD1A) H3K9me1/2 Activation 
Regulates metabolic 
gene expression and 
obesity resistance; 
enhances tumor cell 
growth 
KDM3B (JMJD1B) H3K9me1/2 Activation 
Suppresses MUTZ-1 
cell growth 
KDM3C (JMJD1C) H3K9me1/2 Activation 
Expressed in diffuse-
type gastric cancer 
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KDM4A (JMJD2A) 
H3K9me2/3; 
H3K36me2/3 
Activation      
Repression 
Overexpressed in 
prostate cancer; 
involved in bladder 
cancer initiation and 
progression; regulates 
Kaposi’s sarcoma-
associated herpesvirus  
replication; promotes 
cardic hypertrophy 
KDM4B (JMJD2B) 
H3K9me2/3; 
H3K36me2/3 
Activation      
Repression 
Overexpressed in 
prostate cancer, breast 
cancer and 
desmoplastic 
medulloblastoma; 
enhances breast cancer 
cell growth 
KDM4C (JMJD2C) 
H3K9me2/3; 
H3K36me2/3 
Activation      
Repression 
Overexpressed/amplifi
ed in prostate cancer, 
esophageal squamous 
cell carcinoma, 
desmoplastic 
medulloblastoma, 
metastatic lung 
sarcomatoid 
carcinoma, breast 
cancer, primary 
mediastinal B cell 
lymphoma, and 
Hodgkin lymphoma; 
increases expression of 
Mdm2 oncogene 
KDM4D (JMJD2D) 
H3K9me1/2/3; 
HH3K36me2/3 
Unknown       
Repression 
Not known 
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KDM5A (JARID1A) H3K4me2/3 Repression 
Induces acute myeloid 
leukemia; 
overexpressed in 
gastric cancer and 
prevents senescence of 
malignant cells; 
involved in drug-
tolerant state in cancer 
KDM5B (JARID1B) H3K4me2/3 Repression 
Overexpressed in 
breast, testis, and 
prostate cancer; 
involved in cancer cell 
growth 
KDM5C (JARID1C) H3K4me2/3 Repression 
Mutated in X-linked 
mental retardation; 
involved in neuronal 
survival and dendritic 
development; mutated 
in renal carcinoma 
KDM5D (JARID1D) H3K4me2/3 Repression Not known 
KDM6A (UTX) H3K27me2/3 Activation Mutated in cancer 
KDM6B (JMJD3) H3K27me2/3 Activation 
Involved in 
inflammatory 
signaling cascades; 
acts as a tumor 
suppressor; 
overexpressed in 
Hodgkin’s lymphoma 
KDM7A (KIAA1718) 
H3K9me2;    
H3K27me2 
Activation Not known 
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KDM7B (KIAA1111) 
H3K9me1/2; 
H3K27me2; 
H4K20me1;  
H3K36me2 
Activation   
    
 Repression 
Mutated in X-linked 
mental retardation 
KDM8 (JMJD5) H3K36me2 Activation 
Overexpressed in 
cancer; enhances 
cancer cell growth 
NO66 (MAPJD) 
H3K4me1/2/3; 
H3K36me2/3 
Repression 
Overexpressed in non-
small-cell lung cancer; 
enhances cancer cell 
growth 
Mina53 (NO52) H3K9me3 Activation 
Overexpressed in 
lymphoma, renal cell 
carcinoma, 
neuroblastoma, 
gastric carcinoma, 
lung cancer, and 
hepatocellular 
carcinoma 
PHF2 (KIAA0062) H3K9me1/2 Activation Not known 
Table 5.1. The Lysine Demethylase Family. 
 
 
5.1 Lysine Specific Demethylase 1 and 2 (LSD1 and LSD2) 
LSD1 was first characterized as a member of CtBP complex by Shi et al. in 2004
217
 and 
catalyzes the removal of methyl groups from mono- and dimethylated forms of histone H3 
lysine 4 (H3K4me1/2) through flavin adenine dinucleotide (FAD)-dependent oxidation, 
but not from trimethylated substrates
218
. Subsequently studies by Metzger and co-workers 
revealed that LSD1 is also able to demethylate mono- and dimethylated lysine 9 of histone 
H3 in prostate cell lines, when co-localized with the androgen receptor (AR)
219
. 
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LSD2, is the last encompassed member to the flavin-dependent lysine demethylase family, 
it was identified in 2009
220
, and thus far little is known about it. It has been found that 
H3K4 demethylation by LSD2 seems to cooperate with the DNA methylation during 
oogenesis
221
 and activates transcription
222
, moreover it mediates NF-κB demethylation thus 
affecting the regulatory circuit that controls the expression of pro-inflammatory genes in 
dendritic cells
223
. 
Being a monoamine oxidase (MAO) enzyme, LSD1 catalyzes the specific demethylation 
of mono- or dimethylated histone H3 lysine 4 (H3K4) and H3 lysine 9 (H3K9) via a redox 
reaction. The X-ray crystal structure resolution together with mechanistic studies helped to 
unravel the catalytic mechanism by means of LSD1 demethylates lysine substrates, and in 
particular to understand the reasons lying at the basis of LSD1 inability to act on 
trimethylated lysines. The initial step of the catalysis, the two single electron oxidation of 
the ε amino group and the concurrent reduction of the FAD, requires a free lone pair on the 
nitrogen to occur, and only mono- and dimethyl-lysines accomplish this condition. Then 
the so obtained iminium intermediate can react with a water molecule, turning into an 
unstable hemiaminal intermediate, which spontaneously decomposes into formaldehyde 
and the demethylated lysine. The reduced FADH2 is reoxidized by oxygen in a subsequent 
step to form FAD and hydrogen peroxide
224,
 
225, 226
 (Figure 5.2). 
 
Figure 5.2. Demethylation reaction mechanism catalyzed by LSD1 
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LSD1 crystal structure was solved for the first time by Cheng and et al in 2006
227
. The 
structure of LSD1 contains three domains, two of them, the SWIRM (residues 172-270) 
and AOL (residues 271-417 and 523-833) domains strongly interact each other through 
extensive contacts resulting in a overall globular structure. The SWIRM domain consists 
of α-helices and it is the last characterized structural module, while the AOL domain folds 
into a compact structure which shares several structural topologies with other flavin-
dependent oxidases, especially Mono Amino Oxidase (MAO) enzymes. The third 
structural domain of LSD1 is represented by an aminoacidic insertion (residues 418-522) 
that adopts a tower-like conformation (that’s why Tower domain) protruding 75 Å away 
from the AOL and SWIRM modules
228
 (Figure 5.3). 
 
Figure 5.3. Representation of LSD1 structure. 
The SWIRM domain of LSD1 is characterized by a long helix, SWα4 surrounded by five 
other helices (SWα1-6), moreover it has an additional two-stranded β-sheet formed 
between the SWα4-SWα5 loop and the C terminus of the SWIRM domain. The β-sheet 
motif helps the SWIRM in anchoring into AOL domain by forcing the SWα6–SWα2 loop 
to protrude out and to be harbored into an hydrophobic pocket of the AOL domain.  
A three amino-acids long sequence (F264-G265-I266) between SWα6 and SWα2 seems to 
play an important role in the interaction between AOL and SWIRM domains, involving 
both hydrophobic and hydrogen bonding interactions. These hydrophobic contacts are also 
reinforced by extensive hydrogen-bonding interactions between the backbone of this motif 
and the side chains of R295 and Q348. 
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The AOL domain of LSD1 is functionally subdivided into two well defined subdomains, 
the FAD binding subdomain and substrate binding subdomain. The former has three 
aminoacidic fragments (res. 271-356, 559-657, and 770-833) and adopts a mixed α-β 
structure; whereas the ladder includes three sequences (res. 357-417, 523-558, and 658-
769) and is characterized by a six-stranded mixed β-sheet flanked by six α-helices. The 
space left by the two sub-modules defines a  wide-open cavity where catalysis takes place. 
The cavity protrude into the protein for 23 Å and in its bottom there is the binding site for 
the flavin rings of the FAD cofactor. The cavity delineates four small “chambers” with 
distinct chemical properties that could be used for the specific binding of side chains in 
their native state but also after undergoing post-translational modifications
229
. The first 
pocket exposes the isoalloxazine ring of the FAD cofactor and forms the catalytic chamber 
of LSD1. The residues that create this hydrophobic chamber and lie close to the 
isoalloxazine ring are Val317, Gly330, Ala331, Met332, Val333, Phe538, Leu659, 
Asn660, Lys661, Trp695, Ser749, Ser760 and Tyr761. The remaining three pockets of the 
active site cavity are probably required for the binding of histone tail residues directly 
adjacent to the substrate lysine. Compared with other flavin-dependent oxidases, as PAOs 
(polyamine oxidases) whose catalytic center is placed in a narrow U-shaped tunnel, LSD1 
contains a large catalytic cavity between the FAD- and substrate-binding subdomains and 
this reflects the different nature of substrates of the two enzymes; indeed the substrates of 
LSD1 are methylated histone peptides while the substrates of PAOs are smaller linear 
polyamine like spermidine
230
. Another structural characteristic important for the substrate 
recognition is that the two diagonally interacting helices, Sα1 and Sα3, form a highly 
acidic surface at the entrance of the catalytic cavity thus serving as an additional substrate 
discrimination factor for the basic histone H3 tail. 
The tower domain is formed by two long α-helices, TαA and TαB, which pack each other 
forming a left-handed superhelix. Being organized as a coiled-coil secondary structure, the 
tower domain is composed of a repetitive pattern of seven residues (abcdefg)n, in which 
the position a and d are generally occupied with hydrophobic amino acids (Figure 5.4). 
The tower domain acts as hub for the interaction with other protein, especially molecular 
adaptors like CoREST, owing to that LSD1 is able to express its demethylating activity on 
nucleosomal substrates and to be protected from proteosomal degradation. The tower 
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domain by itself is sufficient for a stable interaction with CoREST, infact a deletion mutant 
of LSD1 (LSD1ΔTower), in which the tower domain was replaced by a pentaglycine loop, 
proved not to be able in reducing the methylation level at K4 on histone H3. These 
evidences indicate that the SWIRM and AOL domains of LSD1 do not significantly 
contribute to the interaction with CoREST and that the tower domain represents the 
binding site for it as well as for other molecular partners. 
 
Figure 5.4. Ribbon diagram of the coiled coil of the tower domain. The amino acids at the d positions of 
the heptad repeat of the two helices are in space-filling representation and colored in red (Tα1) and purple 
(Tα2), respectively. 
(Image courtesy of Cheng Y. et al. Proc.Natl.Acad.Sci. 2006) 
Despite initially recognized as active only on histonic substrates, further studies have 
illustrated that LSD1 can demethylates also lysines on a l arge portfolio of non-histonic 
targets, including: p53
231
, DNA methyltransferase 1 (DNMT1)
232
, transcription factors like 
for E2F1
233
 and STAT3
234
, the myosin phosphatase MYPT120
235
 and other proteins, 
finally modulating their cellular activities.  
Hence, playing essential roles in regulating gene expression and transcription LSD1 can 
affect different cellular functions such as cellular development and differentiation, self-
renewal and pluripotency capacity, that once aberrantly modulated may lead or promote 
cancer onset and progression. Moreover, what reinforces the idea that LSD1 could be an 
attractive target for cancer therapy is that it is found overexpressed in various cancer cells 
and tissues, among these: neuroblastoma
236
, retinoblastoma
237
, prostate
238,239
, breast
240,241
, 
lung
242
, pancreatic
243
 and bladder cancers
189
. 
It has been also found that it regulates viral gene transcription in herpes simplex viruses 
(HSV) and varicella zoster viruses (VZV)
244
. To exploit the host cell transcriptional 
machinery, HSV and VZV require an increase in methylation of H3K4 and decrease in 
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methylation of H3K9, and in doing so viruses recruit host cell factor 1 (HCF-1) and an 
HKMT. LSD1 has been found to interact with HCF-1 and to demethylate H3K9 in virus 
infected cells, moreover its inhibition leads to the arrest of viral gene transcription, 
therefore suggesting that LSD1 inhibitors may be used as anti-HSV and anti-VZV 
agents
245
. 
The role of LSD1 in regulating gene expression and transcription is still not 
straightforward since it has been found in different transcriptional complexes acting as a 
co-repressor or a co-activator, depending on its molecular partner and its target. According 
to this, LSD1 can act as a transcriptional co-repressor within the CoREST-HDAC1/2 and 
in NuRD (Nucleosome Remodelling and Deacetylase) complexes
246
, where it catalyzes the 
demethylation of mono- and dimethyl forms of lysine 4 on histone H3 (H3K4me2/me1), 
which are two transcriptional activating histone marks. In hematopoiesis, the LSD1-
CoREST-HDAC complex interplays with growth factor independent 1 transcription 
repressor (Gfi-1) repressing Gfi-1 target genes
247
. LSD1-CoREST-HDAC plays also an 
important role in silencing mature B-cell genes through the interaction with the 
transcriptional repressor B lymphocyte-induced maturation protein-1 (Blimp-1)
248
. 
Another molecular evidence suggesting the likely impact of LSD1 in cancer as a 
transcriptional co-repressor arises considering the role of CoREST/HDACs/LSD1 complex 
in the recruitment of the oncoprotein  ZNF217, which in turn downregulates the tumor 
suppressor gene p15
INK4B
.
249
 
LSD1 is also a transcriptional co-activator when recruited by nuclear androgen
250
 (AR) and 
estrogen
251
 (ER) receptors, shifting it’s substrate specificity from H3K4me2/me1 to 
H3K9me2/me1, these last two being transcriptional silencing histone marks. Responsible 
of this shifting seems to be the protein kinase C, which once localized on AR target 
promoters, phosphorylates the threonine 6 of histone H3 (H3T6), blocking the H3K4 
demethylating activity by LSD1, which in turn becomes responsive for H3K9me2/me1
252
 
(Figure 5.5). Such a role seems to be corroborated by a cooperation of LSD1 with 
JMJD2C, a jumoji domain-containing demethylase specific for H3K9me3, into a specific 
demethylase complex on AR target genes, which was found to co-localize with the 
androgen receptor in both normal prostate tissue and in prostate carcinoma. Coherently 
with this view, LSD1 knock-down resulted in decreased activation of AR-responsive 
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promoters. Moreover genome-wide analysis of LSD1 promoter occupancy on MCF7 cells, 
previously treated with estrogen hormones, has indicated that LSD1 occupies nearly 20 % 
of the whole tested promoters and 84 % of these promoters were associated with RNA 
polymerase II and additionally with activation markers such as dimethyl-H3K4 and acetyl-
H3K9 suggesting that LSD1 was deeply involved in gene activation
253
. 
 
Figure 5.5. LSD1 complexes regulating gene expression. 
(Image courtesy of Amente S. et al. Biochimica et Biophysica Acta 2013)
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An intriguing hypothesis that has been proposed recently is that ER and Myc interplay 
with LSD1 since, releasing H2O2, it might prompt DNA oxidation and therefore the 
recruitment of base excision repair enzymes, like 8-oxoguanine-DNA glycosylase 
(OGG1), thus favoring chromatin looping for transcriptional activation or repression
255
. It 
has been reported that this mechanism could be exploited also to trigger Myc-induced 
transcription
256
. More recently, LSD1 was found to be part of protein complexes 
responsible for transcription elongation: the ELL complex, containing the P-TEFb 
transcriptional elongation factor, and the MLL super-complex, containing both 
transcriptional activators and repressors
257
. 
As stated above, LSD1 can demethylate also non histonic proteins, thus affecting global or 
specific gene expression patterns not only by direct activity on chromatin dynamics, but 
also through dimethylation of transcriptional factors/modulators. LSD1-mediated 
demethylation of K370me2 on tumor suppressor p53 protein, blocks the interaction of p53 
with its co-activator 53BP1 (p53 binding protein 1). This modification represses the 
transcriptional activation of p53 responsive genes and switches off the DNA damage 
response pathway and the subsequent apoptosis induction
258, 259
. Another way by means of 
LSD1 can inhibit DNA damage-induced cell death is through the modulation of the E2F 
transcription factors stability: demethylation of the activating transcription factor E2F1 on 
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lysine 185 prevents other E2F post-translational modifications that mark E2F degradation, 
thus favoring E2F1 accumulation and un-responsive cell cycle progression even in 
presence of a DNA damage
260
. 
LSD1 also demethylates the myosin phosphatase MYPT1, a phosphatase involved in 
retinoblastoma (Rb) dephosphorylation. Rb is a tumor suppressor protein, its major 
function is to impede cell cycle progression from phase G1 to S by binding E2F 
transcription factors, and thus interfering with the function of the active dimers of E2F-DP 
proteins that finally lead the cell into the phase S
261
. Rb proteins are active when 
hypophosphorylated and indeed during cell cycle progression CDKs (Cyclin Dependent 
Kinases) phosphorylate, thus inactivating, retinoblastoma proteins. LSD1-mediated 
MYPT1 demethylation enhances  its ubiquitination and cellular instability, consequently, 
MYPT1 degradation enhances Rb phosphorylation and inactivation.  
Among the LSD1 substrates there is also DNMT1, which have an important role in the 
development and differentiation in embryonic stem cells (ESC), through the maintaining 
of the whole DNA methylation states in silenced genes. As proof of concept evidences 
have displayed that LSD1 knock out in mouse embryonic stem (ES) cells leads to a 
decrease in DNMT1 protein levels and to a concomitant loss of DNA methylation
262
, 
moreover combination treatment of DNMT and LSD1 inhibitors against colon cancer 
xenograft mice, afforded a remarkably inhibition of the growth of the tumor.
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LSD1 impact on gene expression and transcription affects a multitude of cellular activities, 
notably the early development and pluripotency of embryo stem cells. Genetic studies in 
multiple model systems such as mouse, C. elegans and Drosophila have displayed that 
alteration in the LSD1activity may lead to defects in many meiotic steps. In mice, loss of 
LSD1 causes embryonic lethality at approximately day 6. Other reports indicate that LSD1 
is required for cellular differentiation in adipogenesis
264
, skeletal-muscle apparatus
265
 and 
remarkably in the epithelial to mesenchymal transition (EMT), which is a changing in the 
cell phenotype characterized by the loss of epithelial characteristics and a gaining  of 
mesenchymal properties. One of the distinctive feature of EMT is the reduction of 
H3K9me2 levels and the increasing of H3K4me3 and H3K36me3 levels, that are histone 
marks dependent by LSD1; moreover loss of LSD1 function affects EMT-driven cell 
migration and chemoresistance
266
. Another prove supporting LSD1 role in the EMT, arise 
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if we consider that in human cancer EMT is largely due to Snail mediated transcriptional 
repression of epithelial genes and it has been shown that LSD1 functionally interacts with 
Snail and it is recruited on E-caderine promoters, where it prompts silencing by  
demethylation of H3K4me2 mark
267
. Sequence similarity comparisons between SNAIL 
and the histone H3 protein suggested that SNAIL could bind to LSD1 in the same cleft of 
the histone H3. Accordingly, Baron et al. found that a 20-amino-acid peptide 
corresponding to SNAIL1 N-terminal residues effectively inhibits LSD1-CoREST and as a 
prove of the concept they determined the crystal structure of the ternary complex LSD1-
CoREST/SNAIL1 peptide at 3.0 Å resolution
268
 (Figure 5.6). Alignment of the N-terminal 
sequences of the SNAG domain of SNAIL1 (that is quite conserved among 
SNAIL/Scratch protein families) and H3 reveals that the residues that are key for binding 
to LSD1 are conserved among almost all SNAIL1-related proteins. This observation could 
suggest that other transcription factors of the SNAIL/Scratch family are could interplay 
with LSD1 following the same molecular mechanism. 
 
Figure 5.6. Ribbon representation of LSD1 (cyan), CoREST (blue) and SNAIL (orange). FAD cofactor is 
represented in yellow sticks. 
(Image courtesy of Baron R. et al. Structure 2011) 
Pluripotency and self-renewal capacities are characteristics recognizable in embryonic 
stem cells as well as in cancer cells, therefore unraveling the mechanisms lying behind the 
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“stemness” might be useful to understand the de-differentiation process resulting in cancer. 
Even if this hypothesis is intriguing, presently most of the evidences seem to support the 
fact that the signaling pathways involved in the regulation of stem and cancer cells belong 
to functionally separable modules. Despite that, LSD1 has been reported to control gene 
expression during embryonic stem cell (ESC) differentiation, like, as stated above, in 
controlling the activity of DNMT1, a so the overall DNA methylation status, by regulating 
the methylation state on DNMT1 K1096
204
. Moreover LSD1 occupies the enhancer and 
core promoters of actively transcribed genes in embryonic stem cells and that the enzyme 
is required during differentiation in these cells, for enhancer silencing specific genes 
through the involvement of NuRD complex
269
. 
 
 
5.2 LSD1 aberrations and cancer 
As previously stated LSD1 is involved in many types of cancers. In particular it has been 
found strongly upregulated in a poor treated subset of breast cancer: estrogen receptor 
(ER) negative cancer. Downregulation of LSD1 obtained through the treatment with 
tranylcypromine, a MAO inhibitor, led to ER-negative breast cancer cells growth 
inhibition, coherently LSD1 silencing by siRNA treatment increased the expression of 
tumor suppressor p21
WAF1 
and the downregulation of oncogenes such as CCNA2 and 
ERBB2
270
. 
 
LSD1 is also involved in neuroblastoma, where its upregulation is correlated 
with poor clinical prognosis and cellular indifferentiation
271
. Another brain cancer in which 
LSD1 seem to play a pivotal role is medulloblastoma, a highly malignant primary tumor 
generally affecting children and easily developing metastasis, with a dramatic and poor 
prognosis and for the survivors cognitive and neurological disabilities after aggressive 
treatments. In medulloblastoma LSD1 overexpression has been widely recognized and its 
knockdown induced apoptosis and suppressed proliferation, but also impaired migratory 
capacity. Treating medulloblastoma cells with the specific KDM1A inhibitor, NCL-1, 
significantly inhibited growth in vitro.
272
 
Recent studies in both mouse and human models of human MLL-AF9 leukemia, indicates 
LSD1 as an essential regulator of leukemia stem cells (LSC)
273
. The extent of LSD1 
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knockdown significantly correlated with loss of the LSC potential of acute myeloid 
leukemia (AML) cells through fainting of differentiation and apoptosis, moreover cells 
without active LSD1 are unable to form colonies and are not capable of inducing leukemia 
when transfected into mice
274
. An hypothesis could be that LSD1 might regulate a subset 
of genes that activate the oncogenic program associated with MLL-AF9 leukemia, in this 
concern chromatin immunoprecipitation and next generation sequencing, (ChIP-Seq), 
confirmed that H3K4me2 increase is the only detectable change at MLL-AF9 promoters 
following LSD1 silencing. 
T-cell acute lymphoblastic leukemia (T-ALL) originates from the malignant 
transformation of T-cell progenitors. Mutations in Notch1 leading to aberrant and 
constitutively active Notch1 signaling, contribute to this oncogenic transformation and are 
hallmarks of this disease. It has been recently found that LSD1 takes part into the Notch-
containing complex; and it has been found that together with the PFH8 demethylase it is 
involved in the epigenetic modification of Notch1 target genes. It is known that the DNA-
binding factor CSL binds and represses Notch responsive genes in the absence of Notch 
itself, whereas the presence of Notch converts CSL in a transcriptional activator. LSD1 
interacts with CSL and determines gene repression by removing the H3K4me2 marks at 
the promoters of Notch target genes (in the absence of Notch), while in its presence the 
enzyme acts preferentially on H3K9me2 leading to activation of target genes
275
.  
Recently, high intracellular levels of LSD1 have been also found in pancreatic cancer cells 
too. LSD1 knock-down pancreatic cells exhibited low proliferative rate and, more 
importantly, a decrease in glucose uptake and lactate production
REF 190, Yi Qin, whehwy zuh 
CANCER LETTER 2014
.  
Pancreatic cancer is characterized by numerous and severe hypoxic regions generally  
correlated with tumor aggressiveness and poor prognosis, compared with well-oxygenated 
tumors. An hypoxic environment in pancreatic cancer cells not only favors their resistance 
to chemotherapy but leads to a glycolysis-based metabolism transformation to ensure the 
cell its energetic and biosynthetic demands
276
. The knowledge on the molecular basis for 
glycolytic phenotype in cancer, has been recently deepen owing to advances in the 
understanding of the hypoxia-inducible factor (HIF1α) cellular role277. 
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LSD1 positively correlates with glycolysis process in pancreatic cancer likely owing to an 
increased HIF1α protein stability as a result of the interaction between LSD1 and HDAC2, 
which was reported (together with other members HDACs like HDAC1 and HDAC4) to 
enhance HIF1α protein stability under hypoxia conditions in an deaceylation dependent 
manner. Another evidence showed that a decreased LSD1 expression resulted in 
transcription down-regulation of HIF1a target genes, which are rate-limiting glycolytic 
enzymes.  
Given the wide-spread influence of LSD1 on gene transcription, targeting LSD1 in 
pancreatic cancer cells could be beneficial for two reasons: the expressional gene profile 
could be altered thus dampening the uncontrolled proliferation and metastasis of pancreatic 
cancer cells. On the other hand, intervention of LSD1 may interrupt the glycolysis process, 
the most fundamental and vital step that sustains pancreatic cancer malignancies 
supporting its energetic metabolism. 
 
 
5.3 Targeting Lysine Specific Demethylase 1 
LSD1 shares a sequence similarity of 17.6% with monoamino oxidases (MAOs) A and B, 
and PAO (polyamine oxidases)
278,279
 therefore soon after its discovery, well-known MAO  
and PAOs inhibitors were tested on LSD1 to evaluate their activity. 
Among the MAOs inhibitors, pargiline (1, Figure 5.7), a propargyl-amine-based 
compound, was the first to be tested and weakly showed to block dimethylation of H3K9 
(active at 1 mM) and to arrest androgen receptor-dependent gene transcription
280
. 
Phenelzine (3, Figure 5.7), another anti-MAO drug bearing a hydrazine moiety, was 
initially recognized as ineffective LSD1 inhibitor, and only when its activity was re-
investigated it exhibited an improved potency (Ki=17.6 µM) but with a poor selectivity
281
. 
Finally also tranylcypromine (trans-2-phenyl-cyclopropyl-1-amine or trans-PCPA or 
tPCPA, 2, Figure 5.7) was tested and it inactivated LSD1 with a Ki value ranging from 477 
to 22 µM (depending on the type of assay)
282
. Despite the poor activity trans-TCPA turned 
to be useful for the future development of LSD1 inhibitors. A Schmidt and McCafferty 
study based on kinetics and mass spectrometry analysis demonstrated that the trans-TCPA 
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inhibited LSD1 via an irreversible reaction between the cyclopropyl ring and the N(5) of 
FAD. 
 
Figure 5.7. MAO inhibitors active on LSD1. 
Starting from X-ray crystal structure analysis of LSD1 in complex with tPCPA, three 
different covalent adducts have been identified (Figure 5.8). Yu and co-workers showed 
that the structure of tPCPA-FAD complex in LSD1 is a five-membered ring adduct
283
, later 
Yokohama and co-workers stated that an N(5) adduct intermediate (A) could also 
participate to the tPCPA-FAD construct
284
. Finally, structural analyses of LSD1 
complexed with enantiomeric pure PCPAs and its derivatives showed that (1R,2S)-tPCPA 
reacts with FAD yielding N(5) adducts, whereas (1S,2R)-tPCPA leads to an another 
unexpected  N(5) adduct (B)
285
. 
 
Figure 5.8. LSD1 covalent adducts with tPCPA.  
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Although MAO-inhibitors didn’t exhibit an excellent activity over LSD1, they were 
however able to induce an increase of global H3K4 methylation state at low micromolar 
concentration and a growth inhibition of neuroblastoma cell and bladder cancer cells
,286
. 
These inhibitors were thus used as hit compounds for further development, and this is true 
especially for tPCPA (2). Different groups efficiently synthesized several PCPA 
derivatives, inserting some substitutions on its phenyl ring, and examined their inhibitory 
activity toward LSD1, MAO A, and MAO B, among these, compounds 4 (Figure 5.9; IC50 
LSD1=188 µM; IC50 MAO A=87 µM, IC50 MAO B=21 µM)
287
 and 5 (Figure 5.9; IC50 
LSD1=3.7 µM) displayed higher potency and selectivity for LSD1 than 2. In addition, 
compound 5 (1R,2S)-4-bromo-PCPA exhibited a good inhibition of cellular growth on 
human prostate LNCaP cells
288
. An increased selectivity was achieved by the introduction 
of a branched substituent at the 4 position of the benzene ring, thus exploiting the wider 
space left available by the FAD cofactor into the cavity of the AO domain of LSD1 in 
respect to MAOs. In this view other tPCPA analogs (6-7, Figure 5.9) were designed as 
lysine-PCPA hybrid compounds and proved to be the first cell-active LSD1-selective 
inhibitors with a selectivity of 400-11000 times greater than that of tPCPA (6: IC50 
LSD1=5.7 µM; IC50 MAO A=230 µM, IC50 MAO B=740 µM; 7: IC50 LSD1=3.1 µM; IC50 
MAO A=250 µM, IC50 MAO B=1700 µM)
289
. Almost at the same time Mai and co-
workers reported compound 8 (Figure 5.9) as a selective inhibitor of LSD1 and MAO A 
over LSD2 and MAO B (IC50 LSD1=1.3 µM; IC50 LSD2=38 µM; IC50 MAO A=1.2 µM, 
IC50 MAO B>133 µM), which displayed synergistic effects with retinoic acid, an 
antileukemia drug, thus causing cell growth inhibition in acute promyelocytic leukemia 
cells
290
. Recently, completely new derivatives of tPCPA have been designed and 
synthesized. N-alkylated PCPA analogues such as 9 and 10 (Figure 5.9) have been 
reported to inhibit LSD1 with high potency and selectivity over MAO A and MAO B (9, 
IC50 LSD1=5.0 nM; IC50 MAO A=16 µM, IC50 MAO B=7.4 µM; 10, IC50 LSD1=9.0 nM; 
IC50 MAO A=15 µM, IC50 MAO B>40 µM), even if detailed data haven’t been disclosed 
yet
291
. 
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Figure 5.9. Further LSD1 inhibitors developed by tPCPA. 
According to the notion that LSD1 can demethylate either mono- and dimethylated form of 
Lys 4 on histone H3 as well as H3-tail peptides affording at least 15 flanking aminoacids; 
the H3-peptide scaffold has been functionalized with different warheads, arising from the 
knowledge of MAO inhibitors development. Among these derivatives the propargyl-Lys-
derivatized peptide (11) and the hydrazine-Lys-4 H3-21 peptide (12) were designed as a 
mechanism based inhibitors able to covalently target the FAD cofactor and they exhibited 
an IC50 of 0.77 0.00435 µM, respectively
292,293
. 
 
Figure 5.10. Peptide inhibitors of LSD1. 
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5.4 Jumonji C domain-containing demethylases (JMJDs) 
The second family of histone lysine demethylases is characterized by the presence of the 
catalytic Jumonji C (JmjC) domain. The first JmjC domain protein was characterized in a 
gene profiling for factors involved in neural tube development, these studies showed 
abnormal groove formation on the neural plate and a defect in neural tube closure, this 
abnormality lead to the formation of an additional groove at the future midbrain–hindbrain 
boundary which crossed the normal neural groove, resulting in a ‘‘cross’’-shaped cut on 
the neural plate, for this reason Takeuchi et al. called this mutation jumonji (Jmj), which in 
Japanese means cruciform
294
. The JmjC domain has been found in 31 proteins within the 
human proteome and nearly 20 of these have exhibited to demethylate specific lysines on 
histones (Table 7.1). In contrast with LSD1/2 which require FAD as cofactor to catalyze 
demethylation reaction, JmjC domain-containing demethylases (or JMJDs) are Fe
2+
 ion 
and 2-oxoglutarate (2OG) dependent oxigenases, which act with a different catalytic 
mechanism and for the same reason are able to demehtylate also trimethylated forms of 
lysines.  
The JMJDs belong to the superfamily of oxygenases, which catalyse the introduction of 
oxygen atoms directly from molecular dioxygen into their products. The first 2OG-
dependent oxygenases to be identified were the collagen hydroxylases and since this 
pioneering study the number of proteins belonging to this family increased and emerged as 
a widely distributed family
295
. 2OG oxygenases catalyse a wide range of oxidative 
reactions, possibly the larger of any other enzyme family, ranging from ‘simple’ 
hydroxylations and demethylations (via methyl group hydroxylation) to ring closures and 
epimerisations
296
. Structurally the JMJDs demethylases belong to the broader “cupin” 
superfamily of oxygenases, which are characterized by a distorted double-stranded β-helix 
(DSBH) fold, also known as a ‘jelly-roll’ or ‘cupin’ fold.  
Albeit considerable unexplained points remain in the mechanistic knowledge of JMJDs, 
including a lack of detailed displaying of the conformational changes that occur during 
catalysis, biochemical studies have shed light onto the sequence of chemical events 
occurring during JMJDs catalyzed demethylation. The proposed mechanism of action is 
commonly assumed to be similar to that of other Fe
2+ containing and α-ketoglutarate-
dependent hydroxylases and it is reported in Figure 5.11.
297
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Figure 5.11. Catalytic mechanism of JmjC demethylases. 
The catalytically active Fe
2+
 ion is coordinated by two histidine residues, a glutamate 
residue and three molecules of water. Initially, the co-substrate α-ketoglutarate as well as 
molecular oxygen are coordinated onto the iron center, displacing the water ligands (step 
1). Then, a single electron transfer occurs from the iron(II) ion onto the coordinated 
oxygen affording a reactive peroxide radical anion species (step 2). This can, in turn, 
attack the α-ketoglutarate ligand yelding a mixed anhydride bound to the remaining 
iron(III)-hydroxyl radical anion (step 3). The so formed reactive hydroxyl radical is able to 
attack the stable C-H bond of the incipient lysine methyl group on the substrate thus 
forming an hydroxymethyl lysine via a first proton transfer and then a subsequent addition 
of the hydroxyl group onto the methyl carbon atom (step 4) releasing the central Fe
2+
 ion 
in the same electronic state of the beginning of the catalytic cycle. Upon dissociation of the 
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bound mixed anhydride from the central iron, α-ketoglutarate decomposes into carbon 
dioxide and succinate as byproducts (step 5). Binding of three molecules of water 
regenerates the original catalytic species. As explained, the Fe
2+
 ion catalytic center 
together with the ligands, can affect the trimethylat lysine, as well as the other froms, since 
the overall mechanism, as far as is known so far, does not require the initial formation of 
an intermediate iminium cation, explaining why JMJDs are able to demethylate methyl 
lysines in all their forms. 
Comprehensive crystallographic analyses of 2OG oxygenases afforded insights into the 
iron and cosubstrate binding sites and what emerged is that the active sites contain a very 
highly, but likely not universally, conserved HXD/E…Xn…H iron binding motif 
comprising one aspartyl/glutamyl and two histidyl residues
298
. This three residues forms 
one half of a Fe
2+
 binding site, with an octahedral binding geometry. 2OG (together with 
O2) completes the octahedral complex and it coordinates the metal in a bidentate manner 
via its 1-carboxylate and 2-oxo groups, displacing two ligating water molecules , as seen 
above in Figure 5.11. The observed coordination position of the 2-oxo group is almost 
invariant in the available crystal structures, and is always positioned trans to the metal 
coordinating carboxylate of D/E. In contrast, the position of the 2OG 1-carboxylate varies 
between being flanking to the prime substrate binding site (trans to the N-terminal histidyl 
of the HXD/E. . .Xn. . .H motif) or being in the available coordination position more on the 
interior of the protein
299
. The different coordination modes of 2OG within JMJDs is an 
important aspect of their structural characterization and it can be considered in the design 
of inhibitors that chelate in the active site. 
As far as the substrate binding mode is concerned the target lysine residue is bound in a 
wide cleft formed primarily by the side chains of hydrophobic residues, which position the 
ε-amino methyl group next to the active site Fe2+. Variations in the size of the active site 
region binding the ε amino methyl group are proposed, in part, to confer methylation state 
selectivity; the degree of selectivity varies with the particular enzyme or subfamily. The 
crystal structure of the catalytic core of JMJD2A (Figure 5.12) shows that, although the 
JmjC domain contains the sites of interaction for the two cofactors, Fe(II) and α-
ketoglutarate, additional domains are needed for catalytic activity
300
.  
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Figure 5.12. Catalytic domain of the histone demethylase JMJD2A in complex with a fragment of 
H3K9me3. 
In the JMJD2 family, two regions within the N terminus and a region immediately 
upstream of the JmjC domain complete the catalytic centre. In contrast to LSD1, the 
structure of the JmjC demethylase JMJD2A shows that the binding pocket specifically 
recognizes and fits trimethylated Lys residues. H3K36me3 and H3K9me3, which are 
substrates for JMJD2A, bind JMJD2A equally but in a different conformation, the former 
(H3K9me3) fold into a open conformation while the latter (H3K36me3) exhibits a tightly 
bent U-shaped conformation. JMJD2A in complex with different H3 peptides is a 
straightforward example showingthat it is the sequence of the H3 peptide nearby the Lys 
residues that is determinant for substrate specificity. In the case of H3K9me3 two nearby 
Gly residues seem to be important for acquiring the required conformation, whereas two 
Gly residues and a Pro residue afford binding specificity for H3K36me3
301
. In this concern 
Lys residues on other substrate that lack these adjacent amino acids in their primary 
structure cannot access the catalytic centre.  
Depending on the homology of the JmjC domain and the presence of other domains, these 
histone lysine demethylases can be divided into seven subfamilies
302
. 
FBXL11 (F-box and leucine-rich repeat protein 11) has been the first JmjC domain-
containing protein to be exhibit histone lysine demethylase activity. FBXL11 and FBLX10 
have been demonstrated to catalyze H3K36me2/me1 demethylation
303
. In addition, 
mammalian FBXL10 has been suggested to act as an H3K4me3 demethylase, even if this 
activity is not yet fully elucidated
304
. FBXL10 besides having the catalytic JmjC domain, 
contain an F-box, a signature domain for a component of SCF (SKP1–cullin-1–F-box) E3 
ligases) and a CXXC DNA-binding domain. Interestingly a recent study displayed that 
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FBXL10 regulates the expression of Polycomb target genes suggesting that FBXL10 might 
contribute to tumorigenesis through the regulation of these genes
305
.  
Studies have pointed out that FBXL10 could act either as a tumour suppressor being able 
to cause lymphoma in BLM (Bloom syndrome RecQ protein-like-3 DNA helicase)-
deficient mice after induced mutagenesis
306
 or as a proto-oncogene since expression data 
from human cancers show over-expression of FBXL10 in lymphomas and 
adenocarcinomas, though the same studies revealed reduced expression of FBLX10 and 
FBXL11 in prostate cancer and in the most aggressive of the primary brain tumours, the 
glioblastoma multiform
307
.  
JMJD1A subfamily encompasses histone demethylases specific for H3K9me2/me1 and it 
includes other two homologues in human cells: JMJD1B and JMJD1C
308
.  
JMJD1A has a characteristic LXXLL motif that is involved in nuclear receptor 
interactions. The expression of JMJD1A has been implicated in demethylation of 
H3K9me2 of androgen receptor (AR) target genes. Moreover studies on knockout mice 
revealed a pivotal role for JMJD1 in germ cell development and metabolism
309,310
. Indeed, 
JMJD1A is highly and dynamically expressed during spermatogenesis, and male mice with 
defected JMJD1A are infertile, with small testes and a severe reduction in sperm count. 
JMJD1A knockout mice also exhibit an increased adult onset of obesity phenotype and 
likely as a result of the transcriptional control of metabolic genes in muscle and adipose 
tissues.  
Another effect of JMJD1A is that during hypoxia it stimulates the expression of HIF target 
genes in colon cancer, like adrenomedullin (ADM), which facilitates the growth of colon 
carcinoma cells
311,312
.  
JMJD2 subfamily demethylases, containing four members JMJD2A, JMJD2B, JMJD2C 
and JMJD2D, are selective for the tri- and di-methylated form of different lysines on 
histone H3. JMJD2D can demethylate H3K9me2 and H3K9me3 but not H3K36me2 and 
H3K36me which is turn targeted by.JMJD2A
313
. Sequence alignment of JMJD2A and 
JMJD2D shows that a variable Ser/Ala position in the binding pocket is responsible for 
this different selectivity, and by generating Ser288Ala and Ala291Ser mutations in 
JMJD2A and JMJD2D, respectively, it is possible to switch the substrate specificity of the 
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two enzymes
314
. Strong genetic data have linked the loss of H3K9 trimethylation to the 
development of cancer in various mouse models, therefore being JMJD2 family, a subset 
of demethylases for H3K9me3 and H3K9me2, it is plausible that overexpression of these 
proteins would result in similar effects. Furthermore several studies have shown that 
JMJD2C is required for growth in an array of different cancer cell lines, including 
squamous cell carcinoma
315
, prostate carcinoma
316
, breast carcinoma
317
 and diffuse large B 
cell lymphoma
318
. Introduction of JMJD2C gene in normal breast MCF10A cells could 
increase the capacity to generate mammospheres, a phenotype of cancer stem cells, 
suggesting that GASC1 acts as a transforming gene. The involvement of JMJD2C in 
tumorigenesis has been supported further by a recent study demonstrating the positive 
functional synergism between JMJD2C and AR in prostate carcinoma, especially in the 
transcriptional activation of AR responsive genes and proliferation of prostate cancer cells. 
Although LSD1 and JMJD1A only demethylate H3K9me2/1, JMJD2C is especially 
capable of efficiently demethylating H3K9me3, inducing a robust cooperative stimulation 
of AR transcriptional activity. Thus, specific modulation of JMJD2C activity alone, or in 
combination with LSD1, may be a promising therapeutic strategy (it will be clearly 
reported later) to control AR activity in tissues whereas it has a key physiological role. 
The members of the JARID1 subfamily (JARID1A-D) are able to demethylase tri- and 
dimethylated H3K4. JARID1A has a role in the regulation of circadian clock length that is 
an indirect result of its inhibition of histone deacetylase HDAC1, moreover JARID1A 
forms a complex with CLOCK and BMAL1, transcription factors that are key in the 
regulation of animal circadian rhythms. In mammalian cells, deletion of JARID1A causes 
a reduction in the activation of circadian genes and a shortening of the circadian rhythm
319
. 
These changes in gene expression are accompanied by reduced histone H3K9 acetylation 
which can be obtained again by catalytic inactivation of JARID1A. Moreover JARID1A 
has been shown to be a key effector of retinoblastoma protein (pRB) mediated cell cycle 
withdrawal and differentiation by interacting with the tumor suppressor pRB
320
. 
Recently it has been found that JARID1A is overexpressed in gastric cancer and that its 
inhibition leads to cellular senescence of gastric and cervical cancer cells by derepressing 
cyclin dependent kinase inhibitors like p27, p21 and p16
321
. Enhanced JARID1A 
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expression was found to contribute to drug tolerance in a non-small cell lung carcinoma 
(NSCLC) cell-system , and this was related to its H3K4 demethylating activity
322
. 
Another component of JARID family, JARID1B, targets H3K4me2 and H3K4me3 and it 
is mainly associated with transcription start sites (TSSs) and coding regions in embryonic 
stem (ES) cells
323
. Depletion of JARID1B leads to a failure in the initiation program for 
the ectodermal differentiation in vitro, thus, the most likely function of JARID1B is to 
maintain H3K4me3 at low levels at its target genes, thereby fine-tuning transcription levels 
and ensuring the proper execution of differentiation programmes. More importantly 
JARID1B is overexpressed in various different cancers, including breast
324
, prostate
325
 and 
bladder carcinoma
326
. Differently from the others member of JARID subfamily, JARID1C 
is implicated in X-linked mental retardation and epilepsy
327
.  
UTX (ubiquitously transcribed tetratricopeptide repeat, X chromosome) and JMJD3 are 
histone demethylases able to specifically remove di- and trimethyl marks from H3K27 
and, thereby counteracting PcG-mediated histone modification by EZH2
328
. Despite its 
activity, JMJD3 depletion only affects the expression of relatively few genes and does not 
result in an overall increase of H3K27me3, JMJD3 might instead serve as a safeguard 
against further H3K27 methylation, thereby ensuring the activation of target genes in 
response to LPS treatment. Indeed JMJD3 activity has been correlated to the response of 
macrophages to lipopolysaccharides and to the activation and maintenance of the so called 
“alternatively activated” status of macrophages, which is considered functionally 
associated with to the response to parasites, tissue remodelling and angiogenesis
329,330
. 
UTX is associated with MLL3/4 complexes and was the first reported mutated histone 
demethylase gene associated with cancer
331
. Somatic mutations of UTX in several human 
cancers (with highest prevalence in multiple myeloma) clearly suggested UTX role as a 
tumor suppressor gene
332
. 
Finally PHF2⁄PHF8 subfamily includes PHF2, PHF8 and KIAA1718; which are 
characterized by a plant homeo domain (PHD)-type zinc finger motif in addition to a JmjC 
domain
333
. PHF8 acts on H3K9me1 and H3K9me2, whereas its close relative KIAA1718 
catalyses demethylation reaction of both mono- and dimethylated H3K9 and H3K27
334
. 
The different substrate specificity has been justified with a different distances between the 
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JmjC and PHD finger domains in the two enzymes. Indeed, they associate with H3K4me3 
through their PHD domain, but while PHF8 has a shorter and more flexible linker which 
assumes a bent conformation and allowing to the JmjC domain to interact with 
demethylate H3K9me1 and H3K9me2. For KIAA1718, the linker is longer and more rigid, 
resulting in an relaxed conformation that renders it inactive towards H3K9me1 and 
H3K9me2 in the presence of nearby H3K4me3, and leads to selectivity towards 
H3K27me1 and H3K27me2 in vitro
335
. 
KIAA1718 plays an important role in neural differentiation too, studies on mouse 
embryonic stem cells(ESC) revealed that KIAA1718 mediated neural promoting effect is 
related to FGF4 induced transcription. How KIAA1718 is recruited to the promoter region 
of FGF4 gene remains however unclear, it has been hypothesized that KIAA1718 could 
recruit a protein complex that contains DNA- or histone-binding activities
336
.  
PHF8 also binds to H3K4me3-positive genes but not necessarily to regions that carry its 
target histone modifications. The loss of PHF8 most often affects the expression of genes 
to which it binds, but the expression of 95% of PHF8 target genes remains unchanged. 
Furthermore, the depletion of PHF8 does not lead to detectable changes in H3K9me2 
levels and only produces minor changes in H3K9me1 and H4K20me1 levels associated 
with target genes
337
. 
 
 
5.5 Targeting Jumonji C domain-containing demethylases 
Taking advantages from the notions available on the JMJD demethylases catalytic 
mechanism and three-dimensional crystal structures, several JMJD inhibitors have been 
identified and analysed in recent years. Initially it was discovered that high concentrations 
of succinate (>10 mM, 1) inhibits JMJD demethylases in a yeast model
338
 most probably 
by shifting toward the reactants the equilibrium in the reaction: 
enzyme α-ketoglutarate + methylated lysine   enzyme succinate + demethylated lysine. 
In addition, it was found that Ni(II) ion replaces Fe(II) in the KDM3A catalytic site 
causing inhibition in the micro molar range (IC50 = 25 M), results supporting the 
inhibition of JMJD3A were also found in cellular evaluations on BEAS-2B cells
339
. 
However most interesting inhibitors emerged considering structural analogues of the α-
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ketoglutarate co-factor, which exhibited competitive inhibition. Among them we can 
mention α-hydroxyglutarate (2, Figure 5.13), which is able to bind in the micro molar 
range (24-106 M) the JMJDs KDM2A (or FBXL11), KDM4A (or JMJD2A) and 
KDM4C (or JMJD2C)
340
, N-Oxalylglycine (NOG, 3, Figure 5.13) and its prodrug 
dimethyloxalyglycine (DMOG, 4, Figure 5.13), that can inhibit JMJD proteins in vitro and 
in vivo respectively
341
, supporting indications that DMOG could be hydrolyzed in NOG in 
the intracellular environment. In particular, NOG and DMOG are thought to inhibit JMJDs 
by chelating the Fe (II) ion of the active site in a bidentate manner, moreover co-crystal 
structure of NOG in KDM4A showed that it can also form an hydrogen bond with 
Tyr132
342
. Thanks to this evidence, new and more potent inhibitors have been designed 
and synthesized. Unlike α-hydroxyglutarate (2) and N-oxalylglycine (3), which act on 
several Fe(II)/α-ketoglutarate dependent enzymes such as prolyl hydroxylases domain-
containing proteins (PHDs) and factor-inhibiting hypoxia-inducible factor (FIH), the D-
tyrosine derivative of NOG (5) showed some degrees of selectivity preferring KDM4A 
(JMJD2A) over PHD2, owing to its tyrosinyl side chain which has been hyphotesized to 
interact with a set of hydrophobic amino acids residues in a subpocket of KDM4A active 
site
343
.  
The promiscuous 2,4-pyridinedicarboxylic acid (PCA, 6, Figure 5.13) beside binding to a 
wide range of Fe(II)/α-ketoglutarate oxygenases was also reported to be a potent (IC50= 
0.7-4.7 M) inhibitor of JMJD2A and JMJD2E with a similar binding mode of NOG and 
NOG derivatives, that is it binds to Ni(II) (replacing Fe
2+
 ion) in a bidentate manner 
through its nitrogen atom and 2-carboxylate oxygen. Further insights into crystal structure 
showed that 4-carboxylate oxygen of 6 also forms hydrogen bonds with NH of Lys241 and 
OH of Tyr177 and that the pyridine ring forms hydrophobic interactions with Tyr177, 
Phe185, and Trp208
344
. Analysis of the three-dimensional structures solved for the 
complex KDM4A-PCA allows to identify position (C-3) of the heteroaromatic ring of 
PCA as a suitable site to improve KDM4 selectivity. Steric-hindered groups will not fit 
inside the active cavity of PHD2 while they will accommodate well inside KDM4 active 
site. This notion leads to the aniline analogue of PCA (7, JMJD2E IC50 = 2.5 M, PHD2 
IC50 > 400 M) which retains the potent activity on KDM4A (JMJD2A) while losing the 
ability to bind PHD2
345
.  
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Figure 5.13. JMJDs inhibitors. 
Subsequent efforts in high-throughput screening led to another PCA-related compound (8, 
JMJD2A IC50 =1.7 M, JMJD2E IC50 = 2.4 M, FIH IC50 = 21 M, PHD2 IC50 = 14 M) 
which shares the same chelating ability of PCA using the quinoline nitrogen and the 8-
hydroxyl group to bind the Ni(II) in the active site and the C-5-carboxylate function to 
interact with Lys206 and Tyr132 (Figure 5.14). Interestingly, compound 8 also showed 
dose-dependent JMJD2A-inhibitory activity in vivo at concentrations ranging from 100 to 
300 μM that is around 40-fold more higher than that exhibited by DMOG346. 
As well as 8-hydroxyl quinoline, bypiridine scaffold has been recently associated to 
KDM4E inhibitory activity too. Compound 9 (Figure 5.14) binds KDM4A and KDM4E 
(KDM4E IC50 = 0.18 μM) to the active site metal using the two pyridines nitrogen and is 
able to interact with Lys206 and Tyr132 through its carboxylate moiety whereas the amide 
group establishes two hydrogen bonds via water molecules with the phenolic oxygen atom 
of Tyr177 and the backbone of Glu169
347
. 
The three-dimensional structure of KDM4C predicted by homology modeling techniques 
has also been used to gain insights into the active site and design compound 10 (Figure 
5.14, NCDM-32). It has a 500-fold greater activity towards KDM4C also known as 
JMJD2C (KDM4C IC50 = 1.0 μM, KDM4A IC50 = 3.0 μM) and 9100-fold greater 
KDMC4/PHD selectivity than the lead compound NOG (PHD1 IC50 > 100 μM, PHD2 IC50 
> 100 μM), proving that structure prediction could be helpful in gaining information on the 
structure activity relationships between compounds and enzymes
348
. 
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Recently a novel hydroxamate compound 11 has been found to preferentially inhibit the 
subfamily of Jumonji demethylases in respect to other Fe(II)/α-ketoglutarate oxygenases 
(JMJD2A IC50 = 4.3 μM, JMJD2C IC50 = 3.4 μM, JMJD2E IC50 = 5.9 μM, PHD1 IC50 = 
54 μM, PHD2 IC50 = 83 μM, FIH IC50 = 22 μM). More important methylstat the prodrug 
of 11 electively inhibited JMJD demethylases in cells and showed growth inhibition of 
esophageal carcinoma KYSE150 cells
349
, in which KDM4C is highly expressed.  
Finally disulfiram analogues (Figure 5.14) have been found to inhibit JMJD2A (12, 
JMJD2A IC50 = 3.3 μM), they seems to act by removing Zn
2+
 ion from the Zn-binding site 
of JMJD2A, thus opening the way to Zn removal as an approach to achieve JMJD2 
selectivity over JMJDs that lack Zn-binding site
350
. 
 
Figure 5.14. JMJDs inhibitors. 
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6. PAN-HISTONE DEMETHYLASE INHIBITORS 
SIMULTANEOUSLY TARGETING JUMONJI C AND LYSINE 
SPECIFIC DEMETHYLASES DISPLAY HIGH ANTICANCER 
ACTIVITIES  
As displayed in the text above, histone lysine demethylases play an important role in gene 
expression and transcription regulation, together with the histone mark writers, readers and 
erasers they establish a tangled and cross-talking molecular “dialect” (histone code) which 
acts as a bookmark to gain a controlled and precise access to the genetic information in 
according to the cellular needs. The epigenetic mechanism affects a plenty of cellular 
functions, especially the cell cycle progression control, and when it is aberrant, may lead to 
the onset and progression of different cancers. In one of the recent studies appeared in 
literature, focusing on the effects of KDM4A/C (JMJ2C/E) inhibitors on human prostate 
cancers, it was showed that these inhibitors were found not to inhibit prostate (LNCaP and 
PC3) and colon (HCT116) cancer cell growth in isolation, but displayed anti-proliferative 
effects in combination with NCL-2
351
, an LSD1 inhibitor, suggesting a potential for 
synergy in LSD and JmjC KDM inhibition. In multifactorial diseases such as cancer, 
central nervous system disorders, diabetes, or immunoinflammatory diseases, which 
involve multiple altered cellular pathways and signals, the use of single-target drugs (the 
“one drug, one target” concept) can result in unsatisfactory treatment outcomes352,353,354. 
Combination therapies employing two or more drugs, can be more efficient in controlling 
such complex disease systems and less prone to resistance
355,356
. An alternative strategy to 
combination therapy is to develop a single chemical entity that is able to modulate multiple 
targets simultaneously (designed multiple ligands, DMLs)
357,358,359
. The overall goal of the 
DML approach is to enhance the efficacy and/or improve the safety of therapy respect to 
drug combination. Additional advantages of DMLs are the reduction of pill burden for 
patients, due to the administration of a single compound, a lower risk of drug-drug 
interactions, and improvement in medication adherence. As follow up of previous works
360 
,361,362
, they are describe here pan-demethylase inhibitors 1-6 (Figure 6.1) that 
simultaneously inhibit both LSD1 and JmjC KDMs. Compounds 1-6 were designed by 
coupling tranylcypromine (7), a known LSD1 inhibitor
363
, and 4-carboxy-4'-
carbomethoxy-2,2'-bipyridine 8
364
 or 5-carboxy-8-hydroxyquinoline (9, 5-carboxy-
8HQ)
365
, two 2OG competitive templates developed for JmjC inhibition (Figure 6.1). The 
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molecular weight of these pan-demethylase inhibitors is acceptable because they result 
from combination of low molecular weight molecules.  
 
 
Figure 6.1. Pan-demethylase and their single target precursors structures.  
The compounds were selected based on known inhibition results and crystallographic 
analyses of both the LSDs and JmjC KDMs. Based on manual docking studies (Figure 
6.2), we proposed that conjugation of tranylcypromine to the carboxylate group of either 4-
carboxy-4'-carbomethoxy-2,2'-bipyridine 8 or 5-carboxy-8-hydroxyquinoline 9 (to form 
compounds 1, 2 and 3-6 respectively), would give compounds that are capable of binding 
to both the LSD and KDM4 active sites (details will be presented later in the experimental 
part). Based on the LSD1 structure (PDB 2XAJ)
257
, the bipyridyl (for 1) and 
hydroxyquinoline (for 3) rings are predicted to protrude into the LSD1 substrate binding 
pocket, with the tranylcypromine moiety conjugating to FAD, as occurs during inhibition 
by tranylcypromine 7 alone (Figure 6.2-A). Analysis of the active site of KDM4A (PDB 
3PDQ)
366
 leads to the proposal that both compounds 1 and 3 can chelate the protein-bound 
iron via their bipyridyl and hydroxyquinoline groups respectively, as observed for a known 
bipyridyl inhibitor
367
 and 5-carboxy-8HQ 9. Moreover, the primary amines of 1 and 3 may 
be involved in hydrogen bonding and/or electrostatic interactions with KDM4A (Figure 
6.2-B).  
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Figure 6.2. Manual docking of compounds 1 (yellow) and 3 (blue) in LSD1 (A) and KDM4A (B) active 
sites. In LSD1 (A), 1 and 3 are proposed to react with active site bound FAD, opening the cyclopropyl ring. 
The bipyridyl (in the case of 1), and the 8-hydroxyquinolyl (in the case of 3) groups protrude toward the 
histone substrate-binding pocket. In KDM4A (B), 1 and 3 are proposed to chelate to the active site bound 
Fe(II) via the bipyridyl and 8-hydroxyquinolyl groups respectively. The tranylcypromine moiety in both 
compounds likely protrudes towards the histone substrate binding pocket, potentially forming hydrogen 
bonding and/or electrostatic interactions via the primary amine. Models of both enantiomers of 1 and 3 
bound to KDM4A are shown. 
 
Compounds 1 and 2 (route A) were prepared by coupling 4-carboxy-4'-carbomethoxy-2,2'-
bipyridine 8 with trans-N-Boc-2-(4-aminophenyl)cyclopropylamine 10 using HOBt/EDCI 
to give amide 11; ester hydrolysis to give 12 followed by N-Boc deprotection with 
CF3CO2H gave initial target 1 (Scheme 6.1), all hybrid compounds were prepared as trans 
racemates). Alternatively, 11 was directly hydrolyzed in 4N HCl to give ester 2. To 
prepare 8-hydroxyquinoline compounds 3-6 (route B), 5- carboxy-8HQ 9 as its O-MOM-
protected derivative (13) was condensed with 10, and intermediate 14 was treated with 4N 
HCl to provide 3. Reaction of 13 with the requisite methyl-ω-aminoalkanoate 
hydrochlorides
368
 gave methyl esters 15-17, which after alkaline hydrolysis were 
condensed with 10 to give the intermediates 18-20. Subsequent acid de-protection of 18-20 
afforded final compounds 4-6. Alternatively, intermediates 15-17 were MOM group de-
110 
 
protected to give the 8HQ methyl esters 21-23, which were hydrolyzed to give acids 24-
26. 
 
 
Scheme 6.1. (a) racemic trans-N-Boc-2-(4-aminophenyl)cyclopropylamine 10, HOBt, EDCI, Et3N, DMF, 
RT; (b) 0.2N NaOH, MeOH, RT; (c) CF3COOH, 0 °C to RT; (d) 4N HCl in 1,4-dioxane, THF/MeOH, RT; 
(e) methyl ω–aminoalkanoate hydrochloride, HOBT, EDCI, Et3N, DCM, RT; (f) 2N LiOH, THF, RT. 
 
Compounds 1-6 were tested against LSD1 and a subfamily representative panel of JmjC 
KDMs including KDM4. In the LSD1 inhibition assays, the tested compounds all showed 
single-digit (1, 5, 6) or submicromolar (2-4) IC50 values, with similar or increased 
potencies respect to the reference 7 (Table 6.1). Compounds 1-3 were also tested against 
MAO-A and MAO-B to assess their selectivity towards LSD1: at the tested conditions, 1 
and 3 were definitively more effective in inhibiting LSD1 than MAOs, while 2 was less 
potent against MAO-B but showed similar inhibitory potency against MAO-A respect to 
LSD1, analogously to what observed with other tranylcypromine based compounds. 
Inhibition of the JmjC KDMs by the hybrid compounds 1-6 (Table 6.1) and 8HQ esters 
(21-23) and acids (24-26) was then investigated, using 8 and 9 as references and is 
reported in Table 6.2. Interestingly, both 8HQ (compounds 3-6) and bipyridine (compound 
1) hybrid inhibitors showed similar potencies against JmjC KDMs as the reference 
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compounds 8 and 9, demonstrating that the conjugation of tranylcypromine does not 
adversely affect activity. Compound 1 displayed low- or sub-micromolar activity against 
all the tested JmjCs, thus being the most potent of the series. Importantly, when tested 
against the hypoxia inducible factor hydroxylases FIH and PHD2, the former of which is 
closely related to the JmjC KDMs, 1 showed no/weak inhibition, revealing high KDM-
selectivity. Consistent with previous SAR for the bipyridine derivatives, the free acid is 
required for high potency against JmjC KDMs as the ester “pro-drug” form (2) weakens 
the potency. Single digit (9 out of 10) values were obtained for 2-6 against KDM4, the 
KDM subfamily that has been shown to work synergistically with LSD1
351
(Table 6.1). 
cpd 
IC50, µM 
LSD1 
(KDM1) 
MAO 
A 
MAO 
B 
FBXL11 
(KDM2/7) 
JMJD1A 
(KDM3) 
JMJD2C 
(KDM4) 
JMJD2E 
(KDM4) 
JARID1C 
(KDM5) 
JMJD3 
(KDM6) 
1 2.2 35.4 47.0 0.22 0.14 0.07 0.42 0.19 2.7 
2 0.5 <1 43.3 12.2 37.3 2.7 15.6 8.6 75.5 
3 0.3 8.9 81.0 7.8 30.8 1.2 3.9 26.2 27.1 
4 0.8 - - 12.0 12.5 4.5 5.5 35.7 17.9 
5 1.6 - - 8.2 9.7 3.1 3.5 20.7 14.0 
6 1.0 - - 11.5 9.1 2.5 5.1 36.7 15.7 
7 2.1 4.5 2.5 >100 >100 >100 >100 >100 >100 
8 >100 - - 4.8 1.1 3.5 5.0 0.03 11.2 
9 N.D. - - 15 0.17 0.6 0.3 25 0.14 
Table 6.1. Inhibition of LSD1, MAOs, JmjC and other 2OG-dependent Enzymes by Pan-demethylase 
Inhibitors 1-6.a The KDM Subfamily of Each Demethylase Enzyme is Reported among Brackets. 
Single Family-specific Target Inhibitors 7-9 were used as references. 
a
Inhibition assays were performed in duplicate. The errors in determinations of IC50s are within ±10% 
of their values. 
b
ND, Not Detectable. Compound 9 interferes with the peroxidase used in the coupled 
enzymatic assay and the inhibition could not be reliably measured. 
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cpd 
IC50, µM 
FBXL11 JMJD1A JMJD2C JMJD2E JARID1C JMJD3 
21 57 39 4.5 5.1 38 23 
22 35.6 12.2 8.0 10.1 85.6 13.1 
23 26 22 5.4 9.7 39 13 
24 >100 31 4.7 5.8 37 41 
25 32.5 9.0 9.1 9.5 75 13.7 
26 32 37 4.8 10 57 14 
9 15 0.17 0.6 0.3 25 0.14 
Table 6.2. Inhibitory activities of methyl 2-(8-hydroxyquinoline-5-carboxamido)alkanoates 21-23 
and 2-(8-hydroxyquinoline-5-carboxamido)alkanoic acids 24-26 against JmjC enzymes. 
 
We then investigated whether the pandemethylase inhibitors 1, 2 and 3 affect selected 
global histone methylation states in HeLa cells, using immunofluorescence based methods 
(Figure 6.3). Compounds 7 for LSD1, and 8a (a pro-drug form of 8
369
, Figure 6.1) and 9 
for JmjC enzymes, were used as references. The hybrid inhibitors 2 and 3 caused 
substantial, dose-dependent increases of methyl marks at lower concentrations than 9 
whereas 7 caused essentially no changes in the overall methylation levels (including H3K4 
methylations), in agreement with previous studies
370,371
. The lack of effects on H3K4me3 
may reflect the weaker inhibition of H3K4 demethylases (JARID/KDM5) over H3K9me3 
KDMs (KDM4), coupled to the simultaneous effect of inhibiting the H3K4me2 selective 
demethylase LSD1 (Table 6.1) or more complex effects due to inhibition of multiple 
targets. The 2,2'-bipyridine derivative 2 caused a H3K9me2/3-specific dosedependent 
hypermethylation effect, whereas 8a and 7 alone had no effect. This observation suggests 
that the “hybridization” of the bipyridyl and tranylcypromine motif has a synergistic effect, 
with respect to inhibition of LSD1 and KDM4/3 families. There was a general decrease in 
the immunofluorescence signal at higher doses where toxicity was observed (Figure 6.4-I). 
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Figure 6.4. Detection of changes in the global histone methylation levels in HeLa cells after 
treatment with 1, 2, 3, 7, 8a and 9 over 72 h using an immunofluorescence-based assay (A-H). 
Cytotoxicity of compounds 2, 3 and 8a at high doses is shown as number of cells per fixed field of 
view (I). 
 
Compounds 1-6 (50 μM) were tested in human prostate LNCaP and colon HCT116 cancer 
cells to investigate their effects on cell cycle (after 30 h), apoptosis (after 30 h) and 
differentiation (after 48 h), using 7-9 as references. In LNCaP cells, 2, 3 and 6 caused a 
strong G1 phase arrest (≥ 90%) with a substantial fraction of the cells in pre-G1 stage 
consistent with apoptosis induction, especially for 2 and 3 (Figure 6.5-A). In HCT116 
cells, the pan-inhibitors 3 and 5 and the JmjC selective inhibitor 9 displayed cell cycle 
alteration when compared to controls; however, as with the LNCaP cells, only compounds 
2 and 3 induced the pre-G1 phase accumulation (Figure 6.5-B). Dose-response curves for 
apoptosis in LNCaP and HCT116 cells were detected after treatment of cells for 48 h with 
2 and 3 at doses from 10 to 100 µM (Figure 6.5-C).  
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Figure 6.5. Effects of pan-demethylase inhibitors 1-6 in LNCaP and in HCT116 cells. Cell cycle effect 
(left) and percentage of cells at pre-G1 peak (right) of 1-9 (50 μM, 30 h) in LNCaP (A) and HCT116 
(B) cells. (C) dose-response curves with 2 and 3 for apoptosis (48h) in LNCaP (left) and HCT116 
(right) cells. 
When compared in independent experiments to a combination of the single-family target 
Inhibitors 7 and 8, 2 and 3 showed much more efficacy in inducing apoptosis both in 
LNCaP and HCT116 cells (at 50 μM for 24 h; Figure 6.5). To assess their differential 
toxicity, compounds 2 and 3 were also tested (50 μM, 24 h) in mesenchymal progenitor 
(MePR) cells
372
: in this non-cancer cell line 2 increased the pre-G1 peak percentage from 
8.4 to 12.8% respect to the control, while with 3 the same value was under the control 
value (4.2%), suggesting a cancer cell-selective apoptotic induction for the two pan-KDM 
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inhibitors (Figure 6.6). Despite differences in number of cells in pre-G1 phase among 
Figure 6.5 and 6.6, compounds 2 and 3 induced cell death in cancer specific manner. These 
differences, however, could be due to cell populations (i.e. the value of percentage of pre-
G1 for the untreated HCT116 cells was around 2% in Figure 6.5 and around 8% in Figure 
6.6). Also times of induction (30 h in Figure 6.5 and 24 h in Figure 6.6) could justify the 
differences among percentages in data. 
 
Figure 6.6. Comparison of effects on pre-G1 peak accumulation for 2, 3, 7, 8 and combination of 7 plus 8 
(50 μM, 24 h) in LNCaP, HCT116, and MePR cells. 
Effects on cell proliferation and migration were detected by treating LNCaP and HCT116 
cells with 50 μM 2 and 3 up to 72 h, using the HDAC inhibitor SAHA as a positive 
control. In LNCaP cells, 2 showed similar growth arrest as SAHA, while 3 was less 
effective (Figure 6.7-A, left) (In the experimental section will be presented the whole 72 h-
assay). Nevertheless, differently from SAHA, neither 2 or 3 was able to stop migration in 
this cell line (Figure 6.7-A, right). In HCT116 cells, strong antiproliferative effects for 2 
and 3 were detected even after 6 h (Figure 6.7-B, left), while the corresponding SAHA 
effect appeared only at 72 h (Figure 6.9, Experimental section). In this cell line, 2 and 
SAHA strongly hampered migration, while 3 had no effect (Figure 6.7-B, right). 
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Figure 6.7. Proliferation curves and cell migration relative to LNCaP (A) and HCT116 (B) cell lines after 
24h. The HDAC inhibitor SAHA was used as a reference drug. Left: proliferation curves after 24h. Control 
(untreated cells) in red, cells treated with SAHA (5 μM) in green, cells treated with 2 (50 μM) in blue, cells 
treated with 3 (50 μM) in violet, in sky-blue (LNCaP, A) or yellow-green (HCT116, B) the base lines. 
Right: cell migration after 24 h. Histograms have been represented by slope relative to the control 
(untreated cells), cells treated SAHA (5 μM), cells treated with 2 (50 μM) and cells treated with 3 (50 μM). 
Data show the mean value from three parallel experiments with error bars showing the standard deviations 
on top of each column. 
Western blot analysis using mark-specific antibodies supported the proposal that the 
effects of 2 and 3 in LNCaP and HCT116 cells are due to both LSD1 and JmjC inhibition. 
Figure 6.8 shows increased H3K4me2/3 and H3K9me3 methylation after treatment with 
50 µM 2 and 3. 
117 
 
 
Figure 6.8. Western blot analyses of H3K4me2/3 and H3K9me2/3 methylation after treatment of LNCaP 
(left) and HCT116 (right) cells with 2, 3 and the references 7-9. 
In conclusion, we have shown that “pan-KDM” inhibitors can be obtained by coupling the 
chemical features of tranylcypromine, a known LSD1 inhibitor, with the 2,2'-bipyridine or 
5-carboxy-8HQ scaffolds, two 2OG competitive moieties developed for JmjC inhibition. 
Such compounds are able to inhibit LSD1 as well as JmjC enzymes while have little or no 
effect against other tested 2OG enzymes lacking KDM activity. It is also interesting that 
the tranylcypromine-moieties act as covalently binding inhibitors, whereas the JmjC 
inhibitor scaffolds bind reversibly (note the excellent safety record of covalent clinical 
candidates and marketed agents that has been recently described)
373
. The application of 
such LSD/JmjC hybrid inhibitors to cells enables simultaneous increases in levels of 
H3K4me2/3 and H3K9me2/3 as well as high growth arrest and apoptosis (2 and 3) in 
LNCaP prostate and HCT116 colon cancer cells, whereas the related family-specific 
single-target inhibitors 7-9 as well as a combination of 7 plus 8 were inactive. When tested 
in MePR non-cancer cells to assess their differential toxicity, 2 and 3 showed very low (2) 
or no (3) ability to increase the pre-G1 accumulation. It should be noted that since a single 
KDM may target multiple substrates, different biological effects depending on the context 
could manifest. To the best of our knowledge, these are the first pan-KDM inhibitors to be 
described. More generally, the results demonstrate that hybrid molecules inhibiting 
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different classes of histone modifying enzymes have substantial potential as functional 
probes or histone methylation, and we suggest that combining other types of inhibitors 
targeting histone modifying enzymes may be productive with respect to regulating the 
expression of specific (sets of) genes. Our pan-demethylase inhibitors may also be useful 
for medicinal chemistry efforts relating to cancer, in line with what happens with SAHA, 
which likely owes its anticancer activity to its pan-HDAC inhibitor profile
374
. 
Experimental section 
Chemistry. Melting points were determined on a Buchi 530 melting point apparatus. 
1
H-
NMR and 
13
C-NMR spectra were recorded at 400 MHz using a Bruker AC 400 
spectrometer; chemical shifts are reported in δ (ppm) units relative to the internal reference 
tetramethylsilane (Me4Si). Mass spectra were recorded on a API-TOF Mariner by 
Perspective Biosystem (Stratford, Texas, USA), samples were injected by an Harvard 
pump using a flow rate of 5−10 μL/min, infused in the Electrospray system. All 
compounds were routinely checked by TLC and 1H NMR. TLC was performed on 
aluminum-backed silica gel plates (Merck DC, Alufolien Kieselgel 60 F254) with spots 
visualized by UV light or using a KMnO4 alkaline solution. All solvents were reagent 
grade and, when necessary, were purified and dried by standard methods. Concentration of 
solutions after reactions and extractions involved the use of a rotary evaporator operating 
at reduced pressure of ~ 20 Torr. Organic solutions were dried over anhydrous sodium 
sulfate. Elemental analysis has been used to determine purity of the described compounds, 
that is >95%. Analytical results are within 0.40% of the theoretical values. All chemicals 
were purchased from Sigma Aldrich s.r.l., Milan (Italy) or from TCI Europe N.V., 
Zwijndrecht (Belgium), and were of the highest purity. As a rule, samples prepared for 
physical and biological studies were dried in high vacuum over P2O5 for 20h at 
temperatures ranging from 25 to 40 °C, depending on the sample melting point. 
trans-Methyl 4'-((4-(2-((tert-Butoxycarbonyl)amino)cyclopropyl)phenyl)carbamoyl)-
[2,2'-bipyridine]-4-carboxylate (11). The reagents HOBT (62 mg, 0.39 mmol, 1.2 eq), 
EDCI (75 mg, 0.39 mmol, 1.2 eq) and Et3N (0.15 mL, 1.11 mmol, 3.4 eq) were added in 
sequence to a mixture of compound 8 (101 mg, 0.39 mmol, 1.2 eq) and trans-tert-butyl 2-
(4- aminophenyl)cyclopropylcarbamate 10 (81 mg, 0.33 mmol, 1.0 eq) in dry DMF (2.1 
119 
 
mL), and the resulting solution was stirred at room temperature overnight. The reaction 
was quenched with brine (5 mL) and concentrated under reduced pressure, and the 
aqueous phase was extracted with AcOEt (4 × 30 mL). The combined organic phases were 
washed with NaHCO3 saturated solution (2 × 7 mL) and brine (5 mL). The organic phases 
were collected, dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give a 
crude product that was purified by column chromatography on silica gel (eluent: 
CHCl3/MeOH 100/1) to give compound 11 (127 mg, 80%) as an off-white solid. Mp: 196- 
199 °C (EtOH). 
1
H-NMR (DMSO-d6) δH/ppm: 1.10 (m, 2H, -CH2- cyclopropane ring), 
1.43 (s, 9H, NHCO2C(CH3)3), 1.91 (m, 1H, -CH- cyclopropane ring), 2.62 (m, 1H, -CH- 
cyclopropane ring), 3.98 (s, 3H, CO2CH3), 7.12 (d, 2H, benzene ring), 7.24 (bs, 1H, 
CHNHCO2tBu), 7.70 (d, 2H, benzene ring), 7.97 (m, 2H, bipyridine rings), 8.89 (s, 2H, 
bipyridine rings), 8.93 (m, 1H, bipyridine ring), 8.98 (m, 1H, bipyridine ring), 10.64 (bs, 
1H, ArNHCO). 
13
C-NMR (DMSO-d6) δ/ppm: 15.6, 22.4, 29.3, 31.3, 49.7, 81.2, 117.8, 
118.2, 121.1, 121.8, 122.6, 126.5, 132.4, 137.6, 142.8, 149.2, 150.0, 154.8, 155.3, 156.0, 
159.2, 166.7, 168.8. MS, m/z: 489 [M+H]
+
.  
General Procedure for the Synthesis of trans-Methyl 4'-((4-(2- 
Aminocyclopropyl)phenyl)carbamoyl)-[2,2'-bipyridine]-4-carboxylate hydrochloride 
(2), trans-N-(4-(2-Aminocyclopropyl)phenyl)-8-hydroxyquinoline-5-carboxamide 
hydrochloride (3) and trans-N-(ω-((4-(2-Aminocyclopropyl)phenyl)amino)-ω-
oxoalkyl)-8-hydroxyquinoline-5-carboxamide hydrochlorides (4-6). Example: trans-
N-(4-((4-(2-Aminocyclopropyl)phenyl)amino)-4-oxobutyl)-8-hydroxyquinoline-5-
carboxamide hydrochloride (4). Compound 18 (100 mg, 0.18 mmol, 1.0 eq) was 
dissolved in a mixture of dry THF/MeOH (1.4 mL/1.4 mL) and the solution stirred at 0 °C, 
then 4N HCl in 1,4-dioxane (3.65 mL, 14.58 mmol, 80 eq) was added dropwise and the 
mixture was allowed to warm at room temperature. After 3 hours, the suspension was 
cooled at 0 °C, and 4N HCl in 1,4-dioxane (1.82 mL, 7.29 mmol, 40 eq) was added 
dropwise again. After 8 hours, when conversion was complete, the suspension was filtered 
and washed with dry THF and then with dry Et2O to afford compound 4 (68 mg, 85%) as a 
yellow hygroscopic solid. Mp: >250 °C (THF/MeOH). 
1
H-NMR (DMSO-d6) δH/ppm: 1.15 
(m, 1H, -CHH- cyclopropane ring), 1.35 (m, 1H, -CHH- cyclopropane ring), 1.90 (m, 2H, 
CH2CH2CH2), 2.28 (m, 1H, -CH- cyclopropane ring), 2.42 (m, 2H, CH2CH2CO), 2.74 (m, 
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1H, -CH- cyclopropane ring), 7.06 (d, 2H, benzene ring), 7.30 (d, 1H, quinoline ring), 7.52 
(d, 2H, benzene ring), 7.87 (m, 2H, quinoline ring), 8.47 (bs, 3H, CHNH2 .HCl), 8.65 (bs, 
1H, CONHCH2), 9.02 (d, 1H, quinoline ring), 9.24 (d, 1H, quinoline ring), 10.01 (s, 1H, 
ArNHCO), 11.40 (bs, 1H, quinoline OH). 
13
C-NMR (DMSO-d6) δC/ppm: 14.9, 22.8, 26.2, 
28.5, 34.1, 40.1, 112.4, 119.7, 124.5, 126.7, 128.2, 128.5, 130.5, 131.1, 133.6, 135.3, 
138.9, 150.3, 157.7, 162.1, 180.6. MS (relative to free amine), m/z: 405 [M+H]
+
.  
trans-Methyl 4'-((4-(2-Aminocyclopropyl)phenyl)carbamoyl)-[2,2'-bipyridine]-4-
carboxylate hydrochloride (2). Mp: >250 °C (THF/MeOH). Yield: 61%. 
1
H-NMR 
(DMSO-d6) δH/ppm: 1.22 (m, 1H, -CHH- cyclopropane ring), 1.39 (m, 1H, -CHH- 
cyclopropane ring), 2.34 (m, 1H, -CH cyclopropane ring), 2.81 (m, 1H, -CH- cyclopropane 
ring), 3.97 (s, 3H, CO2CH3), 7.19 (d, 2H, benzene ring), 7.76 (d, 2H, benzene ring), 7.99 
(m, 2H, bipyridine rings), 8.43 (bs, 3H, CHNH2 .HCl), 8.89 (s, 2H, bipyridine rings), 8.94 
(d, 1H, bipyridine ring), 8.98 (d, 1H, bipyridine ring), 10.71 (bs, 1H, ArNHCO). 
13
C-NMR 
(DMSO-d6) δC/ppm: 14.5, 22.4, 28.3, 52.0, 117.6, 118.1, 120.8, 122.1, 123.0, 125.8, 133.4, 
137.5, 144.1, 149.9, 150.5, 155.2, 156.8, 158.2, 165.3, 166.4. MS (relative to free amine), 
m/z: 389 [M+H]
+
. 
trans-N-(4-(2-Aminocyclopropyl)phenyl)-8-hydroxyquinoline-5-carboxamide 
hydrochloride (3). Mp: >250 °C (THF/MeOH). Yield: 71%. 
1
H-NMR (DMSO-d6) 
δH/ppm: 1.23 (m, 1H, -CHHcyclopropane ring), 1.38 (m, 1H, -CHH- cyclopropane ring), 
2.32 (m, 1H, -CH- cyclopropane ring), 2.80 (m, 1H, -CH- cyclopropane ring), 7.17 (d, 2H, 
benzene ring), 7.28 (d, 1H, quinoline ring), 7.72 (d, 2H, benzene ring), 7.79 (m, 1H, 
quinoline ring), 7.94 (d, 1H, quinoline ring), 8.38 (bs, 3H, CHNH2 .HCl), 9.00 (m, 2H, 
quinoline ring), 10.47 (s, 1H, ArNHCO). 
13
C-NMR (DMSO-d6) δC/ppm: 14.8, 22.6, 28.2, 
113.8, 121.7, 125.7, 126.8, 128.0, 129.1, 130.2, 130.9, 134.1, 135.8, 137.9, 152.1, 159.3, 
165.1. MS (relative to free amine), m/z: 320 [M+H]
+
. 
trans-N-(5-((4-(2-Aminocyclopropyl)phenyl)amino)-5-oxopentyl)-8-hydroxyquinoline-
5- carboxamide hydrochloride (5). Mp: >250 °C (THF/MeOH). Yield: 65%. 
1
H-NMR 
(DMSO-d6) δH/ppm: 1.17 (m, 1H, -CHH- cyclopropane ring), 1.33 (m, 1H, -CHH- 
cyclopropane ring), 1.64 (m, 4H, CH2CH2CH2CH2), 2.26 (m, 1H, -CH- cyclopropane 
ring), 2.36 (t, 2H, CH2CH2CO), 2.75 (m, 1H, -CH cyclopropane ring), 7.07 (d, 2H, 
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benzene ring), 7.21 (d, 1H, quinoline ring), 7.53 (d, 2H, benzene ring), 7.78 (m, 2H, 
quinoline ring), 8.35 (bs, 3H, CHNH2 .HCl), 8.57 (bs, 1H, CONHCH2), 8.97 (d, 1H, 
quinoline ring), 9.06 (d, 1H, quinoline ring), 9.92 (s, 1H, ArNHCO), 11.10 (bs, 1H, 
quinoline OH). 
13
C-NMR (DMSO-d6) δC/ppm: 14.5, 22.3, 23.1, 28.0, 29.4, 38.3, 39.0, 
114.4, 121.9, 125.4, 126.6, 127.9, 128.8, 130.5, 131.1, 134.7, 135.4, 138.9, 151.7, 159.3, 
162.4, 179.7. MS (relative to free amine), m/z: 419 [M+H]
+
. 
trans-N-(6-((4-(2-Aminocyclopropyl)phenyl)amino)-6-oxohexyl)-8-hydroxyquinoline-
5- carboxamide hydrochloride (6). Mp: >250 °C (THF/MeOH). Yield: 89%. 
1
H-NMR 
(DMSO-d6) δH/ppm: 1.18 (m, 1H, -CHH- cyclopropane ring), 1.38 (m, 3H, -CHH- 
cyclopropane ring and –CH2- aliphatic chain), 1.61 (m, 4H, aliphatic chain), 2.32 (m, 3H, -
CH- cyclopropane ring and CH2CH2CO), 2.75 (m, 1H, -CH- cyclopropane ring), 3.33 (t, 
2H, NHCH2CH2), 7.06 (d, 2H, benzene ring), 7.33 (d, 1H, quinoline ring), 7.52 (d, 2H, 
benzene ring), 7.85 (d, 1H, quinoline ring), 7.89 (m, 1H, quinoline ring), 8.43 (bs, 3H, 
CHNH2 .HCl), 8.62 (bs, 1H, CONHCH2), 9.03 (d, 1H, quinoline ring), 9.24 (d, 1H, 
quinoline ring), 9.92 (s, 1H, ArNHCO). 
13
C-NMR (DMSO-d6) δC/ppm: 14.3, 22.2, 25.2, 
25.7, 28.1, 29.5, 38.4, 39.5, 114.3, 121.5, 125.8, 126.9, 127.7, 128.7, 130.4, 131.3, 134.5, 
135.3, 138.8, 151.7, 159.5, 162.7, 179.8. MS (relative to free amine), m/z: 433 [M+H]
+
. 
4'-((4-(2-((tert-Butoxycarbonyl)amino)cyclopropyl)phenyl)carbamoyl)-[2,2'-
bipyridine]-4- carboxylic acid (12). Compound 11 (111 mg, 0.227 mmol, 1.0 eq) was 
suspended in 4 mL of MeOH and cooled in an ice bath, then NaOH (27.3 mg, 0.682 mmol, 
3.0 eq) in water (0.7 mL) was added dropwise and the mixture was allowed to stir at room 
temperature. After 9 hours the organic solvent was removed in vacuo and the aqueous 
phase, cooled at 0 °C, was acidified to pH 2 with a solution of 0.5N KHSO4. The obtained 
suspension was filtered to afford the desired compound 12 (96 mg, 89%) as a yellow solid. 
Mp: >250 °C (EtOH). 
1
H-NMR (DMSO-d6) δH/ppm: 1.11 (m, 2H, -CH2- cyclopropane 
ring), 1.39 (s, 9H, NHCO2C(CH3)3), 1.90 (m, 1H, -CH- cyclopropane ring), 2.62 (m, 1H, -
CH cyclopropane ring), 7.12 (d, 2H, benzene ring), 7.24 (bs, 1H, CHNHCO2tBu), 7.70 (d, 
2H, benzene ring), 7.95 (m, 2H, bipyridine rings), 8.88 (s, 2H, bipyridine rings), 8.94 (m, 
2H, bipyridine ring), 10.64 (bs, 1H, ArNHCO), 13.89 (bs, 1H, COOH). 
13
C-NMR 
(DMSO-d6) δC/ppm: 14.1, 21.9, 27.8, 32.7, 80.3, 117.6, 118.2, 118.4, 120.1, 121.5, 124.4, 
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125.3, 134.0, 137.4, 144.9, 149.1, 149.9, 154.9, 155.4, 155.9, 159.5, 164.8, 170.1. MS, 
m/z: 475 [M+H]
+
. 
trans-4'-((4-(2-Aminocyclopropyl)phenyl)carbamoyl)-[2,2'-bipyridine]-4-carboxylic 
acid trifluoroacetate (1). Trifluoroacetic acid (1.04 mL, 13.54 mmol, 230 eq) was added 
to 12 (28.2 mg, 0.059 mmol, 1.0 eq) placed in an ice bath, and the mixture was allowed to 
stir at room temperature. After 5 hours the solvent was removed at low temperature under 
reduced pressure, then the solid was stirred as suspension in dry Et2O for 1 hour and 
filtered to provide the desired compound 1 (26 mg, 90%) as a dark red solid. Mp: >250 °C 
(THF/MeOH). 
1
H-NMR (DMSO-d6) δH/ppm: 1.23 (m, 1H, - CHH- cyclopropane ring), 
1.33 (m, 1H, -CHH- cyclopropane ring), 2.28 (m, 1H, -CH- cyclopropane ring), 2.84 (m, 
1H, -CH- cyclopropane ring), 7.20 (d, 2H, benzene ring), 7.74 (d, 2H, benzene ring), 7.96 
(m, 2H, bipyridine rings), 8.26 (bs, 3H, NH2 .CF3COOH ), 8.88 (s, 2H, bipyridine rings), 
8.94 (m, 2H, bipyridine ring), 10.69 (bs, 1H, ArNHCO). 
13
C-NMR (DMSO-d6) δC/ppm: 
14.9, 22.6, 28.2, 117.3, 117.9, 118.7, 120.7, 121.2, 124.1, 125.5, 134.5, 138.7, 144.9, 
149.2, 149.8, 155.2, 156.1, 159.8, 162.2, 164.9, 170.4. MS (relative to free amine), m/z: 
375 [M+H]
+
. 
8-(Methoxymethoxy)quinoline-5-carboxylic acid (13). 8-Hydroxyquinoline-5-
carboxylic acid (2.41 g, 12.8 mmol, 1 eq) was added portion wise to a stirring suspension 
of 60% NaH (1.28 g, 31.9 mmol, 2.5 eq) in dry THF (30 mL) at 0 °C, and the resulting 
mixture was stirred under inert atmosphere (N2) for 30 min. Then MOM-Br (2.5 mL, 30.6 
mmol, 2.4 eq) dissolved in dry THF (20 mL) was added dropwise, and the suspension was 
allowed to warm to room temperature under inert atmosphere (N2). After 4 hours, a 
solution of LiOH (1.22 g, 51.0 mmol, 4.0 eq) in water (25.5 mL) was added at 0 °C, and 
the resulting mixture was stirred at room temperature overnight. The reaction mixture was 
acidified with glacial acetic acid to pH 4 and then extracted with DCM (5 × 90 mL); the 
organic phases were collected, dried over anhydrous Na2SO4, filtered and the solvent 
removed under reduced pressure to give compound 13 (2.92 g, 98%) as a white solid. Mp: 
157-159 °C (CH3CN/MeOH). 
1
H-NMR (CD3OD) δH/ppm: 2.09 (s, 3H, CH2OCH3), 4.08 
(s, 2H, OCH2OCH3), 5.97 (d, 1H, quinoline ring), 6.18 (m, 1H, quinoline ring), 6.83 (d, 
1H, quinoline ring), 7.39 (d, 1H, quinoline ring), 8.06 (d, 1H, quinoline ring). 
13
C-NMR 
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(CD3OD) δC/ppm: 55.1, 95.3, 104.5, 119.0, 122.7, 126.5, 131.3, 133.1, 140.0, 148.1, 
159.7, 167.5. MS, m/z: 234 [M+H]
+
. 
trans-tert-Butyl(2-(4-(8-(Methoxymethoxy)quinoline-5-carboxamido)phenyl)cyclo-
propyl) carbamate (14). Compound 14 was prepared following the same procedure used 
for 11, starting from 13 and 10. Mp: 188-191 °C (CH3CN). Yield: 67%. 
1
H-NMR (CDCl3) 
δH/ppm: 1.19 (m, 2H, -CH2- cyclopropane ring), 1.49 (s, 9H, NHCO2C(CH3)3), 2.07 (m, 
1H, -CH- cyclopropane ring), 2.74 (m, 1H, -CH- cyclopropane ring), 3.61 (s, 3H, 
CH2OCH3), 5.58 (s, 2H, OCH2OCH3), 7.21 (d, 2H, benzene ring), 7.44 (d, 1H, quinoline 
ring), 7.56 (m, 3H, quinoline ring and benzene ring), 7.67 (s, 1H, CONHAr), 7.80 (d, 1H, 
quinoline ring), 8.93 (d, 1H, quinoline ring), 9.04 (d, 1H, quinoline ring). 
13
C NMR 
(CDCl3) δC/ppm: 15.2, 23.3, 29.0, 32.8, 55.4, 80.5, 95.1, 107.8, 121.8, 125.3, 126.0, 127.7, 
128.3, 130.0, 131.4, 133.8, 136.5, 138.1, 151.5, 156.4, 161.2, 164.4. MS, m/z: 464 
[M+H]
+
. 
General Procedure for the Synthesis of 8-(Methoxymethoxy)quinoline-5-
carboxyamidoalkyl Methyl Esters (15-17). Example: Methyl 4-({[8-
(Methoxymethoxy)quinolin-5- yl]carbonyl}amino)butanoate (15). The reagents HOBT 
(382 mg, 2.40 mmol, 1.2 eq), EDCI (460 mg, 2.40 mmol, 1.2 eq) and Et3N (1.12 mL, 8 
mmol, 4.0 eq) were added in sequence to a mixture of 13 (560 mg, 2.40 mmol, 1.2 eq) and 
methyl 4-aminobutanoate hydrochloride (306 mg, 2 mmol, 1 eq) in dry DCM (12 mL), and 
the solution was stirred at room temperature. After overnight stirring, the reaction mixture 
was diluted with DCM (90 mL) and the organic phase washed with Na2CO3 (2 × 50 mL) 
and brine (2 × 50 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo to 
give a residue that was purified by column chromatography on silica gel (eluent: 
DCM/MeOH 35/1). The collected fractions were evaporated and the resulting crude was 
finally recrystallized from benzene/cyclohexane to afford compound 15 (550 mg, 83%) as 
a white solid. 
1
H-NMR (CDCl3) δH/ppm: 2.04 (m, 2H, NCH2CH2CH2), 2.52 (t, 2H, 
CH2CH2CO2Me), 3.61 (m, 5H, NHCH2CH2 and CO2CH3), 3.70 (s, 3H, OCH2OCH3), 5.56 
(s, 2H, OCH2OCH3), 6.32 (bs, 1H, CONHCH2), 7.39 (d, 1H, quinoline ring), 7.53 (m, 1H, 
quinoline ring), 7.66 (d, 1H, quinoline ring), 8.91 (d, 1H, quinoline ring), 9.01 (d, 1H, 
quinoline ring). 
13
C-NMR (CDCl3) δC/ppm: 22.8, 29.5, 40.3, 50.7, 55.4, 92.7, 107.8, 126.3, 
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129.7, 130.1, 131.3, 131.9, 137.5, 151.3, 163.4, 165.0, 176.1. m.p.: 115-117 °C 
(benzene/cyclohexane). MS, m/z: 333 [M+H]
+
.  
Methyl 5-({[8-(Methoxymethoxy)quinolin-5-yl]carbonyl}amino)pentanoate (16). 
1
H-
NMR (CDCl3) δH/ppm: 1.77 (m, 4H, CH2CH2CH2CH2), 2.44 (t, 2H, CH2CH2CO2Me), 
3.53 (m, 2H, NHCH2CH2), 3.60 (s, 3H, CO2CH3), 3.71 (s, 3H, OCH2OCH3), 5.56 (s, 2H, 
OCH2OCH3), 6.16 (bs, 1H, CONHCH2), 7.39 (d, 1H, quinoline ring), 7.53 (m, 1H, 
quinoline ring), 7.67 (d, 1H, quinoline ring), 8.89 (d, 1H, quinoline ring), 9.00 (d, 1H, 
quinoline ring). 
13
C-NMR (CDCl3) δC/ppm: 22.3, 30.1, 32.4, 39.7, 52.6, 56.6, 92.7, 111.2, 
128.1, 128.7, 130.2, 132.1, 133.7, 137.9, 155.3, 163.4, 164.1, 176.7. m.p.: 96-98 °C 
(benzene/cyclohexane). Yield: 52%. MS, m/z: 347 [M+H]
+
.  
Methyl 6-({[8-(Methoxymethoxy)quinolin-5-yl]carbonyl}amino)hexanoate (17). 
1
H-
NMR (CDCl3) δH/ppm: 1.50 (m, 2H, aliphatic chain), 1.72 (m, 4H, aliphatic chain), 2.38 
(t, 2H, CH2CH2CO2Me), 3.55 (m, 2H, NHCH2CH2), 3.60 (s, 3H, CH2OCH3), 3.69 (s, 3H, 
CO2CH3), 5.56 (s, 2H, OCH2OCH3), 6.06 (bs, 1H, CONHCH2), 7.39 (d, 1H, quinoline 
ring), 7.53 (m, 1H, quinoline ring), 7.65 (d, 1H, quinoline ring), 8.87 (d, 1H, quinoline 
ring), 9.01 (d, 1H, quinoline ring).
13
C-NMR (CDCl3) δC/ppm: 24.3, 25.2, 30.1, 32.9, 41.6, 
51.7, 57.6, 93.2, 109.8, 123.2, 128.9, 129.6, 131.2, 132.3, 135.2, 153.8, 161.1, 162.8, 
175.8. m.p.: 121-123 °C (benzene/cyclohexane). Yield: 66%. MS, m/z: 361 [M+H]
+
. 
General Procedure for the Synthesis of trans-tert-Butyl (2-(4-(ω-(8-
(Methoxymethoxy)quinoline-5-carboxamido)alkylamido)phenyl)cyclopropyl) 
carbamate (18-20). Example: trans-tert-Butyl(2-(4-(6-(8-(Methoxymethoxy)quinoline-
5-carboxamido)hexanamido)phenyl) cyclopropyl)carbamate (20). LiOH (102 mg, 4.26 
mmol, 4.0 eq.) dissolved in water (3 mL) was added to a stirred solution of 17 (360 mg, 
1.07 mmol, 1.0 eq.) in THF (4 mL) placed on an ice bath, and the resulting mixture was 
stirred at room temperature overnight. The reaction was acidified with glacial acetic acid 
to pH 4-5, then diluted with DCM (50 mL) and extracted; the aqueous phase was further 
extracted with DCM (9 × 50 mL). The organic phases were collected, dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo to afford the 5-({[8-
(methoxymethoxy)quinolin-5-yl]carbonyl}amino)hexanoic acid (300 mg, 85%) as a white 
solid that was used in the next step without further purification. HOBT (92 mg, 0.58 mmol, 
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1.1 eq.), EDCI (110 mg, 0.58 mmol, 1.1 eq.) and Et3N (0.24 mL, 1.70 mmol, 3.2 eq.) were 
added in sequence to a mixture of 5-({[8-(methoxymethoxy)quinolin-5-
yl]carbonyl}amino)hexanoic acid (190 mg, 0.58 mmol, 1.1 eq.) and trans-tert-butyl 2-(4-
aminophenyl)cyclopropylcarbamate 10
 
(132 mg, 0.53 mmol, 1.0 eq.) in dry DMF (4.2 mL) 
and the resulting solution was stirred at room temperature. After 18 hours the solvent was 
evaporated under reduced pressure and the residue partitioned between AcOEt (100 mL) 
and brine (20 mL). The organic phase was further washed with NaHCO3 saturated solution 
(2 × 40 mL) and the aqueous phases back-extracted with AcOEt (40 mL). The organic 
phases were collected, dried over anhydrous Na2SO4, filtered and concentrated in vacuo to 
give a crude product that was purified by column chromatography on silica gel (eluent: 
CHCl3/MeOH 30/1) to give compound 20 (226 mg, 74%) as a yellow foam. 
1
H-NMR 
(CDCl3) δH/ppm: 1.15 (m, 2H, -CH2- cyclopropane ring), 1.47 (s, 9H, NCO2C(CH3)3), 1.53 
(m, 2H, aliphatic chain), 1.72 (m, 2H, aliphatic chain), 1.81 (m, 2H, aliphatic chain), 2.02 
(m, 1H, -CH- cyclopropane ring), 2.40 (t, 2H, CH2CH2CO), 2.68 (m, 1H, -CH- 
cyclopropane ring), 3.57 (m, 5H, NHCH2CH2 and CH2OCH3), 4.88 (bs, 1H, 
CHNHCO2tBu), 5.55 (s, 2H, OCH2OCH3), 6.28 (bs, 1H, CONHCH2), 7.07 (d, 2H, 
benzene ring), 7.35 (m, 2H, quinoline ring and ArNHCO), 7.40 (d, 2H, benzene ring), 7.50 
(m, 1H, quinoline ring), 7.65 (d, 1H, quinoline ring), 8.87 (d, 1H, quinoline ring), 9.00 (d, 
1H, quinoline ring). 
13
C-NMR (CDCl3) δC/ppm: 16.3, 21.7, 24.6, 26.7, 29.1, 29.7, 32.5, 
37.6, 39.3, 53.8, 79.1, 89.4, 107.5, 124.6, 127.3, 127.8, 128.2, 129.3, 132,5, 133.6, 135.0, 
139.2, 140.6, 151.0, 153.3, 159.8, 162.7, 182.9. m.p.: 69-72 °C (cyclohexane). MS, m/z: 
577 [M+H]
+
. 
trans-tert-Butyl-(2-(4-(4-(8-(Methoxymethoxy)quinoline-5-carboxamido)butanamido) 
phenyl) cyclopropyl)carbamate (18). 
1
H-NMR (CDCl3) δH/ppm: 1.14 (m, 2H, -CH2- 
cyclopropane ring), 1.47 (s, 9H, NCO2C(CH3)3), 2.02 (m, 1H, -CH- cyclopropane ring), 
2.09 (m, 2H, CH2CH2CH2), 2.53 (t, 2H, CH2CH2CONH), 2.69 (m, 1H, -CH- cyclopropane 
ring), 3.59 (s, 3H, CH2OCH3), 3.66 (m, 2H, NHCH2CH2), 4.89 (bs, 1H, CHNHCO2tBu), 
5.54 (s, 2H, OCH2OCH3), 6.65 (bs, 1H, CONHCH2), 7.08 (d, 2H, benzene ring), 7.32 (d, 
1H, quinoline ring), 7.50 (m, 3H, benzene ring and quinoline ring), 7.65 (d, 1H, quinoline 
ring), 8.46 (bs, 1H, ArNHCO), 8.89 (d, 1H, quinoline ring), 9.00 (d, 1H, quinoline ring). 
13
C-NMR (CDCl3) δC/ppm: 16.0, 22.1, 26.8, 27.5, 32.3, 35.8, 39.0, 53.5, 80.2, 95.5, 107.4, 
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119.6, 126.6, 126.9, 128.3, 129.3, 131.5, 133.9, 135.1, 137.7, 141.8, 148.8, 155.9, 159.5, 
165.6, 184.4. m.p.: 184-186 °C (benzene/cyclohexane). Yield: 88%. MS, m/z: 549 
[M+H]
+
. 
trans-tert-Butyl-(2-(4-(5-(8-(Methoxymethoxy)quinoline-5-carboxamido)penta 
namido)phenyl) cyclopropyl)carbamate (19). 
1
H-NMR (CDCl3) δH/ppm: 1.15 (m, 2H, -
CH2- cyclopropane ring), 1.47 (s, 9H, NHCO2C(CH3)3), 1.78 (m, 2H, aliphatic chain) 1.87 
(m, 2H, aliphatic chain), 2.02 (m, 1H, -CH- cyclopropane ring), 2.09 (m, 2H, 
CH2CH2CH2), 2.49 (t, 2H, CH2CH2CO), 2.68 (m, 1H, -CH- cyclopropane ring), 3.58 (m, 
5H, NHCH2CH2 and CH2OCH3), 4.87 (bs, 1H, NHCO2tBu), 5.56 (s, 2H, OCH2OCH3), 
6.41 (bs, 1H, CONHCH2), 7.07 (d, 2H, benzene ring), 7.38 (d, 1H, quinoline ring), 7.45 
(m, 3H, benzene ring and quinoline ring), 7.64 (bs, 1H, ArNHCO), 7.68 (d, 1H, quinoline 
ring), 8.85 (d, 1H, quinoline ring), 9.00 (d, 1H, quinoline ring). 
13
C-NMR (CDCl3) δC/ppm: 
15.8, 21.7, 21.9, 27.8, 29.1, 29.8, 37.7, 39.4, 53.0, 80.1, 93.8, 106.9, 123.4, 126.6, 127.0, 
127.5, 128.4, 130.0, 131.8, 136.1, 137.7, 138.1, 149.7, 156.5, 161.2, 164.4, 182.2. m.p.: 
111-114 °C (cyclohexane). Yield: 74%. MS, m/z: 563 [M+H]
+
. 
General Procedure for the Synthesis of ω-(8-Hydroxyquinoline-5-carboxamido)alkyl 
Methyl Esters (21-23). Example: Methyl 5-(8-Hydroxyquinoline-5-
carboxamido)pentanoate (22). Compound 16 (150 mg, 0.43 mmol, 1.0 eq.) was 
dissolved in a mixture of dry THF/MeOH (2 mL/2 mL) and the solution was stirred at 0 
°C, then 4N HCl in 1,4-dioxane (6.5 mL, 25.98 mmol, 60 eq.) was added dropwise, and 
the mixture was allowed to warm to room temperature. After 6 hours, when conversion 
was complete, the suspension was filtered and washed with dry Et2O to give compound 22 
(125 mg, 95%) as a yellow solid. 
1
H-NMR (DMSO-d6) δH/ppm: 1.60 (m, 4H, 
CH2CH2CH2CH2), 2.38 (t, 2H, CH2CH2CO2Me), 3.32 (m, 2H, NHCH2CH2), 3.60 (s, 3H, 
CO2CH3), 7.44 (d,1H, quinoline ring), 7.92 (d, 1H, quinoline ring), 8.00 (m, 1H, quinoline 
ring), 8.70 (bs, 1H, CONHCH2), 9.08 (d, 1H, quinoline ring), 9.39 (m, 1H, quinoline ring), 
12.17 (bs, 1H, ArOH). 
13
C-NMR (DMSO-d6) δC/ppm: 22.9, 29.7, 32.8, 40.1, 50.8, 111.6, 
126.5, 128.5, 131.6, 132.0, 134.9, 140.2, 153.0, 161.2, 163.8, 175.9. m.p.: 175-177 °C 
(CH3CN). MS, m/z: 303 [M+H]
+
.  
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Methyl 6-(8-Hydroxyquinoline-5-carboxamido)hexanoate (23). 
1
H-NMR (DMSO-d6) 
δH/ppm: 1.37 (m, 2H, aliphatic chain), 1.59 (m, 4H, aliphatic chain), 2.33 (t, 2H, 
CH2CH2CO2Me), 3.30 (m,  2H, NHCH2CH2), 7.28 (d, 1H, quinoline ring), 7.82 (d, 1H, 
quinoline ring), 7.87 (m, 1H, quinoline ring), 8.57 (bs, 1H, CONHCH2), 9.02 (d, 1H, 
quinoline ring), 9.18 (d, 1H, quinoline ring), 11.35 (bs, 1H, ArOH). 
13
C-NMR (DMSO-d6) 
δC/ppm: 24.5, 26.4, 30.0, 32.7, 40.4, 51.5, 109.5, 122.6, 130.4, 130.8, 133.0, 133.7, 134.0, 
152.5, 160.8, 163.0, 174.1. m.p.: 164-166 °C (CH3CN). Yield: 97%. MS, m/z: 317 
[M+H]
+
.  
Methyl 4-(8-Hydroxyquinoline-5-carboxamido)butanoate (21). 
1
H-NMR (DMSO-d6) 
δH/ppm: 1.84 (m, 2H, CH2CH2CH2), 2.42 (t, 2H, CH2CH2CO2Me), 3.61 (s, 3H, CO2CH3), 
7.09 (d, 1H, quinoline ring), 7.62 (m, 1H, quinoline ring), 7.69 (d, 1H, quinoline ring), 
8.43 (bs, 1H, CONHCH2), 8.87 (m, 2H, quinoline ring), 10.21 (bs, 1H, ArOH). 
13
C-NMR 
(DMSO-d6) δC/ppm: 23.6, 30.0, 39.7, 50.2, 107.7, 126.8, 129.8, 130.0, 133.1, 133.8, 136.8, 
151.2, 162.7, 164.9, 176.0. m.p.: 185-186 °C (CH3CN). Yield: 77%. MS, m/z: 289 
[M+H]
+
.  
General Procedure for the Synthesis of ω-(8-Hydroxyquinoline-5-
carboxamido)alkanoic acids (24-26). Example: 5-(8-Hydroxyquinoline-5-
carboxamido)pentanoic acid (25). A solution of LiOH (47 mg, 1.11 mmol, 3.0 eq.) in 
water (0.6 mL) was added to a stirred solution of compound 22 (112 mg, 0.37 mmol, 1.0 
eq.) in THF (1.3 mL) placed on an ice bath, and the resulting mixture was stirred at room 
temperature overnight. The solvent was removed, NaHCO3 saturated solution (10 mL) was 
added and the aqueous phase was washed with AcOEt (3 × 10 mL). The aqueous solution 
was acidified with glacial acetic acid to pH 4, then extracted with AcOEt (5 × 20 mL). The 
organic phases were collected, dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo to afford compound 25 (102 mg, 96%) as an off yellow solid. 
1
H-NMR (DMSO-d6) 
δH/ppm: 1.58 (m, 4H, aliphatic chain), 2.30 (t, 2H, CH2CH2CO2H), 7.08 (d, 1H, quinoline 
ring), 7.62 (m, 1H, quinoline ring), 7.68 (d, 1H, quinoline ring), 8.41 (bs, 1H, CONHCH2), 
8.84 (d, 1H, quinoline ring), 8.88 (d, 1H, quinoline ring), 10.17 (bs, 1H, ArOH), 11.98 (bs, 
1H, CH2CO2H). 
13
C-NMR (DMSO-d6) δC/ppm: 22.6, 29.8, 33.3, 39.9, 111.1, 126.3, 128.4, 
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128.7, 131.8, 132.7, 136.0, 151.0, 160.1, 162.9, 177.9. m.p.: 207-209 °C (EtOH). MS, m/z: 
289 [M+H]
+
.  
5-(8-Hydroxyquinoline-5-carboxamido)hexanoic acid (26). 
1
H-NMR (DMSO-d6) 
δH/ppm: 1.38 (m, 2H, aliphatic chain), 1.57 (m, 4H, aliphatic chain), 2.23 (t, 2H, 
CH2CH2CO2H), 7.08 (d, 1H, quinoline ring), 7.62 (m, 1H, quinoline ring), 7.69 (d, 1H, 
quinoline ring), 8.41 (bs, 1H, CONHCH2), 8.83 (d, 1H, quinoline ring), 8.88 (d, 1H, 
quinoline ring), 10.16 (bs, 1H, ArOH), 12.00 (bs, 1H, CH2CO2H). 
13
C-NMR (DMSO-d6) 
δC/ppm: 24.3, 27.2, 29.0, 34.5, 40.1, 110.4, 125.8, 128.8, 129.1, 131.9, 132.5, 133.9, 153.4, 
158.5, 162.3, 175.5. m.p.: 187-189 °C (CH3CN). Yield: 66%. MS, m/z: 303 [M+H]
+
.  
5-(8-Hydroxyquinoline-5-carboxamido)butanoic acid (24). 
1
H-NMR (DMSO-d6) 
δH/ppm: 1.79 (m, 2H, CH2CH2CH2), 2.32 (m, 2H, CH2CH2CO2H), 7.08 (d, 1H, quinoline 
ring), 7.62 (m, 1H, quinoline ring), 7.69 (d, 1H, quinoline ring), 8.44 (bs, 1H, CONHCH2), 
8.84 (d, 1H, quinoline ring), 8.89 (d, 1H, quinoline ring), 10.20 (bs, 1H, ArOH), 12.05 (bs, 
1H, CH2CO2H). 
13
C-NMR (DMSO-d6) δC/ppm: 23.2, 33.2, 39.5, 110.8, 126.0, 128.5, 
128.7, 131.9, 132.2, 135.5, 151.0, 159.7, 162.9, 178.8. m.p.: 217-218 °C (EtOH). Yield: 
86%. MS, m/z: 275 [M+H]
+
. 
 
The chemical and physical data of the intermediate 11-26 and final compounds 1-6 are 
reported in Table 6.3 and Table 6.4, respectively. 
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Table 6.3. Chemical and physical data of intermediates 11-26. 
 
Table 6.4. Chemical and physical data of intermediates 1-6. 
The elemental analyses of compounds 1-6 and 11-26 are reported in Table 6.5. 
compd MW 
calculated, % found, % 
C H N C H N 
1 488.42 56.56 3.92 11.47 56.13 3.80 11.79 
2 424.88 62.19 4.98 13.19 62.34 5.09 12.95 
3 355.82 64.13 5.10 11.81 63.89 4.98 12.07 
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4 440.92 62.65 5.71 12.71 62.98 5.86 12.43 
5 454.95 63.36 5.98 12.31 63.06 6.11 12.12 
6 468.98 64.03 6.23 11.95 64.32 6.30 11.72 
11 488.54 66.38 5.78 11.47 66.11 5.84 11.67 
12 474.51 65.81 5.52 11.81 65.64 5.50 12.02 
13 233.22 61.80 4.75 6.01 62.08 4.89 5.77 
14 463.53 67.37 6.31 9.07 67.54 6.42 8.88 
15 332.35 61.44 6.07 8.43 61.21 5.93 8.62 
16 346.38 62.42 6.40 8.09 62.58 6.49 7.87 
17 360.40 63.32 6.71 7.77 63.11 6.64 7.98 
18 548.63 65.68 6.61 10.21 65.33 6.52 10.45 
19 562.66 66.17 6.81  9.96 65.94 6.74 10.16 
20 576.68 66.65 6.99 9.72 66.44 7.09 9.88 
21 288.30 62.49 5.59 9.72 62.69 5.64 9.43 
22 302.33 63.56 6.00 9.27 63.79 6.13 8.89 
23 316.35 64.54 6.37 8.86 64.19 6.31 9.09 
24 274.27 61.31 5.14 10.21 61.17 5.01 10.44 
25 288.30 62.49 5.59 9.72 62.57 5.64 9.49 
26 302.33 63.56 6.00 9.27 63.19 5.92 9.59 
Table 6.5. Elemental Analyses of Compounds 1-6, 11-26. 
LSD1 assay. His-tagged recombinant form of human LSD1 comprising residues 171-836 
was copurified with a glutathione transferase-tagged CoREST protein (residues 308-440) 
as described. The potency of the inhibitors was evaluated by measuring their IC50 using a 
coupled enzymatic assay monitoring hydrogen peroxide formation. A peptide 
corresponding to the N-terminal 21 amino acids of H3 monomethylated on Lysine 4 was 
used as substrate at the fixed concentration of 29 µM (five-fold the Km). The reaction 
mixture contained 50 mM Hepes pH 7.5, 0.1 mM 4-aminoantipyrine, 1 mM 3,5- dichloro-
2-hydroxybenzenesulfonic acid, 2.8 μM horseradish peroxidase, 1 μM LSD1/CoREST. 
The enzyme was incubated for five minutes at room temperature before measuring the 
enzymatic activity. 
MAO-A and MAO-B assays. Recombinant human MAO-A and -B were expressed in P. 
pastoris and purified as described. IC50 values were measured with the peroxidase-coupled 
assay using benzylamine (MAO-B) and kynuramine (MAO-A) as substrates, at the fixed 
concentration of 333 µM (1.5 fold the Km). The protein (16.7 nM) was titrated with 
increasing concentrations of inhibitor (5-minute incubation at room temperature). The 
reaction mixture contained 50 mM Hepes pH 7.5, 0.025% (w/v) reduced Triton-X100, 0.1 
mM Amplex Red, 2.8 μM horseradish peroxidase, 16 nM enzyme. 
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JmjC inhibitory assays. Materials. Anti-histone H3 (dimethyl K9) (Abcam, cat. No.: 
ab1220), antihistone H3 (trimethyl K9) (Abcam, cat. No.: ab8988), anti-histone H3 
(dimethyl K4) (Abcam, cat. No.: ab32356), anti-histone H3 (trimethyl K4) (Diagenode, 
cat. No.: pAb-003-010) goat anti-mouse Alexafluor 488 (Invitrogen, cat. No.: A21121) or 
goat anti-rabbit Alexafluor 488 (Invitrogen, cat. No.:A11034).  
2OG oxygenase enzyme assay. All recombinant 2OG oxygenase enzymes were produced 
as described
375
. The IC50 values of inhibitors against JmjC containing KDMs were 
determined using AlphaScreen as described
375
. RapidFire mass spectrometry based assay 
methods used for PHD2 and FIH will be reported elsewhere. 
Cell culturing. HeLa cells were maintained in OptiMEM media supplemented with 0.5% 
foetal calf serum and 1% penicillin-streptomycin. Cells (1500 cells per well) were seeded 
into 96-well optical grade plate (Becton Dickinson) and left overnight to adhere. Test 
compounds were diluted in culture medium at a concentration of 100 μM, further serially 
diluted at a ratio of 1:2 (1% DMSO final), and incubated on the adhered HeLa cells. Media 
containing inhibitors was replaced every 24 h for 3 day period. 
Immunostaining. Cells were rinsed with phosphate buffered saline (PBS) and fixed in 4% 
paraformaldehyde (20 min) and permeabilised with 0.5% TritonX-100 (10 min), followed 
by another PBS rinse. The cells were blocked (30 min) with 3% foetal calf serum diluted 
in PBS and further incubated overnight in primary antibody (1:500) diluted in blocking 
solution. Cells were rinsed three times with PBS, followed by incubation with the 
secondary antibody for 1 hour. After PBS rinses (×3), cells were stained with DAPI. 
Image acquisition and analysis. The Pathway (Beckton Dickinson), an automated high-
content imaging platform, was used to image the immunostained cells in the 96-well plate 
configuration. For each well, the system acquired a 3-by-3 tile-scanned image for 
Alexafluor 488 and DAPI. During analysis, the Pathway’s software used the DAPI 
staining to identify nuclei as regions-of-interests (ROI). For each nucleus, the software 
extracted the average intensity of the histone staining, followed by the average intensity of 
all the nuclei in that particular well. The number of remaining cells and average nuclear 
size of each well was also calculated from the DAPI image. These three parameters from 
each well were then plotted against the corresponding concentration to obtain a dose 
response curve, which was plotted in GraphPad Prism 5. 
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LNCaP prostate cancer, HCT116 colon cancer and MePR mesenchimal progenitor 
cell assays.  
Cell lines. HCT116 (human colorectal carcinoma cell line-ATCC) were grown at 37 °C in 
air and 5% CO2 in DMEM medium (Euroclone) and LNCaP (human prostate cancer cell 
line-ATCC) and MePR (Mesenchimal PRogenitor non cancer-cell line) were grown at 37 
°C in air and 5% CO2 in RPMI medium (Euroclone). Both media were supplemented with 
10% heat-inactivated FBS (Euroclone), 1% glutamine (Lonza), 1% penicillin/streptomycin 
(Euroclone) and 0.1% gentamycin (Lonza). 
Cell cycle analysis. 2.5 × 105 cells (HCT116, LNCaP and MePR) were collected by 
centrifugation after stimulation at several times with reference or testing compounds at 50 
μM. The cells were resuspended in 500 XL of hypotonic buffer (0.1% NP-40, 0.1% 
sodium citrate, 50 Xg/mL PI, RNAse A) and incubated in the dark for 30 min. The 
analysis was performed by FACS-Calibur (Becton Dickinson) using the Cell Quest Pro 
software (Becton Dickinson) and ModFit LT version 3 software (Verity). Pre- G1 picks 
were analyzed as indicative of sub-G1 apoptotic population. The experiments were 
performed in triplicate and shown data represent independent media values. 
Dose-dependent apoptosis evaluation. 2.5 × 105 HCT116 and LNCaP cells were treated 
with increasing doses (10, 25, 50, 100 μM) of 2 and 3. Cell cycle distribution of 10,000 
cells was analyzed with a FACS-Calibur flow cytometer (Becton Dickinson, Franklin 
Lakes, NJ) by ModFit version 3 Technology (Verity). Pre-G1 picks were analyzed as 
indicative of sub-G1 apoptotic population. All the experiments were performed at least 3 
times and values were expressed in mean •± SD. 
Histone Extraction. After stimulation with compounds, cells (HCT116 and LNCaP) were 
collected by centrifugation and washed two times with PBS. Then the samples were 
resuspended in Triton extraction buffer (PBS containing 0.5% Triton X 100 (v/v), 2 mM 
PMSF, 0.02% (w/v) NaN3), and the lysis was performed for 10 min at 4 °C. Next, samples 
were centrifugated at 2000 rpm for 10 min at 4 °C, and the pellets were washed in TEB 
(half the volume). After a new centrifugation under the same conditions, the samples were 
re-suspended in 0.2 N HCl and the acidic histone extraction was carried out overnight at 4 
°C. The supernatant was recovered by centrifugation and the protein content was 
quantified with BCA™ Protein Assay (Pierce). 
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Western blot analysis. Histone extracts (10 μg) were denatured and boiled in buffer (0.25 
M Tris-HCl pH 6.8, 8% SDS, 40% glycerol, 5% 2-mercaptoethanol, bromophenol blue 
0.05%) for 3 min before electrophoresis. Proteins were subjected to SDS–PAGE (15% 
polyacrylamide gels) in Tris-glycine- SDS (25 M Tris, 192 M glycine, 0.1% SDS). 
After electrophoresis, proteins were transferred to nitrocellulose membranes (Biorad Mini-
protean gel and Transblot Turbo, Transfer System Biorad). The membranes were stained 
with Ponceau red, before to start with blocking (5% non-fat dry milk in TBS 1x/Tween 
0.1%), and then incubated with the primary antibodies overnight at 4 °C. The employed 
antibodies were H3K4me2 and H3K4me3, H3K9me2 and H3K9me 3 (Abcam); total H4 
(Cell Signalling) was used to normalize for equal loading of histone extracts. 
Determining cell proliferation with the xCELLigence system. Tumour cell proliferation 
was monitored with the xCELLigence system (Roche, Mannheim, Germany). LNCaP and 
HCT116 cells were suspended in DMEM and RPMI media respectively and added into a 
96 well microtiter plate that is specifically designed to measure cellular impedance (E-
Plate, Roche, Mannheim, Germany). The measured impedance, which is dependent on the 
level of confluence, was expressed as an arbitrary unit called Cell Index. The Cell Index at 
each time point is defined as (Rn-Rb)/(15X), where Rn is the cell electrode impedance of 
the well when it contains cells and Rb is the background impedance of the well with the 
media alone. xCELLigence monitors cellular events in real time measuring electrical 
impedance across interdigitated micro-electrode integrated on the bottom of tissue culture 
E-Plates. The impedance measurement provides quantitative information about the 
biological status of the cells, including cell number, viability, and morphology. For 
experiments, both LNCaP and HCT116 cell lines, were starved in DMEM/10% FBS and 
RPMI/10% FBS respectively, overnight before being seeded on an E-Plate 96. Two hours 
after seeding, scalar cell concentrations were added in triplicate. Dynamic CI values were 
monitored in 30-minute intervals from the time of plating until the end of the experiment. 
CI values were calculated and plotted on the graph. Standard deviation of tetraplicates of 
wells for the two types cells with different treatments were analysed with the RTCA 
Software. 
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Figure 6.9. Proliferation curve relative to LNCaP and HCT116 cell lines after 72 h. In red is 
described the control (untreated cells), in green cells treated with the HDAC inhibitor SAHA used 
at a final concentration of 5 μM, in blue cells treated with the compound 2, used at a final 
concentration of 50 μM, in violet cells treated with the compound 3, used at a final concentration 
of 50 μM and in sky-blue the base line. 
Cell migration assay. The kinetic information about cell migration by dynamically 
recording the whole cell migration process in real time without labelling cells, has been 
performed with the Roche xCELLigence Real-Time Cell Analyzer (RTCA) DP 
instrument. The RTCA DP instrument uses the CIM (cellular invasion/migration)-Plate 16 
featuring microelectronic sensors integrated into the underside of the microporous 
polyethylene terephthalate (PET) membrane of a Boyden-like chamber. In this way cells 
migrate from the upper chamber through the membrane into the bottom chamber in 
response to the chemoattractant (we used foetal bovine serum) so contacting and adhering 
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to the electronic sensors on the underside of the membrane, resulting in an increase of the 
impedance. The impedance increase is proportional to increasing numbers of migrated 
cells on the underside of the membrane. Moreover cell-index values reflecting impedance 
changes are recorded by RTCA DP instrument. The CIM-Plate has been assembled by 
placing the top chamber into the bottom chamber and snapping the two together. Serum-
free medium has been placed in the top chamber to hydrate and pre-incubate the 
membrane for 1 h in the CO2 incubator at 37 °C before obtaining a background 
measurement. LNCaP and HCT116 cells were resuspended at the indicated concentration 
in serum-free medium. Once the CIM-Plate has equilibrated, it has been placed in the 
RTCA DP station and the background cell index values have been measured. The CIM-
Plate was then removed from the RTCA DP station and then cells have been added to the 
top chamber at the desired concentration. The CIMPlate was placed in the RTCA DP 
station and migration has been monitored every 2 minutes for several hours. Cells have 
been analysed in absence or presence of 10% FBS in the bottom chamber. Cell migration 
was detected by automated real time monitoring and the low and high seeding densities 
were quantitatively monitored and reflected by the cell index values. 
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